University of Missouri, St. Louis

IRL @ UMSL
Dissertations

UMSL Graduate Works

8-2-2011

Synthesis of (±)-Cyclophostin, (±)-Cyclipostin P,
Their Phosphonate Analogs and New Chemistry of
Vinyl Phosphonates
Raj Kumar Malla
University of Missouri-St. Louis, rkmy7d@umsl.edu

Follow this and additional works at: https://irl.umsl.edu/dissertation
Part of the Chemistry Commons
Recommended Citation
Malla, Raj Kumar, "Synthesis of (±)-Cyclophostin, (±)-Cyclipostin P, Their Phosphonate Analogs and New Chemistry of Vinyl
Phosphonates" (2011). Dissertations. 416.
https://irl.umsl.edu/dissertation/416

This Dissertation is brought to you for free and open access by the UMSL Graduate Works at IRL @ UMSL. It has been accepted for inclusion in
Dissertations by an authorized administrator of IRL @ UMSL. For more information, please contact marvinh@umsl.edu.

Synthesis of (±)-Cyclophostin, (±)-Cyclipostin P,
Their Phosphonate Analogs and New Chemistry
of Vinyl Phosphonates

by

Raj Kumar Malla

A Dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy (Chemistry)

University of Missouri-St. Louis
August, 2011

Committee
Prof. Christopher D. Spilling
(Chair and Advisor)
Prof. Alexei V. Demchenko
Prof. Cynthia M. Dupureur
Prof. Eike B. Bauer

Abstract
Synthesis of (±)-Cyclophostin, (±)-Cyclipostin P, Their Phosphonate
Analogs and New Chemistry of Vinyl Phosphonates
Raj Kumar Malla
Doctor of Philosophy
University of Missouri-St. Louis
Prof. Christopher D. Spilling, Advisor

This work is divided into 2 parts: a) total synthesis of (±)-cyclophostin, (±)-cyclipostin P
and their monocyclic analogs b) development of a metathesis based methodology for
transformation of vinyl phosphonates.
Cyclophostin (1) and cyclipostins (2) are bioactive natural bicyclic organophosphates.
Cyclophostin is a powerful inhibitor of acetyl cholinesterase (AChE), whereas members
of the cyclipostins are potent inhibitors of hormone sensitive lipase (HSL). Cyclophostin
(1) and cyclipostin (2) have the same structural core unit, but different phosphate ester
substituents. While cyclophostin is a methyl ester, the members of the cyclipostins are
phosphate esters of different alkyl groups of various length and structure at the phosphate
center.
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First total synthesis of (±)-cyclophostin (1) and 14 monocyclic phosphonate analogs is
reported. Similarly, synthesis of the natural product (±) cyclipostin P was achieved via a
novel, high yielding one-pot transesterification of diastereomer of (±)-cyclophostin. This
method acts as bridge from cyclophostin to any member of cyclipostins. The conversion
can also be carried out with monocyclic phosphonate analogs.
(±)-Cyclophostin and 14 monocyclic phosphonate analogs were tested against different
members of the serine hydrolase family of enzymes at UMSL and at CNRS-Marseilles in
France. The biological evaluation of these analogs was helpful in understanding the
relationship between the structure and biochemistry of the molecules towards the
inhibition of various enzymes.
Vinyl phosphonates have the potential to be useful intermediates in organic synthesis.
However, there are only a limited number of transformations reported for vinyl
phosphonates. Although terminal vinyl phosphonates easily undergo cross metathesis
reaction, internal vinyl phosphonate do not. A method for cross metathesis of allyl vinyl
phosphonates

based

on

relay

process

has

been

developed.
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1. Chapter I
Introduction
1.1. Cyclophostin and the cyclipostins: Isolation and biological
properties
During the search for natural organophosphate insecticides, Kurokawa and coworker
isolated cyclophostin (1.1) from a fermentation broth of Streptomyces levundalae (strain
NK901093) as an optically active crystalline solid with melting point 113-114 oC and
[α]D20 -7.56o (c 1.35, EtOH). Based on spectroscopic analysis, it was proposed that the
structure consisted of a [5.0.3] bicyclic core with a butyrolactone ring fused to a 7membered phosphate ring. The phosphate ring consists of an endocyclic enol-phosphate
bond in conjugation with the lactone ring. There are chiral centers at C3a and the
phosphate atom (Figure 1.1).1

Figure 1.1 Structure of (–)-cyclophostin
Finally, structure of the molecule was confirmed by X-ray crystallographic analysis. By
using anomalous scattering methods, the absolute stereochemistry of cyclophostin was
reported as (3aR, 6S).1 More accurately, the stereochemistry should be described as
(3aR,6R) based on the Cahn-Ingold-Prelog (CIP) rule.2 According to the rule, pπ-dπ
bonding such as that in phosphoryl group (-P=O) gets the least priority.
The compound exhibits potent inhibition of acetylcholine esterase (AChE) from housefly
(CSMA strain) with an IC50 value of 7.6 x10-10 M which is 8000 and 60 times stronger
1

than that of than propaphos (1.2) and physostigmine sulfate (1.3), respectively. Similarly,
the compound showed 70,000 and 70 times stronger inhibition than 1.2 and 1.3 against
AChE from brown plant hopper (IC50 =1.3 x10-9 M), respectively. Both propahos and
physiostigmine are known irreversible inhibitors of AChE (Figure 1.2).

Figure 1.2 Irreversible inhibitors of acetylcholine esterase (AChE)
A decade later, a family of compounds called cyclipostins (1.4) was isolated from a
fermentation broth of Streptomyces species strain DSM13381 (Table 1.1 and 1.2).3,4 It is
a family of 19 novel organophosphates (A to T2) whose production could be influenced
by the choice of nutrient media. Streptomyces sp. when cultured on oat flake medium
produced cyclipostin A to F whereas cyclipostin N to T2 were produced in glycerol/soy
meal nutrient medium.3
Isolation of the cyclipostins was complicated by the instability of the compounds on
silica gel and reverse phase column chromatography. However, the compounds were
found to be sufficiently stable towards reverse phase supports between pH 3 and pH 4.
Therefore, the individual compounds were purified by repeated reverse phase
chromatography.3
The structures of all cyclipostins were elucidated by various 2D-NMR analyses including
DQF-COSY, HMQC and HMBC. After comparing data with that of cyclophostin,
presence of the bicyclic core structure was deduced. Individual cyclipostins were
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characterized by mass spectroscopic analysis which revealed that members differ from
each other by the nature and length of the lipophilic alkyl side chain attached at the
phosphate center. The structure of isolated cyclipostins is presented in the following table
(Table 1.1).4

Table 1.1 Structures of isolated cyclipostins
Cyclipostin R

R1

Mol. Wt.

A, 1.4a

Me

460.55

F, 1.4b

Me

458.54

N, 1.4c

Me

416.50

P, 1.4d

Me

444.55

P2, 1.4e

Me

444.55

R, 1.4f

Me

430.53

R2, 1.4g

Me

430.53

S, 1.4h

Et

458.58

T, 1.4i

n-Pr

472.61

T2, 1.4j

n-Pr

472.61

3

Additional cyclipostins were also detected but not preparatively isolated. The structures
of these cyclipostins are tabulated below (Table 1.2).4

Table 1.2 Structures of cyclipostins (detected but not preparatively isolated)
Cyclipostin R

R1

Mol. Wt.

A2, 1.4k

Me

460.55

B, 1.4l

Me

460.55

C, 1.4m

Me

460.55

D, 1.4n

Me

460.55

E, 1.4o

Me

460.55

G, 1.4p

Me

458.54

H, 1.4q

Me

458.54

Q, 1.4r

Et

458.58

Q3, 1.4s

nPr

458.58

The cyclipostins are nanomolar inhibitors of hormone sensitive lipase (HSL) from rat
adipocytes. The inhibition of HSL by cyclipostins, indicated by IC50 values, was found to
4

be a close match both in cell-free conditions and cellular assays in isolated rat adipocytes.
In both cases, the IC50 values were found to be less than 200 nM (Table 1.3).
Furthermore, cyclipostins were able to block lipolysis completely from adipocytes in
basal and stimulated state. The overall inhibition by cycliopostins was not affected by
the total incubation and assay time (in cellular systems) and preincubation time (in cellfree assay). All these observations provided evidence for the facts that cyclipostins cross
the plasma membrane with high efficiency and the inhibition of HSL is direct rather than
a disruption of the signaling cascade for the activation of HSL.4
Table 1.3 Inhibition of rat HSL by cyclipostins
IC50 (nM)
Cyclipostin

Cell-free Isolated rat
adipocytes

A

29

190

P

30

85

P2

40

150

S

20

40

Acetyl cholinesterase (AChE) is a very important enzyme in human biology. Its role in
neurodegerative diseases like Alzheimer’s disease makes it a very good target for
therapeutic development for the corresponding diseases.6 Similarly, hormone sensitive
lipase (HSL) is an enzyme involved in type II diabetes. The increased activity of this
enzyme over that of insulin, is a key factor leading to type II diabetes. A rational way to
check the activity of these enzymes is to develop molecules that inhibit the enzyme
activity.

5

As mentioned above, cyclophostin is a very potent inhibitor of AChE whereas the
cyclipostins are very potent inhibitors of HSL. The reported bioactivities of both natural
products coupled with their novelty make them attractive targets for synthesis and also
for the development of structure-activity relationships between these molecules, their
analogs, and their biological activity.

1.2. Specific aim of the study
Prior to this work, there has been no report of the synthesis of cyclophostin and
cyclipostins. The only reported work in this field is the synthesis of the first phosphonate
analogs of cyclophostin by Spilling and coworkers.6
This project has the following specific aims:
I.
II.

Synthesis of cyclophostin and cyclipostins
Synthesis of monocyclic phosphonate analogs of cyclophostin and
cyclipostins

The syntheses will be followed by assay of their biological activities against various
serine hydrolase enzymes in collaboration with biochemistry groups at this University
and at CNRS, Marseilles, France. Structure complexities of the target molecules and
synthetic strategies along with an earlier effort for the synthesis is discussed in the
following section.

1.3. Structural feature and retro synthetic analysis
Cyclophostin and the cyclipostins are small but highly functionalized natural products.
Because cyclophostin shares its bicyclic core structure with the cyclipostins, the synthesis

6

of individual cyclipostins can be achieved by replacing the methyl group at the phosphate
center of cyclophostin. Therefore, the synthesis of cyclophostin is the primary goal.
Among the challenges involved in the synthesis of cyclophostin is the construction of the
7-membered enol-phosphate heterocycle. The enol-phosphate bond, in general, is
susceptible towards acids, bases and oxidizing agents.5 Moreover, the phosphate is a
good leaving group making it susceptible to attack by any good nucleophile leading to
rupture of the phosphate ring. Hence, these structural features of cyclophostin demand a
cautious plan for synthesis which should avoid strong reagents or harsh reaction
conditions.
A retrosynthetic analysis of cyclophostin leads to two viable routes: route a and b. The
first route involves a late stage construction of the cyclic phosphate ring by attack of the
enolate oxyanion on the activated phosphate center. This approach was successful in the
synthesis of the phosphonate analog.6
The alternative route (route b) involves an early stage construction of the enol-phosphate
bond followed by intramolecular condensation between the activated phosphoric acid and
free alcohol (Figure 1.3).

7

Figure 1.3 Retro synthetic analysis of cyclophostin
The acetylated phosphate intermediate (1.5) and the enol-phosphate (1.8) could be
prepared from acetylated hydroxy lactone (1.6). Since this type of hydroxylactone
undergoes intramolecular ketalization leading to bicyclic product (1.10), the alcohol must
be protected prior to acetylation of the butyrolactone (1.9).

1.4. Earlier synthesis of cyclophostin: route a 7
The first attempt towards the synthesis of cyclophostin was based on route a and was
reported in the PhD dissertation of Saibal Bandyophdyay.7 The synthesis of cyclophostin
using started with phosphorylation of the known hydroxymethyl butyrolactone (1.9). The
known -butyrolactone8 (1.9) was phosphorylated using bromophosphate to give the
phosphate (1.11). The bromophosphate was generated in situ by reaction between
molecular bromine and trimethyl phosphite at -50 oC. Initial attempts to install acetyl
group at the 2-position of butyrolactone (1.11) using an excess of acetyl chloride
produced enolacetate (1.12) in modest yield (64%) as a mixture of two geometrical
8

isomers. Methanolysis of these enolacetate using a catalytic amount of DMAP resulted
the required acetyl lactone (1.13).
The phosphate (1.13) was converted to mono phosphoric acid (1.5) by mono
demethylation of the phosphate ester using a stoichiometric amount of sodium iodide
followed by a proton exchange reaction with a sulfonic acid resin (Amberlite IR120)
(Scheme 1.1).

Scheme 1.1 Synthesis of cyclophostin: route a
The phosphoric acid (1.5) was subjected to various reaction conditions for cyclization.
Surprisingly, intramolecular cyclization of the activated monophosphoric acid with the
enolate was not successful under the coupling condition (EDC, HOBt and the Hunig’s
base) applied to the synthesis of the phosphonate analog. Further attempts at cyclization
using TsCl and pyridine were partially successful, but with very low yield (<10%). The
formation of the natural product was confirmed by spectral comparison with the
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literature.1 A fused tetracyclic byproduct (1.15) was obtained from the crude reaction
mixture and the structure was determined by X-ray diffraction study.
Lack of success in the synthesis of the cyclic phosphate under different conditions not
only demanded alternative methods for cyclization, but also led to the exploration of
various methods for the synthesis of cyclic phosphates and phosphonates. A brief review
of literature for methods of synthesis of cyclic phosphate is presented in the following
section.

1.5. Methods for synthesis of cyclic phosphates and phosphonates
A survey of literature for methods for synthesis of cyclic phosphate and phosphonates
reveals several practical methods which broadly fall into following types: methods based
on: a) pyrophosphate, phosphoric acid, phosphonic acid; b) reactions of phosphite (P
(III)) followed by oxidation to P (V); c) nucleophilicity of the phosphoryl oxygen; and d)
ring closing metathesis (Figure 1.4). While each method has its own advantage and
utility, some of them are general in their scope and substrate range while others are
specific for synthesis of a particular class of cyclic phosphate or phosphonate.

Figure 1.4 Methods of preparation of cyclic phosphates and phosphonates
10

Acyclic phosphoric acids (1.17) containing a suitably placed hydroxyl group undergo
acid or base catalyzed trans-esterification to give 5- and 6-membered cyclic phosphates.
Similar transformation using pyrophosphates (1.18) requires use of alkaline conditions
leading to intramolecular phosphorylation. These methods are quite successful towards
preparation of phosphorylated sugars.9,12b
Khorana and coworkers introduced a milder way of activating phosphoric acid for cyclic
phosphate synthesis.10 They were able to synthesize 5-, 6-, 7-membered cyclic
phosphates at room temperature by using dicyclohexyl carbodimide (DCC) as an
activating agent for phosphoric acid.11,12 It was suggested that the attack of vicinal
hydroxyl group on phosphate center of intermediate O-phosphorylisourea (1.24) produces
the cyclic phosphate (1.23) (Scheme 1.2).

Scheme 1.2 DCC-mediated synthesis of cyclic phosphates
It was also reported that on longer reaction time, 5-membered cyclic product (1.23)
further reacted with DCC to produce acyclic N-phosphoryl urea (1.24a and 1.24b). It was
suggested that cyclic phosphate undergoes 1, 2-addition to DCC and initially form Ophosphorylisourea (1.25) which after coming in contact with water, undergoes rapid
rearrangement to give N-phosphoryl urea. However, 6- and 7-membered cyclic product
did not give the N-phosphoryl urea. The phosphoryl urea (1.24a and 1.24b) could be
converted back to cyclic product under acidic or basic conditions (Scheme 1.3).10a,11b
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Scheme 1.3 Proposed mechanism for formation of N-Phosphoryl urea
The mild reaction conditions and wide substrate scope make this reaction a good general
method for synthesis of cyclic phosphates. However, different reaction conditions have
been proposed for the reaction. Literature examples show cyclization reactions carried
out with DCC in a) aqueous pyridine,10a,14 b) anhydrous conditions13, and c) boiling
pyridine.14
During their investigation of synthesis and reactions of enol phosphates, Marecek and
Griffith synthesized a cyclic phosphate of ethyl hydroxy cinnamic acid (1.29) by using
the DCC coupling reaction. An initial attempt to synthesize mono phosphoric acid (1.27)
from corresponding ethyl ester (1.26) under acid or base catalyzed hydrolysis of the
phosphate ester led to extensive dephosphorylation. This problem was overcome by using
NaI for mono dealkylation of the phosphate diester, followed by acidic workup (Scheme
1.4).13a

Scheme 1.4 Synthesis of cyclic phosphate of hydroxyl cinnamic acid
This method was adopted by Pratt and coworkers to prepare a cyclic phosphate (1.34) for
the investigation of inhibition of β-lactamase by monocyclic acyl phosphates and
phosphonates (Scheme 1.5).13b
12

Scheme 1.5 Synthesis of cyclic phosphate inhibitors of β-lactamase
The DCC mediated cyclization of phosphates was extensively used for the syntheses of
cyclic adenosine mono phosphate (cAMP) analogs during an effort to prepare antitumor
drugs.
Moffatt and coworkers reported the first isosteric phosphonate analogs of nucleotide
phosphates (1.36). The synthesis involved cyclization of phosphonate isostere of
adenosine (1.35) with DCC in hot pyridine solution under high dilution to form the 3’,6’cyclic adenosine phosphonate. In another set of reaction conditions, tributylammonium
salt (1.37) was cyclized with 4 equivalents of DCC in refluxing 95:5 pyridine-water
solution to give the cyclic product in similar yield (Scheme 1.6).14

Scheme 1.6 Synthesis of phosphonate isostere of nucleotide cyclic phosphates
Synthesis of 3’5’-cyclic phosphonate (1.41) was also reported. The phosphonylated sugar
(1.38) was first, acetylated at the 2’-hydroxyl group followed by removal of
methoxytrityl group and cyclization using the DCC method. Deacetylation using
ammonium hydroxide not only gave the desired cyclic phosphonic acid (1.41) but also 5membered cyclic phosphonate analog (1.42) (Scheme 1.7).
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Scheme 1.7 Synthesis of phosphonate isostere of nucleotide cyclic phosphates
Spilling and coworkers reported the first phosphonate analogs of cyclophostin (1.45a and
b) by EDC and HOBt mediated synthesis of cyclic enol phosphate ring. During the
synthesis, the phosphonic acid (1.43) was activated by mixture of EDC and HOBt
followed by attack of enolate oxyanion of β-keto ester leading to formation of
monocyclic precursor (1.44) (Scheme 1.8).6

Scheme 1.8 Synthesis of phosphonate analogs of cyclophostin
Prestwich and coworker synthesized phosphonothioate (1.48) and fluoromethylene
phosphonate analogs (1.51) of phosphatidic acid as novel antagonists of lysophosphatidic
acid receptors. During the synthesis of the thio analogs, they utilized a PPTS mediated
cyclization of O-phosphonate (1.46) leading to a 5-membered cyclic phosphonate ring
(1.47). A similar acid mediated reaction failed to give the cyclic phosphate moiety in the
case of corresponding fluoro analog (1.49). Finally, the cyclic fluoro phosphonate ring
(1.50) was successfully synthesized from fluoro-phosphonate (1.49) using DCC. It was
reported that for both phosphates and phosphonates, formation of 5-membered rings was
favored over 6-membered rings when formation of either was possible (Scheme 1.9).23
14

Scheme 1.9 Synthesis of phosphonate analogs of phosphatidic acid
Other methods of activation of phosphoric acid have been reported. For example,
Mukaiyama and coworkers reported an alternative method of activation of phosphoric
acids for synthesis of oligonucleotides and nucleoside cyclic phosphates. This method is
defined as oxidation-reduction condensation and the phosphoric acid (1.55) is activated
by a complex (1.54) derived from triphenyl phosphine (1.53) and 2, 2’-dipyridyl disulfide
(1.52). The activated phosphoric acid intermediate (1.57) undergoes intramolecular attack
by alcohol to produce the cyclic phosphate (1.58) (Scheme 1.10).15

Scheme 1.10 Oxidation-reduction condensation of phosphoric acids for synthesis of
cyclic phosphates
Smith and coworkers reported synthesis of a cyclic phosphate by intramolecular
phosphorylation in the presence of strong base and anhydrous conditions. Thus, the
ammomnium phosphate salt (1.60) was treated with potassium t-butoxide in t-butyl
15

alcohol at room temperature to give the corresponding cyclic phosphate (1.61). In this
cyclization, the phosphonate center was activated by presence of 4-nitro benzyl group
(Scheme 1.11).16

Scheme 1.11 Base promoted synthesis of cyclic phosphate
Ikehara and coworker carried out a direct synthesis of nucleoside cyclic phosphates
(1.66) using pyrophosphate (1.63). Thus, ribonucleoside (1.62) was treated with 2
equivalent of pyrophosphate (1.63) along with 2, 6-lutidine, as acid scavenger, to give the
monophosphates (1.64 and 1.65), which were subsequently converted to cyclic phosphate
(1.66) by treatment with dilute alkali (Scheme 1.12).17

Scheme 1.12 Synthesis of nucleoside cyclic phosphate using pyrophosphate
Phosphorylation has also been carried out by using dichloro derivatives of phosphoric
acids. However, this method suffers from poor reproducibility and low yield.
Penney and Belleau described a method using phenyl phosphorodichloridate (1.67) for
the synthesis of cyclic phosphates. Six- to nine- membered cyclic phosphate rings were
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synthesized, but attempts to form give five membered cyclic phosphates failed because
they the latter underwent rapid polymerization. This behavior of five membered rings
was explained on the basis of high ring strain and inability of the ring to resist
decomposition. However, the reagent demonstrated marked superiority over phosphorus
oxychloride for the synthesis of cyclic phosphates.18a
The cyclic phosphates (1.69 and 1.70) were synthesized by Coats and coworkers by
reaction of diol (1.68) with phenyl phosphorodichloridate (1.67) as diastereomeric
mixture of cyclic phosphates (Scheme 1.13). 18b

Scheme 1.13 Synthesis of cyclic phosphate using phenyl phosphodichoridate
Cyclic phosphates have been successfully synthesized via initial formation of the cyclic
phosphite. In this method, initial phosphitylation is carried out by reacting an alcohol
with a trivalent phosphorus reagent containing suitable leaving groups. Then, the P(III) is
oxidized to P(V) species by using mild oxidizing agents.20,21
Crich and coworkers investigated radical contraction of 7-membered cyclic phosphates.
The required cyclic phosphates (1.74, 1.75, 1.76 and 1.77) were synthesized by reaction
of butane diol (1.71) with phenyl dichlorophosphite (1.72) followed by in situ oxidation
using either TBHP or, molecular iodine and 17O-labled water. When the individual cyclic
phosphates were treated with tributyltin hydride and a catalytic amount of diphenyl
diselenide, ring contraction product(s) with scrambling of stereochemistry at phosphate
center (1.78 and 1.79) were obtained (Scheme 1.14).19
17

Scheme 1.14 Radical contraction of cyclic phosphates
O’Neil and coworkers reported the synthesis of a cyclic phosphate of 2’-homouridine
(1.83). The synthesis of the cyclic phosphate was achieved by reaction of diol (1.80) with
phosphoradiamidite (1.81) followed by in situ oxidation of phosphorus by aqueous iodine
(Scheme 1.15).20a

Scheme 1.15 Synthesis of cyclic phosphate of 2- homouridine
Shaw and coworkers synthesized borano-monophosphate analogs of cAMP (1.93). After
the DCC method and cyclization of nitrophenyl phosphate ester using strong base failed
to produce cyclic borano phosphate, the phosphite route was employed. Thus, the
reaction between adenosine (1.84) with phosphorodiamidate (1.81) catalyzed by
diisopropylamine hydratetrazolide (1.85) gave acyclic phosphite (1.86), which was
converted to cyclic phosphite (1.88) using tetrazole (1.87). Borane was introduced at the
phosphate center by reacting phosphite (1.88) with different borane complexes (1.90 or
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1.91). The phosphites were subsequently converted to phosphates, borano-phosphate or
thio-phosphate analogs of cAMP (1.93) (Scheme 1.16).20b

Scheme 1.16 Synthesis of borano-monophosphate analogs of cAMP
Similarly, Reddy and coworker applied the phosphite method to prepare cyclic
phosphates during the synthesis of nucleotide analogs as inhibitors of the hepatitis C
virus (1.96). Different nucleoside analogs (1.94) were reacted with phosphorodiamidate
(1.95) to give cyclic phosphite intermediates as mixtures of cis- and trans- isomers. Cisand trans- isomers differ by axial or equatorial orientation of isopropoxy group at
phosphite center with respect to methyl group on furan ring. The oxidation of phosphite
to phosphate was achieved by use of peroxide (Scheme 1.17). 20c

Scheme 1.17 Synthesis of phosphate inhibitors of the Hepatitis C virus
19

During the synthesis, they could convert the trans- isomer of cyclic phosphite (1.97) to
the thermodynamically more stable cis- isomer (1.98) by heating the mixture at 50 oC for
several hours (Scheme 1.18).

Scheme 1.18 Isomerization of trans-phosphite to cis-phosphite
Potter and coworkers synthesized a conformationally restricted cyclic phosphate analog
of

inositol

trisphosphate

(1.103).

Phosphitylation

of

diol

(1.99)

with

(benzyloxy)bis(diisopropylamino) phosphite (1.100) and 1H-tetrazole (1.87) gave the
phosphite. This was followed by in situ oxidation with m-CPBA gave two diastereomers
of the cyclic phosphate (1.101 and 1.102) (Scheme 1.19).20d These phosphates were
subsequently converted to the required phosphate (1.103).

Scheme 1.19 Synthesis of cyclic phosphate analog of inositol triphosphate
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Rosenberg and coworkers reported ring enlargement of cyclic acetals and ketals as a
viable method for synthesis of 7-membered cyclic phosphonates (1.106). When 3’5’acetals or ketals of deoxyxylose nucleotides (1.104) were treated with diethyl
chlorophosphite (1.105) in presence of catalytic amount of Lewis acids such as SnCl4,
TMSOTf and BF3:Et2O, corresponding 7-membered cyclic phosphonates (1.106) were
obtained (Scheme 1.20).22

Scheme 1.20 Ring enlargement of cyclic acetals and the suggested mechanism
According to the suggested mechanism, the reaction proceeds through heterolysis of P-Cl
bond of diethyl phosphite forming cationic (EtO)2P+ species which coordinates to the 5’alcohol to give phosphite (1.107). This is followed by ring opening of the acetal (1.108)
and intramolecular Arbusov reaction to cyclic phosphonium species (1.109) which
undergo dealkylation by chloride ion to give the final product (Scheme 1.20).
Unsaturated C-C bonds can undergo nucleophilic attack by suitably placed O, N, S and P
nucleophiles leading to formation of the corresponding heterocycle(s). For the synthesis
of phosphorus heterocycles, phosphoryl (or phosphonyl) oxygen or trivalent phosphorus
appropriately located within the molecule can play the role of the nucleophile. 5- and 6membered phosphate and phosphonate rings have been successfully synthesized using
this strategy.
21

Macomber and coworker studied reaction of propargyl alcohols (1.110) with phosphorus
trihalides (1.111). During the study, they found that the propargyl phosphite (1.112)
undergoes

acid-promoted

cyclization

leading

to

phosphorus

heterocycle

(halophosphonate, 1.113) in presence of hydrogen halide (generated in situ). If hydrogen
halide is removed from the reaction mixture, the intermediate dihalophosphite (1.112)
undergoes sigmatropic rearrangement leading to formation of allenic halophosphonates
(1.114). The allenic phosphonyl halide upon hydrolysis gets converted into allenic
phosphonic acid (1.116) which undergoes acid catalyzed cyclization to produce 5membered cyclic phosphonate (1.117). On extended exposure to acid, the allenic
phosphonyl halide (1.114) also undergoes cyclization leading to formation of cyclic
trihalophospholane (1.113). The nature of alkyl substituents influenced overall outcome
of these cyclization reaction (Scheme 1.21).24a

Scheme 1.21 Chemistry of propargyl phosphite
Bartlett and coworker demonstrated that homoallylic phosphate (1.119) can undergo
iodocyclization to give cyclic phosphate (1.121). It was suggested that the cyclization
proceeds though intermediate phosphonium ion (1.120) which undergoes subsequent
dealkylation to give the product. The cyclic phosphate was taken further for synthesis of
22

epoxy phosphate (1.122) in excellent diastereoselectivity (Scheme 1.22). The generality
of the strategy was also explored with various acyclic homoallylic alcohols. It was
reported that 1,3- asymmetric induction took precedence over the 1,2-effect resulting
hight level of selectivities.24b

Scheme 1.22 Synthesis of epoxides via iodocyclization of phosphate
A similar reaction of phosphonate was reported by Zhao and coworkers. Iodocyclization
of phosphonate (1.123) was carried out using excess of iodine to give a 6- membered
phosphonate heterocycle (1.126). A similar reaction using bromine instead of iodine
failed to give the desired product. They also investigated the effect of amount of iodine
and solvent on the reaction. In presence of excess iodine, the phosphonium salt (1.125)
was formed (Scheme 1.23).24c

Scheme 1.23 Synthesis of cyclic phosphonate ring via iodocycliation
Ding and Peng demonstrated that O-ethynyl phenylphosphonic acid monoester (1.127)
undergoes intramolecular cyclization in presence of base or basic solvent and catalytic
amount of CuI to produce phospha-isocoumarins (1.128) in excellent yield. In contrast to

23

its alkynoic acid counterpart, these phosphonic acids underwent highly selectivity 6endo-dig cyclization leading to exclusive formation of coumarins (Scheme 1.24).24d

Scheme 1.24 Synthesis of phospha-isocoumarins via metal catalyzed cyclization of
phosphonic acid
The reaction was hypothesized to proceed through following mechanism where the
activated alkyne moiety undergoes nucleophilic attack by phosphoryl oxygen (Scheme
1.25).

Scheme 1.25 Suggested mechanism of metal catalyzed cyclication of phosphonic acid
An extension of this work appeared as a method of incorporation of “iodo-“ substituent at
4- position which in combination with palladium and related catalysis leads to further
structural elaboration. The O-(1-alkynyl)phenyl phosphonates (1.131) was subjected to
iodocyclization using ICl or I2 as electrophile to give the corresponding 4-iodo
phosphaisocoumarins (1.132) in moderate to excellent yield (Scheme 1.26).24e

Scheme 1.26 Method for structure elaboration of phospha-isocoumarins
24

A subsequent paper by Ding and coworkers described a method to synthesize
oxaphosphorin 2-oxide, or simply, phosphorus 2-pyrone analogs (1.135) by silver
carbonate catalyzed cyclization of (Z)-2-alken-4-ynyl phosphonic acid monoester (1.134)
in comparatively milder conditions in moderate to good yield. This cyclization was
suggested to proceed through 6-endo-dig mode leading to 6-membered rings only
(Scheme 1.27).25f

Scheme 1.27 Silver catalyzed synthesis of cyclic phosphonate
Liu and Lin reported organosulfur- and organoselenium induced intramolecular
cyclization of difluoro allenic phosphonic acid monoesters for the synthesis of cyclic
difluoro

phosphonate

analog

of

phosphates.

Thus,

β-allenic

α-difluoro

methylenephosphonic acid (1.130) was reacted with ArX-Cl (1.131) (X= S, Se) at room
temperature to give 6-membered cyclic α-difluoro phosphonate (1.132) through endo
cyclization (1.133) (Scheme 1.28). 24g

Scheme 1.28 Synthesis of cyclic difluoro phosphonates
Rousseau and coworkers reported synthesis of 6- to 8-membered cyclic halo enol
phostone by electrophilic cyclization of monoacid of acetylenic phosphonate in presence
of (bis-collidine)halo hexafluorophosphate. Product distribution was dependent on the
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size of the heterocyclic rings. Higher yields were obtained using (bis-collidine)iodo
hexafluorophosphate. While reaction followed endo- cyclization for the synthesis of 6membered cyclic phosphonates, reactions leading to synthesis of rings larger than 6membered ring either suffered from low yield or a competition between endo- and exomode for cyclization leading to mixtures of products.24h
Ring closing metathesis (RCM) has become one of the most powerful methods of organic
transformation in organic synthesis. This method has been applied towards synthesis of
cyclic phosphates and phosphonates.
Hanson and coworkers applied a ring closing metathesis approach towards synthesis of
various types of cyclic phosphonates. During the synthesis of phosphonosugars, they
subjected mixed allylic phenyl esters of allylphosphonic acid (1.140) to a ring closing
metathesis reaction to yield the corresponding six-membered allylic phosphonates (1.141)
in excellent yields. The cyclic phosphonates were then transferred to an array of
phosphonosugar analogs (1.142) (Scheme 1.29).25a

Scheme 1.29 Synthesis of phosphonosugars using ring closing metathesis
In a subsequent paper, Hanson and coworkers used ring closing metathesis in
combination with Curtius rearrangement to synthesize conformationally constrained
mono- and bicyclic α-Boc-aminophosphonates such as 1.146, 1.150 and 1.152 from tertbutyl phosphonoacetates (1.143 and 1.147).25c The intramolecular cyclopropanation of
diallyl azaphosphonoacetate (1.143) in presence of rhodium (II) acetate led to formation
26

of diastereomeric mixture of bicyclic phosphonates (1.144 and 1.145) (Scheme 1.30).
These phosphonates were subjected to Curtius rearrangement to give corresponding
aminophosphonate (1.146)

Scheme 1.30 Rhodium (II) catalyzed cyclopropanation of aza phophonoacatete
On the other hand, constrained mono- (1.150) and bicyclic aminophosphonates (1.152)
were synthesized from tert-butyl phosphonoacetates (1.147) by iteration of base
catalyzed allyation and cross metathesis using Grubbs I catalyst, followed by Curtius
rearrangement (Scheme 1.31).

Scheme 1.31 Synthesis of constrained mono- and bicyclic aminophosphonates
In a recent paper from the Hanson group, phosphorodiamidates were used to synthesize
cyclic phosphates (1.154), which were further elaborated by followed by cross metathesis
to prepare a key phosphate intermediates (1.155) for the synthesis of (–)tetrahydrolipstatin (Scheme 1.32).25f
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Scheme 1.32 Synthesis of a key intermediate for synthesis of (-)-tetrahydrolipstatin
Barrett and coworkers synthesized phosphonate analog of 1-hydroxyvitamin D2 (1.158)
by using ring closing metathesis of precursor phosphonate (1.157) (Scheme 1.33).25d

Scheme 1.33 Synthesis of phosphate analog of 1-hydroxyvitamin D2
Van Boom and coworkers reported an expeditious route to phosphorus heterocycle based
on ring closing metathesis. They synthesized different vinylphosponates (1.160 and 1.62)
from bis(diisopropylamino)vinyl phosphine (1.159) by treating latter with different
alcohols followed by oxidation with t-butyl hydroperoxide. Then, these vinyl
phosphonates were subjected to ring closing metathesis using both Grubbs 1st generation
and 2nd generation catalysts to give corresponding phosphorus rings in excellent yield.
The results revealed the superiority of Grubbs 2nd generation catalyst over the 1st
generation catalyst (Scheme 1.34).
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Scheme 1.34 Synthesis of phosphorus heterocycle using ring-closing metathesis
In a subsequent paper, van Boom and coworkers applied ring closing enyne metathesis to
synthesize mono- and fused bicyclic phosphonates. Thus, bis(alkenyl) ethynylphosphonate(s) (1.164) were subjected to enyne metathesis reaction using Grubbs 2nd
generation catalyst to get mixture of mono and bicyclic phosphonates (1.165 and 1.166)
(Scheme 1.35). 25b

Scheme 1.35 Synthesis of phosphorus heterocycle using enyne metathesis
Campbell reported the first application of a Mitsunobu reaction for the synthesis of
acyclic phosphonate esters.27a Pungente and coworker reported synthesis of 14-membered
ring phosphonate (1.168) using intramolecular Mitsunobu reaction of the corresponding
monophosphonic acid having terminal alcohol (1.167) (Scheme 1.36).26b
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Scheme 1.36 Application of Mitsunobu reaction for synthesis of macrocyclic
phosphonates
Drueckhammer and coworker reported synthesis of cyclic phosphonate analogs of
hexopyranoses with phosphorus replacing the anomeric carbon. Treatment of glucoselike and mannose-like phosphonate (1.171) with catalytic amount of sodium methoxide in
methanol gave deformylated product (1.172) which underwent spontaneous cyclization to
give pyranose analogs (1.173) (Scheme 1.37).27a

Scheme 1.37 Synthesis of cyclic phosphonate analogs of hexopyranoses
Weiler and coworker applied this method towards synthesis of cyclic phosphonate
analogs of ribose and arabinose.27b

1.6. Summary
Cyclophostin (1.1) and cyclipostins (1.4) were isolated from fermentation solutions of
Streptomyces levundale (strain NK901093) and Streptomyces sp. (DSM0138),
respectively. Cyclophostin is a potent inhibitor of AChE whereas members of
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cyclipostins are potent inhibitors of HSL. The bioactivity of cyclophostin and
cyclipostins as well as their novel structural features makes them attractive target for
synthetic studies. Earlier attempts by our group to synthesize the molecule were
unsuccessful which led to exploration of different methods for the synthesis of cyclic
phosphates and phosphonates. Based on the review on methods of the synthesis of cyclic
phosphates, alternative methods of synthesis of the target molecules will be investigated
in this work.
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2. Chapter II
Synthesis of (±)-Cyclophostin and (±)-Cyclipostin P
2.1. Structural features of cyclophostin
As mentioned in the previous chapter, cyclophostin is a small but densely functionalized
molecule. Any synthetic effort towards this molecule must involve a cautious plan to
circumvent the complexity present in the molecule. The most obvious challenge is to
construct the enol-phosphate heterocycle. The previous chapter also described an earlier
effort for the racemic synthesis of the target molecule using a strategy based on the late
synthesis of the enol phosphate bond.
This chapter discusses the successful racemic synthesis of cyclophostin using a different
approach, which involves the early stage synthesis of the enol-phosphate bond followed
by synthesis of the phosphate heterocycle by intramolecular condensation of a phosphoric
acid and an alcohol.
Among the different methods for synthesis of the cyclic phosphates discussed in the last
chapter, two methods, namely, condensation based on the Mitsunobu reaction and the
application of DCC, seemed quite favorable for this purpose. Both the Mitsunobu and
DCC reactions provide mild conditions required for the synthesis of the 7-membered
cyclic enol-phosphate ring.
In general, enol-phosphate bonds are among the most reactive functional groups.1a They
are sensitive towards acidic, basic, and oxidizing conditions. For example, under acidic
conditions, they rearrange to the ketonic precursor whereas under basic conditions, they
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can undergo phosphate-phosphonate rearrangement.1d There are also reported examples
of epoxidation of enol-phosphate bonds. 1b,1c

2.1. Results and discussion
2.1.1. Synthesis of (±)-cyclophostin
The synthesis of (±)-cyclophostin started with protection of the hydroxyl group of
butyrolactone (2.1, Scheme 2.1). The known butyrolactone (2.1) was prepared by using
literature method.2,3,4,5,6 The synthetic plan required a robust, yet easily removable
protecting group which should be compatibile with subsequent planned reaction
conditions. The sensitivity of silicon based protecting groups towards halide ions make
them incompatible with reactions in the planned synthesis. Hence, silicon based
protecting group for alcohol such as tertiary butyl silyl (TBS-) or analogous groups were
not considered.
An alternative method for protection of alcohol uses benzyl (Bn-) protecting group;
however, its removal by hydrogenation can cause side reactions as there are reports of
hydrogenation of enol-phosphate bonds.1a However, the p-methoxy benzyl (PMB) group
can be removed under conditions other than hydrogenation such as oxidative conditions.
The PMB protection of an alcohol can be carried out in two ways: a) using p-methoxy
benzyl chloride or bromide in presence of base like sodium hydride; b) lewis acid
catalyzed protection using p-methoxybenzyl trifluoroacetamide (PMB-TCA).
Since the lactone (2.1) contains acidic α-hydrogens, methods involving a base mediated
protection of the alcohol are obviously incompatible. A good alternative is to use a Lewis
acid mediated protection. Based on this premise, lactone (2.1) was subjected to a copper
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(II) triflate catalyzed reaction with p-methoxybenzyl trifluoroacetimide (PMB-TCA)
(2.2) which successfully gave the corresponding PMB-protected lactone (2.3) in 78%
yield (Scheme 2.1).7

Scheme 2.1 pmb protection of lactone
The initial attempt to install the acetyl group in 2- position of the protected lactone using
acetyl chloride (2.4) and lithium hexamethyldisilazide (LHMDS) as base, led to the
formation of required acetyl lactone (2.5) and its enol acetate (2.6) almost in 1:1 ratio.
After quick screening of different conditions, the best condition for the transformation
was found to be acetylation with acetic anhydride (2.7) using NaHMDS as base, and
maintaining the reaction temperature at -78 oC throughout the reaction (including the
reaction quench). Using this condition, the acetylated lactone (2.5) was obtained in 63 %
yield (Scheme 2.2).8

Scheme 2.2 Acetylation of PMB-protected lactone
Among different methods for the preparation of enol-phosphate bonds,1a the most
straightforward method is the trapping of the enolate anion by phosphorylation. This
method is therefore the most obvious approach for the synthesis of the enol-phosphate
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from acetyl lactone (2.5). The E/Z- selectivity during the enolate formation reaction can
be manipulated by use of base: inorganic vs. organic bases. In the presence of inorganic
bases like sodium hydride (NaH), the Z-enolate is formed primarily leading to formation
of corresponding product with Z- geometry at the enolate bond. On the other hand, the Eenolates are formed predominantly in presence of organic bases like triethyl amine (TEA)
and di-isopropyl ethyl amine (Hünig’s base) (Figure 2.1).9,10a

Figure 2.1 Enolate chemistry of β-keto esters (E- and Z-enol formation methods)
Since the enol-phosphate geometry in the target molecule is of E-orientation, use of
organic bases should produce the required E-enol-phosphate bond. Hence, subsequent
reaction of the acetyl lactone (2.5) with dimethyl chlorophosphate (2.8) in presence of
Hünig’s base exclusively gave E-enol phosphate (2.9) (Scheme 2.3).11

Scheme 2.3 Synthesis of (E)-enol-phosphate
The removal of PMB-ether was achieved by reaction of 2.9 with DDQ in wet CH2Cl2 and
enol-phosphate (2.10) was obtained in 72 % yield (Scheme 2.4).10

Scheme 2.4 Deprotection of the alcohol 2.9
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The demethylation of phosphate diesters can be carried out by using soft nucleophiles
like iodide (I -). Alternatively, the demethylation can be carried out using nucleophilic
organic bases like pyridine or, triethyl amine.11a,12d For this work, demethylation using
sodium iodide was chosen. Hence, the enol-phosphate (2.10) was treated with a
stoichiometric amount of sodium iodide (NaI) in refluxing acetone to give the required
sodium salt in an hour with quantitative yield.

11b

The sodium salt was subsequently

converted to the mono phosphoric acid (2.11) by proton exchange with amberlite resin in
methanolic solution. Both formation of sodium salt and mono phosphoric acid was
followed by 31P NMR and the products were used without further purification (Scheme
2.5).

Scheme 2.5 Synthesis of the phosphoric acid
The mono phosphoric acid (2.11) was subjected to various cyclization reactions. The
cyclization was first attempted with typical Mitsunobu reaction conditions12 using PPh3
(1.5 eq) and DIAD (1.5 eq) in THF at room temperature. Reaction successfully produced
both the natural product (2.12) and unnatural product (2.13) in 1:1.7 ratio, respectively
(Scheme 2.6). However, the purification of the product was complicated by
triphenylphosphine oxide.
Alternatively, DCC mediated intramolecular coupling between monophosphoric acid and
alcohol was employed for the cyclization. Indeed, the reaction successfully produced the
natural product (2.12) and unnatural diastereomer (2.13) in 55 % yield (Scheme 2.6).13
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Scheme 2.6 Synthesis of cyclophostin
The opposite ratio of cyclophostin and its unnatural diastereomer reflects the different
modes of cyclization. Under the Mitsunobu condition, the alcohol is activated and
phosphoric acid acts as the nucleophile while under the DCC condition, the phosphoric
acid is activated and alcohol acts as the nucleophile.
The diastereomers of (±)-cyclophostin (2.12 and 2.13) were separated by column
chromatography. The identity of natural product (2.12) was confirmed by spectroscopic
comparison with reported values and by X-ray crystallographic study (Figure 2.2). The
crystal of (±)-cyclophostin exhibits temperature dependant phase transition without loss
of crystallinity. This particular aspect of cyclophostin is discussed in the following
section.

2.2. X-ray crystallographic study of (±)-cyclophostin
The x-ray quality crystals of natural diastereomer of (±)-cyclophostin (2.12) were
prepared from ethyl actate and hexane solution at room temperature by the slow diffusion
method. Single crystal studies of the two polymorphs were carried out at 296 K and
100K. X-ray analysis revealed that the crystal at 296K belongs to the monoclinic system
with space group P21/c, whereas the crystal at 100 K belongs to the triclinic system with
space group P-1. The crystal structures of cyclophostin at room temperature and at low
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temperature are shown below (Figure 2.2a and b). The monoclinic crystal polymorph is
labeled as “M” while the triclinic is labeled as “T” hereafter. There are two unique
molecules in the triclinic asymmetic cell and they are labeled T1 and T2 hereafter. The
natural (-)-cyclophostin was reported to crystallize in a monoclinic system with a P21
space group.14 A comparison of the crystal structure parameters of crystals of synthetic as
well as the natural cyclophostin is presented below (Table 2.1).

Figure 2.2 Projection view of (±)-cyclophostin (2.12) at 298K (a) and at 100K (b)
The unit cell of the crystal at room temperature contains 4 molecules. The lactone ring is
planar while the phosphate ring assumes a chair conformation. When the crystal packing
is observed along the c-axis shows that two molecules lie close to each other with the
phosphoryl bond (-P(=O)-) oriented in antiparallel fashion. The phosphoryl bond of one
molecule is pointed towards the lactone ring of the second molecule with the closest
intermolecular distance of 3.016 Å between the phosphoryl group and O(2) of the ester
group from the second molecule (Figure 2.3).
c
b

a
Figure 2.3 Crystal packing of (±)-cyclophostin at room temperature (view along c-axis)
42

When the temperature is lowered to 100 K, the crystal undergoes non-destructive phase
transition and changes to the triclinic form and the unit cell contains four molecules with
two unique molecules per asymmetric unit (z’ = 2) (Figure 2.4).
c
b

a

Figure 2.4 Crystal packing of (±)-cyclophostin at 100 K (view along b-axis)
In both cases, the lactone ring is planar while the 7-membered enol-phosphate ring adopts
a chair conformation. Similarly, the methoxy group at the phosphate center is equatorial
and the phosphoryl oxygen is axial. The phosphate center is a distorted tetrahedron.
The nature of packing in the triclinic polymorph is similar to the packing of the crystal
obtained at room temperature. However, the phosphoryl groups of the two unique
molecules are pointing away from each other and the methoxy groups at the phosphorus
center are pointing towards the ester oxygen (O(2)) of the other molecule at a distance of
3.534 Å.
Since the crystal is racemic in nature. the stereochemistry of the molecules in the unit cell
reveals that the monoclinic unit cell is racemic in nature as expected. Therefore, one
molecule has (6R,3aR) stereochemistry while the second molecule has (6S,3aS)
stereochemistry.
The C-H bond lengths and bond angles in both polymorphs vary within ca 1- 2% of each
other. This fact is validated by the molecular overlay using Mercury 2.3 which shows that
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the molecular conformation of the polymorphs remains mostly the same. Molecule T1 fits
better with polymorph M than molecule T2.
Table 2.1 Physical properties of X-ray crystal of cyclophostin (observed vs. reported14)
Parameters

M

T

(-)-cyclophostin

Temperature

296(2) K

100 (2) K

293 K

Crystal system

Monoclinic

Triclinic

monoclinic

Space group

P21/c

P-1

P21

a = 9.4378(6) Å

a = 8.9222(6)Å

a = 9.821(1) Å

b = 12.8490(8)Å

b = 6.0420(7)Å

b = 5.988(0.6)Å

c = 9.1927 (6)Å

c = 12.5071(9)Å

c = 9.8.681 (1)Å

 = 90 °

= 88.813°

 = 90 °

 112.609(3) °

= 83.234 (3)°

 103.14(1) °

90°

γ = 79.477(3)°

90°

Volume

1029.07 (11) Å3

985.13(12) Å3

429.11(9) Å3

Density

1.511 Mg/m3

1.579 Mg/m3

1.554 g/cm3

Absorption
Coefficient

0.274 mm-1

0.286 mm-1

24.38 cm-1

Crystal Size (mm3)

0.45 x 0.33 x0.17

0.33 x 0.28 x 0.21

0.23 x 0.30 x 0.45

Unit cell dimensions

The bond angle differences between structures are less in the case of polymorph M and
T1 than between M with T2 which is apparent in wireframe structure overlay of the
molecules. Selected bond lengths are tabulated below (Table 2.2).
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Table 2.2 Bond length comparison of polymorphs
Bond
P(1)- O(5)

Polymorph M
[Å]
1.445(3)

Polymorph T1
[Å]
1.4578(6)

Polymorph T2
[Å]
1.4598(6)

O(3)- C(5)

1.413(4)

1.3981(9)

1.3977(9)

O(4)- C(6)

1.457(4)

1.4539(9)

1.4507(10)

C(5)- C(2)

1.312(5)

1.3384(10)

1.3374(10)

C(3)- C(6)

1.493(5)

1.5178(10)

1.5178(11)

C(4)- O(2)

1.437(5)

1.4464(10)

1.4439(12)

The bond angles in both polymorphs are a close match to each other within the limit of
experimental error. There are, however, some subtle differences among them. The bond
lengths showing some differences are tabulated below (Table 2.3). The difference in P-O
bond lengths in both polymorphs reveals some role of the exo-anomeric effect.15
The molecular overlay of the two unique molecules in the unit cell of the low temperature
crystal system reveals that there is not much difference in the puckering of the ring
system. However, the phosphate center exhibits some difference in the torsional angle of
the methoxy group.
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Table 2.3 Bond angle comparison of polymorphs
Bond Angle
O(5)-P(1)-O(6)

Polymorph
M[°]
113.30 (19)

Polymorph
T1[°]
113.74(4)

Polymorph
T2[°]
113.86(4)

O(5)-P(1)-O(4)

116.33(19)

116.41(3)

116.32(4)

O(5)-P(1)-O(3)

112.78(17)

112.79(3)

113.02(4)

O(6)-P(1)-O(4)

103.57(16)

103.48(3)

103.33(3)

O(6)-P(1)-O(3)

103.11(15)

102.86(3)

102.42(3)

O(3)-P(1)-O(4)

106.49(15)

106.23(3)

106.50(3)

C(5)-O(3)-P(1)

120.2(2)

120.92(5)

122.32(5)

C(2)-C(5)-O(3)

118.7(3)

119.01(3)

119.05(6)

C(2)-C(5)-C(8)

129.6(3)

128.64(7)

128.84(7)

C(2)-C(3)-C(6)

115.8(3)

114.8(6)

115.33(6)

C(2)-C(3)-C(4)

102.8(3)

102.83(6)

102.48(6)

C(5)-C(2)-C(3)

127.2(3)

126.98(6)

127.12(7)

C(5)-C(2)-C(1)

124.2(3)

124.42(6)

124.17(7)

C(1)-O(2)-C(4)

112.3(3)

112.10(6)

111.67(6)

O(1)-C(1)-O(2)

121.2(4)

120.89(7)

120.89(7)

O(1)-C(1)-C(2)

130.3(4)

130.18(7)

130.54(8)

C(2)-C(1)-O(2)

108.5(3)

108.85(6)

108.48(7)

C(6)-C(3)-C(4)

110.7(3)

110.98(6)

109.70(6)

C(6)-O(4)-P(1)

120.3(3)

120.58(5)

120.00(5)

C(3)-C(6)-O(4)

111.4(3)

110.22(6)

110.57(6)

O(3)-C(5)-C(8)

111.7(3)

112.34(6)

112.09(6)

C(7)-O(6)-P(1)

122.2(2)

121.51(5)

121.39(5)
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a

b

Figure 2.5 Overlay of molecules: (a) monoclinic polymorph vs. triclinic polymorph (T1)
and (b) two unique molecules (T1 and T2) of triclinic polymorph
The shortest distance between the molecules in the unit cell of the monoclinic polymorph
is 4.298 Å whereas that in between molecules in the triclinic unit cell is 3.432 Å. It is
possible that as the temperature decreases the volume of the crystal “shrinks”. To avoid
the unfavorable intermolecular interactions, the unit cells change their orientation leading
to a new crystal system.
The original report by Kurokawa and coworkers reveals a completely different
conformation of (-)-cyclophostin.14 The phosphate ring has a twist boat configuration
with the methoxy group being axial and the phosphoryl group in an equatorial
orientation. Also, the lactone ring has a slightly twisted envelop conformation.

Figure 2.6 Packing of (-)-cyclophostin (kurokawa & coworkers)14
Molecular overlay of the monoclinic crystal with the original crystal structure reveals the
obvious difference in the conformation of the molecule (Figure 2.7).
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Figure 2.7 Molecular overlay of monoclinic polymorphs of cyclophostin: observed vs.
reported
The monoclinic polymorph crystal has a 2-fold screw axis along the b-axis, and a glide
plane perpendicular to the b-axis with glide component [0, 0, 1/2]. However, the crystal
in the triclinic system possesses only identity and inversion symmetry. The molecule was
reported to have identity symmetry along with a 2-fold screw axis along the b-axis at (x,1/2+y,-z) with direction [0, 1, 0] at 0, y, 0 and screw component [0, 1/2, 0]. A
comparison of symmetry operations of the racemic crystal of cyclophostin along with that
from the original report is listed below (Table 2.4).
The monoclinic polymorph crystal has a 2-fold screw axis along the b-axis, and a glide
plane perpendicular to the b-axis with glide component [0, 0, 1/2]. However, the crystal
in the triclinic system possesses only identity and inversion symmetry. The molecule was
reported to have identity symmetry along with a 2-fold screw axis along the b-axis at (x,1/2+y,-z) with direction [0, 1, 0] at 0, y, 0 and screw component [0, 1/2, 0]. A
comparison of symmetry operations of the racemic crystal of cyclophostin along with that
from the original report is listed below (Table 2.4).

48

Table 2.4 Symmetry operations in cyclophostin polymorphs
Crystal

Symmetry

description

Order type

Identity

1

1

"Screw axis (2-fold)"

2

2

operation
Monoclinic

x,y,z

-x,1/2+y,1/2-z

"2-fold screw axis with direction [0, 1,
0] at 0, y, 1/4 with screw component
[0, 1/2, 0]"

-x,-y,-z

Inversion centre (Inversion at [0, 0, 0])

2

-1

x,1/2-y,1/2+z

"Glide plane"

2

-2

"Glide plane perpendicular to [0, 1, 0]
with glide component [0, 0, 1/2]"
Triclinic

x,y,z

Identity

1

1

-x,-y,-z

Inversion centre

2

-1

"Inversion at [0, 0, 0]"
(-)-cyclophostin

x,y,z

Identity

1

1

(monoclinic)14

-x,1/2+y,-z

Screw axis (2-fold) (2-fold screw axis 2

2

with direction [0, 1, 0] at 0, y, 0 with
screw component [0, 1/2, 0])

2.3. Transesterification of phosphate esters and synthesis of (±)cyclipostin P from (±)-cyclophostin
Cyclipostins and cyclophostin differ from each other by having different alkyl group at
the phosphate center. In essence, cyclipostins can be synthesized by exchanging the
methyl group with corresponding long lipophilic alkyl group(s). Such transformations
could be carried out by condensation of the activated phosphoric acid of cyclophostin

49

with the corresponding alcohol. Such a transformation involves at least 2 steps and
proceeds through some reactive/unstable intermediates.
There are alternative methods for this type of transformation. A brief revision of relevant
works is presented which reveals that such transformations are possible given the
structural complexity of the substrate allows.
Laughlin studied the reaction of phosphonates and phosphates with suitable alkylating
agents to give the mixed esters of phosphonic and phosphoric acids. The reaction was
carried out in forcing conditions which involved heating the reaction mixture at 200 or
220 oC for up to 20 hours in a solvent free condition and the mixed esters were produced
in moderate yield (35 - 58 %) (Scheme 2.7).16

Scheme 2.7 Transesterification of phosphonate esters
Trialkyl phosphate (2.17) underwent a similar tranesterification reaction to give
corresponding mixed phosphate esters after heating at 220 oC for 16 - 18 hours (Scheme
2.8).16

Scheme 2.8 Transesterification of phosphate esters
Similarly, the Michaelis-Arbuzov reaction of trialkyl phosphite (ethyl and methyl) with
alkylating agents also produced the mixed esters of phosphonic acids under the above
conditions (Scheme 2.9).16
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Scheme 2.9 Transesterification of trialkyl phosphites
The general reactivity of alkyl halides towards this reaction follows the trend of general
nucleophilic reactions: R-I > R-Br > R- Cl. Corresponding tosylate underwent pyrolytic
elimination of p-toluene sulfonic acid, producing corresponding terminal olefin.
According to the proposed mechanism, the reaction proceeds through initial alkylation of
the phosphoryl oxygen forming phosphonium salt (2.22). Then, the bromide ion removes
alkyl group to give the transesterified product (2.18) (Scheme 2.10).16

Scheme 2.10 Proposed mechanism of transesterification of phosphate/phosphonate
esters
Blackburn and coworkers reported a “mild and selective” method for dealkylation of
phosphate and phosphonate esters using iodotrimethyl silane (2.24). These silyl ester
products, on contact with water, are converted to the corresponding phosphoric and
phosphonic acid (eg. 2.29) (Scheme 2.11).17

Scheme 2.11 Dealkylation of phosphate and phosphonate by TMS-iodide
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Ogilvie and coworkers described a method of transesterification for synthesis of mixed
trialkyl phosphates using cesium fluoride. When the phosphate diester with an activated
alkyl group (eg. –CH2CCl3) (2.30) was treated with alcohol as solvent in presence of
excess CsF (10 -15 eq) at room temperature, the mono transesterification product (2.32)
was obtained in excellent yield. The second transesterification required refluxing
conditions with the desired alcohol to get non symmetrical phosphate (2.33) (Scheme
2.12).18

Scheme 2.12 Fluoride based transesterification of phosphates
Using this method, Ogilvie and cowokers were successful to synthesize of cyclic
phosphates from diols. For example, phosphate 2.35 was converted to cyclic phosphate
(2.37) in 95 % yield. The cyclic phosphate was further treated with 10 equivalents of CsF
and various alcohols and heated at 80 oC for 2 days to get corresponding transesterified
phosphate in quantitative yield (Scheme 2.13).18

Scheme 2.13 Synthesis of cyclic phosphates by fluoride based transesterification
Modro and coworkers described titanium alkoxide (2.40) mediated transesterification of
dialkyl phosphites (2.38). The reaction between dialkyl phosphite and various alcohols in
presence of different alkoxides of titanium gave diesterified phosphite in moderate to
good yield. However, the reaction was inert towards trialkyl phosphites, phosphates and
dialkyl phosphonates (Scheme 2.14).19
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Scheme 2.14 Titanium alkoxide mediated transesterifcation of phosphites
Polozov and coworkers reported reaction of diazoacetates with trialkyl phosphate and
thiophosphate triester to get the corresponding O-alkoxycarbonyl, or S-alkoxycarbonyl
methyl phosphates thorough zwitterionic intermediate(s) (2.46). Intermediacy of
zwitterions (2.45) was confirmed by deuterium labeling (Scheme 2.15).20

Scheme 2.15 Transesterification and diazoacetates
Recently, Nolan and coworkers reported a transesterification of phosphonate esters by Nheterocyclic carbenes (NHC). Dimethyl methyl phosphonate (2.47) was reacted with
benzyl alcohol (2.55) in presence of different N-heterocyclic carbenes (2.49, 5 mol%) to
give the transesterfied product (2.50) in various yields and ratios of mono- to dibenzyl
ester (2.51). It was reported that longer reaction times, higher equivalences of alcohol and
higher temperature led to better conversion, but the selectivity between mono and
diesterified products is compromised (Scheme 2.16).20

Scheme 2.16 N-heterocyclic carbene catalysed transesterification of phosphonates
Keillor and coworkers have reported transesterification of trialkyl phosphates with alkyl
bromides. It was shown that trialkyl phosphates (2.48) on treatment with different alkyl
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bromides (2.53) and a substoichiometric amount of lithium bromide (2.55), undergo
facile transesterification to give mixed phosphate esters (2.56 & 2.57) with mono
substituted phosphate always being the major product (Scheme 2.17).21

Scheme 2.17 Tranesterification of trialkyl phosphates using lithium bromide
According to the suggested mechanism, the reaction proceeds through formation of
phosphate anion (2.53) which attack alkyl bromide (2.53) to give the alkylated product
(2.56) releasing back the bromide ion (Scheme 2.18).20

Scheme 2.18 Suggested mechanism for transesterification
Based on the above reports, it can be concluded that the tranesterification of phosphate
and phosphonate were successful using a) dealkylating agents to generate the phosphate
and phosphonate ion b) the nucleophilicity of phosphate or, phosphonate oxyanion; c)
alkyl bromide as alkylating agent; d) higher reaction temperature.
It was thought that the process could be made catalytic in nature by exploiting the the
nucleophilicity of iodide and using alkyl bromide as alkylating agent. Iodide ion can
dealkylate phosphate diesters forming alkyl iodide. The resulting phosphate ion can be
alkylated by alkyl bromide. So, the plan for a new and better method for
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transesterification includes conditions that use a catalytic amount of iodide, excess alkyl
bromide, and heat (Figure 2.8).

Figure 2.8 Planned catalytic transesterification of phosphates
Based on this plan, the synthesis of (±)-cyclipostin P (2.69) the second most potent
member of the cyclipostins family, was carried out by one pot transesterification of
cyclophostin (2.12) or its unnatural distereomer (2.13) catalyzed by tetra n-butyl
ammonium iodide (TBAI).
Initially, the synthesis of (±)-cyclipostin P was attempted with the unnatural diastereomer
of (±)-cyclophostin and 2 equivalent of hexadecanyl bromide (2.68) in presence of 5
mol% TBAI in toluene at 90

o

C. This reaction led mainly to epimerization of

cyclophostin and little product formation (ca 10%). The spectroscopic analysis of the
new product suggested the formation of desired product, (±)-cyclipostin P and its
diastereomer, with the cyclophostin ring remaining intact. The isomerization between
cyclophostin diastereomers suggested that the reaction might proceed through the mono
anion of the phosphate which could be formed by demethylation of the (±)-cyclophostin
phosphate ester (Scheme 2.19). The alkylation of the phosphate ion could happen at
either oxygen, a case similar to the reactivity of carboxylate anions.
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Scheme 2.19 Formation of phosphate anion
The isomerization also suggested the existence of competition between the alkylating
power of methyl iodide (MeI, 2.63) formed in situ and hexadecanyl bromide (2.68). Since
alkyl iodides are better alkylating agent as compared to alkyl bromide, the rate of
alkylation by methyl iodide seemed faster than that of the intended bromide (Scheme
2.20).

Scheme 2.20 Possible competitive alkylation
It was planned to force the competition towards the desired transesterification by using an
excess of the alkyl bromide and raising the temperature. The reaction with 4 equivalents
of the bromide at 100 oC in toluene also resulted mostly epimerization of cyclophostin
along with very little formation of the desired product.
Next, the solvent was switched to 1,4-dioxane. The switching of solvent had a dramatic
effect on the reaction. The starting material was consumed almost completely, and the
product formation was observed after 10 hours of refluxing at 100 oC.
Finally, when the unnatural diastereomer of (±)-cyclophostin was refluxed with 10
equivalents of hexadecanyl bromide (2.68) in 1, 4-dioxane solution at 110 oC, (±)cyclipostin P (2.69) along with its unnatural diastereomer (2.70), was obtained in 1:1
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mixture in combined 77% isolated yield (Scheme 2.21). The individual diastereomer
were successfully separated by using column chromatography.

Scheme 2.21 Synthesis of (±)-cyclipostin P from (±)-cyclophostin
As a follow up of the reaction, a 31P NMR study of this reaction was carried out. Hence,
the natural (±)-cyclipostin P (2.69) was treated with excess hexadecyl bromide (2.68) in
presence of TBAI in the above mentioned reaction conditions. After 5.5 hours, the
reaction yielded a 1:1 mixture of both natural and unnatural diastereomers (2.69 & 2.70)
(Scheme 2.22).

Scheme 2.22 Equilibration among diastereomers of (±)-cyclipostin P
On the other hand, when the unnatural distereomer of (±)-cyclipostin P (2.70) was
refluxed with hexadecyl bromide (2.68) in absence of TBAI, there was no equilibration
between the two diastereomers of (±)-cyclipostin P. However, after the addition of TBAI,
the reaction indeed went to such equilibration. This set of experiments shows the role
played by TBAI and validated the fact that the reaction goes through formation of
phosphate anion (2.67b and 2.67c) (Scheme 2.23).
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Scheme 2.23 Role of TBAI in equilibration between diastereomers of (±)-cyclipostin P
The success of the above transesterification reaction of cyclophostin demonstrated not
only the efficiency of the reaction itself but also provided the required bridge from
cyclophostin to the cyclipostins.

2.4. Biological testing of cyclophostin and cyclipostin P against serine
hydrolases.
Cyclophostin was tested for their ability to inhibit AChE, Human Pancreatic lipases
(rHPL), Dog Gastric Lipases (rDGL), Guinea Pig Lipase related protein 2(GPLRP2),
cutinase from Fusarium solani pist and Rv0183 from Mycobacterium tuberculosis.
No significant inhibition was observed with rHPL, rDGL and DPLRP2.

However,

cutinase and Rv0183 were inhibited by cyclophostin. For cutinase, the IC 50 value was
found to be 4 μM. While for Rv0183, the IC50 value was found to be 162μM.
Cyclophostin and its unnatural diastereomer were found to be strong inhibitors of AChE
with IC50 values of 39 nM and 45 nM respectively.
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2.5. Summary
The first total synthesis of racemic (±)-cyclophostin has been accomplished. The
synthesis also provided the unnatural diastereomer of cyclophostin. Cyclophostin
exhibited temperature dependant phase transition in the solid state which is believed to be
the result of the unit cell trying to adjust itself with increasing density of the crystal at
low temperature. The biological assay of cyclophostin and its unnatural diastereomer
revealed its high potency against human acetyl cholinesterase and other serine
hydrolases.
The synthesis of cyclipostin P and its unnatural diastereomer from cyclophostin was
accomplished by using a novel one-pot method of transesterification of phosphates. This
method provides a synthetically useful tool to synthesize other cyclipostins from
cyclophostin.
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2.6. General Experimental
General Experimental Procedures
All experiments were carried out in oven-dried glassware under Argon atmosphere unless
otherwise mentioned. 1H,

13

C and

31

P NMR were taken in Bruker Avance ARX-300

NMR spectrometer at 300, 75 and 121 MHz respectively. Tetramethylsilane (TMS, δ =
0.00) or chloroform-D (CDCl3, δ = 7.27 ppm for 1H NMR and 77.23 ppm in 13C NMR) or
methanol-D4 (δ = 4.78 ppm for 1H NMR and 49.23 ppm for

13

C NMR) were used as

internal reference. Phosphoric acid (H3PO4, 85%) was used as external reference for

31

P

NMR. High resolution mass spectral analyses were carried out on a JEOL MStationJMS700 spectrometer. X-ray crystallographic studies were carried out in Bruker Apex- II
CCD single crystal diffractometer.

(4-(((4-methoxybenxyl)oxy)methyl)dihydrofuran-2-(3H)-one (2.3). To a solution of
2.1 (1.3 g, 11.28 mmol) and PMB-TCA (2.2) (3.52 mL, 16.92 mmol) in dry toluene (220
mL) was added copper (II) triflate (0.204 g, 0.564 mmol) in single batch at room
temperature. The resulting mixture was stirred at room temperature. After completion of
the reaction (TLC analysis), solvent was removed under reduced pressure and the crude
product was purified by column chromatography (SiO2, 10 - 20% EtOAc in hexanes) to
give 2.3 (2.17 g, 81%) as pale yellow oil. IR (neat, NaCl) 1778, 1612, 1514 cm-1; 1H
NMR (CDCl3) δ 7.17 (2H, m), 6.82 (2H, m), 4.38 (2H, s), 4.32 (1H, dd, JHH = 7.5, 9.2
Hz), 4.1 (1H, dd, JHH = 5.5, 9.2 Hz), 3.74 (3H, s), 3.37 (2H, m), 2.72 (1H, m), 2.53 (1H,
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dd, JHH = 8.9, 17.7 Hz), 2.29 (1H, dd, JHH = 6.3, 17.7 Hz);

13

C NMR (CDCl3) δ 177.3,

159.8, 130.1, 129.8, 114.3, 73.4, 71.2, 70.5, 55.7, 35.8, 31.6; HRMS (FAB, NBA, MNa+)
calcd. for C13H16O4Na 259.0946, found 259.0952.

3-acetyl-4-(((4-methoxybenxyl)oxy)methyl)dihydrofuran-2(3H)-one

(2.5).

To

a

solution of 2.3 (0.437 g, 1.85 mmol) in dry THF (14 mL) at -78 oC was added NaHMDS
(3.7 mL, 3.7 mmol, 1M solution in THF) dropwise. After 10 minutes, acetic anhydride
(2.7) (0.57 mL, 5.55 mmol) was added dropwise. The resulting mixture was stirred at -78
o

C for 4 hours. After completion of the reaction (TLC analysis), the reaction was

quenched by addition of saturated aqueous NH4Cl (10 mL) -78 oC. The resulting mixture
was partitioned between Et2O and water (50 mL). The organic layer was separated and
the aqueous phase was re-extracted with EtOAc (20 mL  3). The collected organic
phases were dried over anhydrous Na2SO4. Solvent was removed under reduced pressure
and the crude product was purified by column chromatography (SiO2, 5 - 10% EtOAc in
hexanes) to get 2.5 (0.32 g, 61%) as pale yellow oil. IR (neat, NaCl) 1778, 1718, 1611,
1513 cm-1; 1H NMR (CDCl3) δ 7.17 (2H, m), 6.82 (2H, m), 4.38 (2H, s), 4.32 (1H, dd,
JHH = 7.5, 9.2 Hz), 4.09 (1H, dd, JHH = 5.5, 9.2 Hz), 3.74 (3H, s), 3.37 (2H, m), 2.72 (1H,
m), 2.53 (1H,dd, JHH = 8.9, 17.7 Hz), 2.29 (1H, dd, JHH = 6.3, 17.7 Hz);

13

C NMR

(CDCl3) δ 200.3, 172.3, 159.7, 129.7, 129.6, 114.2, 73.2, 69.5, 68.4, 56.0, 55.5, 37.4,
29.9; HRMS (FAB, NBA, MNa+) calcd. for C15H18O5Na 301.1052, found 301.1049.
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(E)-1-(4-(((4-methoxybenxyl)oxy)methyl-2-oxodihydrofuran-3-(2H)-ylidene)-ethyl
dimethyl phosphate (2.9). To a solution of 2.5 (0.06 g, 0.22 mmol) in CH2Cl2 (0.6 mL)
was added Hunig’s base (0.19 mL, 1.08 mmol) at room temperature, stirred for 5 minutes
and taken to ice bath. To the solution was added dimethyl chlorophosphate (2.8) (0.04
mL, 0.33 mmol) dropwise at 0 oC and the resulting mixture was slowly let come to room
temperature. After completion of the reaction (TLC and

31

P NMR analysis), aliquot was

diluted with CH2Cl2 and treated with saturated aqueous NH4Cl solution. Organic layer
was collected and the aqueous phase was re-extracted with EtOAc. The combined
organic phases were dried over anhydrous Na2SO4. The solvent was removed under
reduced pressure and crude product was purified by column chromatography (SiO2, 20 30% EtOAc in hexanes) to give pure 2.9 (0.06 g, 71%) as oil. IR (neat, NaCl) 1752,
1683, 1612, 1514 cm-1; 1H NMR (CDCl3) δ 7.22 (2H, m), 6.89 (2H, m), 4.45 (d, JHH =
1.3Hz), 4.31(2H, m), 3.82 (3H, d, JHP = 11.5 Hz), 3.8 (3H, s), 3.8 (3H, d, JHP =11.5 Hz),
3.62 (1H, dd, JHH = 3.5, 8.7 Hz), 3.54 (1H, m), 3.37 (1H, t, JHH = 8.7 Hz), 2.55 (3H, t, JHH
= 1.5 Hz); 13C NMR (CDCl3) δ 170.5, 159.6, 158.9 (d, JCP = 6.2 Hz), 130, 129.6, 114.1,
112.2 (d, JCP = 10 Hz), 73.1, 69.6, 68.4, 55.5, 55.2 (d, JCP = 6.3 Hz), 55.2 (d, JCP = 6.3
Hz), 39, 16.8;

31

P NMR (CDCl3) δ - 4.88; HRMS (FAB, NBA, MNa+) calcd. for

C17H23O8PNa 409.1028, found 409.1024.
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(E)-1-(4-(hydroxymethyl)-2-oxodihydrofuran-3(2H)-ylidene)ethyl

dimethyl

phosphate (2.10). To a stirring solution of 2.9 (0.94 g, 2.43 mmol) in wet CH2Cl2 (44
mL) at 0 oC was added DDQ (0.66 g, 2.91 mmol, 1.2 equivalents) in a single batch. The
reaction mixture was stirred at this temperature. After completion of the reaction (TLC
and

31

P NMR analysis), aliquot was diluted with CH2Cl2 (15 mL) and 10% Na2SO3 (10

mL) was added. Organic layer was separated and aqueous phase was re-extracted with
additional CH2Cl2. Combined organic phases were treated with saturated NaHCO3 (25
mL) and dried over anhydrous Na2SO4. Solvent was removed under reduced pressure and
crude product was purified by column chromatography (SiO2, 40 - 50% EtOAc in
hexanes) to give 2.10 (0.47 g, 75%) as pale yellow liquid. IR (neat, NaCl) 3426, 1751,
1684 cm-1; 1H NMR (CDCl3) δ 4.32 (2H, m), 3.88 (6H, d, JHP = 11.5 Hz), 3.62 (1H, dd,
JHH = 3.47, 8.66 Hz), 3.78 (1H, m), 3.68 (1H, m), 3.48 (1H, m), 2.55 (3H, t, JHH = 1.55
Hz);

13

C NMR (CDCl3) δ 170.6, 158.9 (d, JCP = 6.5 Hz), 112.6 (d, JCP = 9.8 Hz), 68.1,

62.8, 55.4 (d, JCP = 1.3), 55.3 (d, JCP = 1.5), 41.1, 16.9; 31P NMR (CDCl3) δ - 4.6; HRMS
(FAB, NBA, MH+) calcd. for C9H16O7P: 267.0633, found 267.0644.

Sodium Salt of the enol phosphate. To the solution of 2.10 (0.027 g, 0.1 mmol) in dry
acetone (0.4 mL), sodium iodide (0.017 g, 0.11 mmol) was added and stirred at room
temperature for 5 minutes. Then, the septum was replaced with a condenser connected to
an argon bubbler. The flask was immersed in an oil bath preheated to 40 oC. After
completion of the reaction (31P NMR analysis), solvent was removed under reduced
pressure to give sodium salt (0.03 g, 100%) as white solid. The salt was used without
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further purification. 1H NMR (CD3OD) δ 4.25 (2H, m), 3.73 (1H, dd, JHH = 3.6, 12.2 Hz),
3.63 (3H, d, JHP = 11.3 Hz), 3.55 (2H, dd, JHH = 7.6, 10.6 Hz), 3.41 (1H, br s), 2.5 (3H, s);
13

C NMR (CD3OD) δ 174.8, 164.5 (d, JCP = 5.1 Hz), 109.9 (d, JCP = 9.1 Hz), 69.9, 63.6,

54.3 (d, JCP = 6.5 Hz), 42.7, 17.4; 31P NMR (CD3OD) δ - 4.18.

(E)-1-(4-(hydroxymethyl)-2-oxodihydrofuran-3-(2H)-ylidene)ethyl methyl hydrogen
phosphate (2.11). To the solution of sodium salt (0.03 g) in dry methanol (1 mL) was
added Amberlite resin IR120® (0.07 g, prewashed with dry methanol) and the resulting
mixture was shaken in an Orbit® shaker at room temperature. After completion of the
reaction (31PNMR analysis), resin was filtered off and further washed with additional
methanol. Solvent was removed under reduced pressure to give 2.11 (0.03 g, 100%) as
orange viscous liquid. 1H NMR (CD3OD) δ 4.12 (2H, m), 3.63 (3H, d, JHP = 11.58 Hz),
3.55 (1H, dd, JHH = 3.82, 10.76 Hz), 3.39 (1H, dd, JHH = 7.32, 10.74 Hz), 3.26 (1H, br s),
2.34 (3H, t, JHH = 1.4 Hz); 13C NMR (CD3OD) δ 173.4, 161.1 (d, JCP = 6.2 Hz), 113.5 (d,
JCP = 9.7 Hz), 69.8, 63.3, 55.6 (d, JCP = 6.4 Hz), 42.6, 17.2; 31P NMR (CD3OD) δ – 5.66.
Cyclophostin (2.12) and its unnatural diastereomer (2.13)
a) Mitsunobu reaction condition: To a solution of 2.11 (0.03 g, 0.11 mmol) in dry
THF (0.6 mL) was added ground and activated 4Å molecular sieve (40 mg) and
stirred for 5 mins. Then, PPh3 (0.05 g, 0.17 mmol) was added followed by DIAD
(0.04 mL, 0.17 mmol) at room temperature. After completion of the reaction (TLC
and

31

P NMR analysis), solvent was removed under reduced pressure and the crude
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product was subjected to reverse phase column chromatography (C18-silica gel, 60%
H2O in CH3OH) to give the mixture of diastereomers which was further subject to
normal column chromatography (SiO2, 20 - 40% EtOAc in hexanes) to give
individual products.
b) DCC coupling: To the solution of 2.11 (0.02 g, 0.1 mmol) in CH2Cl2 (0.5 mL) was
added ground and activated 4Å molecular sieve (40 mg) and stirred for 5 mins. Then,
DCC (0.05 g, 0.25 mmol) was added followed by DMAP (0.001 g, 0.01 mmol) at
room temperature. After completion of the reaction (TLC and

31

P NMR analysis),

solvent was removed under reduced pressure and the resulting mass was washed with
cold acetonitrile and DCC urea was filtered out. Purification of the crude product
from acetonitrile wash by column chromatography (SiO2, 20 - 50% EtOAc in
hexanes) gave 2.12 (0.007gm), its unnatural diastereomer (2.13) (0.006 g) in 55%
yield. The diastereomers of (±)-cyclophostin were separated by repeated column
chromatography (SiO2, 20 - 50% EtOAc in hexanes).

Cyclophostin

{(3R,8aR)-3-methoxy-5-methyl—8,8a-dihydrofuro[3,4-e]

[1,3,2)

dioxaphosphepin-6(1H)-one 3-oxide} (2.12). IR (neat, NaCl) 1747, 1682 cm-1; 1H NMR
(CDCl3) δ 4.46 (1H, m), 4.34 (1H, dt, JHH = 4.5, 10.7 Hz), 4.16 (1H, m), 3.96 (3H, d, JHP
=11.5 Hz), 3.8 (2H, m), 2.48 (3H, d, JHH = 2.1 Hz); 13C NMR (CDCl3) δ 169 (d, JCP = 1.6
Hz), 161.6 (d, JCP = 7.7 Hz), 113.2 (d, JCP = 3.3 Hz), 67.7 (d, JCP = 5.6 Hz), 64.3, 56.0 (d,

65

JCP = 6 Hz), 39.8, 18.3 (d, JCP = 4.8 Hz); 31P NMR (CDCl3) δ – 7.68; HRMS (FAB, NBA,
MH+) calcd. for C8H12O6P: 234.0371, found 235.0377.

(3R,8aS)-3-methoxy-5-methyl-8,8a-dihydrofuro[3,4-e][1,3,2]dioxaphosphepin-6(1H)one 3-oxide (2.13). IR (neat, NaCl) 1751, 1676 cm-1; 1H NMR (CDCl3) δ 4.46 (1H, t, JHH
= 9.3Hz ), 4.31 (1H, ddd, JHH = 2.6, 9.8 Hz, JHP = 21 Hz), 4.00 (1H,m), 3.91 (3H, d, JHP
=11.5 Hz), 3.8 (1H, dd, JHH = 5.7, 9.6 Hz), 2.45 (3H, d, JHH = 2 Hz); 13C NMR (CDCl3) δ
169.1, 161.5(d, JCP = 10.5 Hz), 111.2, 69.6 (d, JCP = 7.5 Hz), 64.6, 55.5 (d, JCP = 6 Hz),
38.7, 18 (d, JCP = 5.8 Hz); 31P NMR (CDCl3) δ – 11.52; HRMS (FAB, NBA, MH+) calcd.
for C8H12O6P: 257.0191, found 257.0192.
Synthesis of Cyclipostin P and its unnatural diastereomer (2.69 & 2.70): To a
solution of the unnatural diastereomer of (±)-cyclophostin (2.13) (31P NMR  - 11.6
ppm) (0.012 g, 0.05 mmol) and 1-bromohexadecane (0.16 g, 0.51mmol) in dry dioxane
(0.2mL) was added TBAI (0.003 mmol, 0.001 g, 5 mol%) at room temperature. After
stirring the mixture for 1 min at room temperature, the septum was quickly replaced by a
reflux condenser attached to argon bubbler. Then, the assembly was taken to an oil bath
preheated at 110 oC and continued to reflux. After completion of the reaction (TLC and
31

P NMR analysis), solvent was removed under reduced pressure and the crude product

was taken to column chromatography (SiO2, 10 – 30% EtOAc in hexanes) to give 1:1
mixture of (±)-cyclipostin P (2.69) and its unnatural diastereomer (2.70) (0.018 g, 85 %)
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which were further separated by repeated column chromatography (SiO2, 10 – 30%
EtOAc in hexanes).

Cyclipostin

P

[(3R,8aR)-3-(hexadecyloxy)-5-methyl-8,8a-dihydrofuro[3,4-

e][1,3,2]dioxa-phosphepin-6(1H)-one 3-oxide] (2.69). IR (neat, NaCl) 2916, 2849,
1747, 1668 cm-1; 1H NMR (CDCl3) δ 4.45 (1H, m), 4.34 (1H, m), 4.24 (2H, m), 4.13
(1H, m), 3.79 (1H, m), 2.47 (3H, d, JHH = 1.95 Hz), 1.74 (2H, p, JHH = 6.78 Hz ), 1.39
(2H, m), 1.26 (24H, br s) 0.87 (3H, t, JHH = 6.73 Hz); 13C NMR (CDCl3) δ 169.12, 161.76
(d, JCP = 7.76 Hz), 112.10 (d, JCP = 3.30 Hz), 70.36 (d, JCP = 6.14 Hz), 67.57 (d, JCP =
5.70 Hz), 64.36, 39.87, 32.14, 30.33 (d, JCP = 6.52 Hz ), 29.90, 29.88, 29.84, 29.76,
29.58, 29.26, 25.46, 22.91, 18.38 (d, JCP = 4.81 Hz), 14.35; 31P NMR (CDCl3) δ – 8.58;
HRMS (FAB, NBA, MH+) calcd. for C23H42O6P: 445.2718, found 445.2723.

Unnatural Cyclipostin P [(3R,8aS)-3-(hexadecyloxy)-5-methyl-8,8a-dihydrofuro[3,4e][1,3,2]dioxaphosphepin-6(1H)-one 3-oxide] (2.70). IR (neat, NaCl) 2958, 2917, 2849,
1747, 1667 cm-1; 1H NMR (CDCl3) δ 4.46 (1H, t, 9.30 Hz), 4.31 (1H, m), 4.18 (2H, m),
4.08 (2H, m), 3.79 (1H, dd, JHH = 9.54, 5.7 Hz), 2.45 (3H, d, JHH = 1.77 Hz), 1.73 (2H,
p, JHH = 6.78 Hz), 1.33 (2H, m), 1.27 (24H, br s) 0.89 (3H, t, JHH = 6.69 Hz); 13C NMR
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(CDCl3) δ 169.27, 161.58 (d, JCP = 10.47 Hz), 110.98 (d, JCP = 2.71 Hz), 69.82 (d, JCP =
6.24 Hz), 69.53(d, JCP = 7.50 Hz), 64.70, 39.63, 32.14, 30.38 (d, JCP = 6.49), 29.90,
29.87, 29.83, 29.75, 29.66, 29.58, 29.27, 25.50, 22.91, 18.06 (d, JCP = 5.86 Hz), 14.34;
31

P NMR (CDCl3) δ – 12.39; HRMS (FAB, MNa+) calcd. for C23H41O6PNa: 467.2538,

found 467.2528.
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3. Chapter III
Synthesis of Monocyclic Phosphonate Analogs of Cyclophostin
and the Cyclipostins
3.1. Background
As mentioned in chapter I, cyclophostin and cyclipostins are very potent inhibitors of
AChE and HSL, respectively. Variation of the nature of the alkyl group at the phosphate
center, methyl versus long lipophilic alkyl groups, leads to a dramatic switch of the
enzyme selectivity by these organophosphates. This particular fact provides a unique
opportunity to investigate the enzyme selectivity of this class of compounds or their
analogs, based on structure manipulation of the parent molecule.
Phosphonates have garnered a reputation for being excellent structural mimic of natural
phosphates. The mimicry is well reflected by their remarkable ability to copy the
biological role of phosphate esters. Because of their chemical stability, they are excellent
tools for investigating the nature of the interaction of phosphates with their target
enzyme(s) and provide a more systematic approach to understand the metabolic
regulation of phosphates.1a Unlike phosphates and pyrophosphates, phosphonate analogs
can penetrate cell membranes.1b This particular feature is quite helpful for investigating
the cell-based assay of biological activity of inhibitors towards their enzymes.
Although phosphonate analogs of natural phosphate inhibitors provide better
opportunities for biochemical investigation because of their longer in vivo life time,
there can exist an unwanted decrease in biological potency of phosphonate as compared
to their phosphate counterparts.3a
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For a bioactive molecule to increase the desired biological effect and reduce unwanted
properties like the cytotoxicity, precise tuning of its chemical properties is required.
Such chemical tuning can be achieved by different methods such as changing the pKa
values of ionizable functionalities, electronegativity of the substituents, size,
hydrophobicity, etc.1d
Alpha-fluorophosphonates can often be better mimics of phosphates. Seminal work by
Blackburn2a and McKenna2b have shown that the α-fluorination of phosphonates leads to
improved second pKa values closer to that of phosphates (Figure 3.1). The degree of
fluorination can lead to fine tuning of the pKa values. While α-monoflurophosphonate
have almost identical pKa values compared to that of phosphate, α, α’difluorophosphonate have a significantly lower pKa values (vide infra).3a

Figure 3.1 General trends of pKa values of phosphates, phosphonates and
fluorophosphonates
Enhancement of fluorophosphonates as phosphate mimics has been credited to a)
increase in pKa, b) increased polarity, c) the possibility of H-bonding, d) increased
dihedral angle of –C-CHF-P and –C-CF2-P bonds, and e) increased hydrolytic stability
as well as oxygen stability. In case of α-monofluorophosphonate, the -CHF- stereocenter
provides an additional site for tuning the bioactivity of these phosphonates.3
From this perspective, phosphonate analogs of cyclophostin and the cyclipostins (3.5 to
3.10) are very attractive synthetic targets for the study of related biochemical activities.
These bicyclic phosphonate analogs have the O-ester of the 7-membered phosphate ring
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replaced by carbon (-CX2, X = H, F or, both) while retaining the other structural feature
(Figure 3.2).

Figure 3.2 Bicyclic phosphonate and fluorophosponate analogs of cyclophostin and the
cyclipostins
Spilling and coworkers reported synthesis of the first phosphonate analogs (3.5a and
3.5b) of cyclophostin.4 The main feature of the synthesis was the successful application
of -allyl chemistry of carbonates of α-hydroxy phosphonate developed in the Spilling
laboratory, and synthesis of cyclic phosphonate rings via enolate attack at the activated
phosphonate center.
Both diastereomers of the phosphonate analog (3.5a and 3.5b) were found to preserve
inhibitory activity against acetyl cholinesterase (AChE) with a potency 100- fold weaker
than that of the natural product. Moreover, the monocyclic precursors of bicyclic
analogs (3.11a and 3.11b) were also good inhibitors of AChE with activities comparable
to that of the bicyclic analogs. The diastereomeric monocyclic precursors exhibited 6fold difference in their activity. The stereochemistry at both the phosphorus and carbon
centers of more active monocyclic precursor (3.11b) was opposite to that of the more
active bicyclic analog (3.5a). Cyclization of these monocyclic precursors leads to
complete reversal their activity along with a 10-fold difference in activity among the two
diastereomers of the bicyclic analogs (vide infra, Figure 3.3).
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Figure 3.3 Inhibition activity of bicyclic analogs of cyclophostin and its monocyclic
precursors towards human AChE.
Since cyclic phosphates and phosphonates are good phosphorylating agents, these
phosphonates inhibitors were proposed to be mechanism based inhibitors of AChE.
Mass spectrometric analysis of AChE after exposure to analog 3.5a revealed that the
inhibition was due to phosphorylation of serine residue of the enzyme.5 It is believed
that the enol-phosphate bond acts as a leaving group.

Scheme 3.1 Proposed mechanism of inhibition of AChE by phosphonates
Fluorophosphate serine hydrolase inhibitors like diisopropyl flurophosphonate (DIFP,
3.13) are very important tools for investigating the biochemistry of hydrolases.6a
Similarly, phenyl phosphonate esters (3.14) are another example of irreversible
inhibitors of hydrolases.6c The major issue with these two types of inhibitors of serine
hydrolase is their stability and promiscuous behavior.
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Compared to fluorophosphates and phenyl phosphate inhibitors, cyclic enol-phosphate
and phosphonate like cyclophostin and cyclipostins, have better chemical as well as
physical stability.5 Therefore, cyclic enol-phosphonates have huge potential to be a new
class of inhibitors of serine hydrolases. It was hypothesized that compounds with this
particular set of structural features (3.15) could be general inhibitors for serine
hydrolases and structural modifications of the basic phosphonate heterocycle should
bring selectivity towards different members of the family (Figure 3.4).

Figure 3.4 Probes for biochemical assay of serine hydrolases

3.2. Specific aim of the study
The results from earlier work on the bicyclic phosphonate analogs of cyclophostin and
their biochemical activity provided impetus to synthesize and examine the biological
activity of the parent heterocycle containing different alkyl substituents at the C4-carbon
against other members of serine hydrolases. Additionally, essential structural motifs of
these phosphonates for their inhibition activity were also targeted for evaluation.
The specific aim of this work is to synthesize monocyclic phosphonate analogs of
cyclophostin and cyclipostins to address the following structural properties: i)
requirement of the formal lactone ring; ii) effect of removal of conjugation between the
enol- phosphonate bond and the ester functional group; iii) effect of the ring size on the
overall activity; and iv) effect of the enol-phosphate geometry on the bioactivity.
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Figure 3.5 Rationale for the synthesis of monocyclic phosphonate analogs of
cyclophostin and cyclipostins
To address these questions about the possible structure-activity relationship of
phosphonate analogs of cyclophostin and cyclipostins, the following monocyclic analogs
were proposed for synthesis (Figure 3.6). It was also hoped that by having an alkyl group
with short, medium, and long chain length, at the C4-carbon should address some of the
requirements for substrate selectivity against different serine hydrolases. Additionally,
the monocyclic phosphonate analogs of cyclipostins were also planned for synthesis.

Figure 3.6 Targets for synthesis: monocyclic phosphonate analogs of cyclophostin and
cyclipostins
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3.3. General strategy for the synthesis of 7-membered monocyclic
phosphonate analogs
The general strategy applied toward the synthesis of monocyclic phosphonate analogs
involves the application of π- allyl chemistry of allylic phosphono-carbonates (3.33)
catalyzed by a palladium(0) catalyst as one of the key transformations (Figure 3.7). This
method was developed by Zhu and Lu and expanded by the Spilling group8,9 and
successfully applied toward synthesis of bicyclic analogs of cyclophostin.4,5 The method
is general in its scope as a wide variety of substrates containing “allyllic phosphonocarbonate” moieties can undergo the palladium (0) catalyzed addition of nucleophile,
either internal or external in origin.4,5,7,8,9
The addition takes place through a palladium - allyl complex and there is complete
chirality transfer from the carbonate center () to the site of nucleophilic addition (carbon).9 For this study, this method allows the flexibility for introduction of different
side chains at the C4 center.
The Pudovik reaction between an aldehyde(s) (3.29) and dialkyl phosphite(s) (3.30) gives
α-hydroxy phosphonate(s) (3.31). Recent developments of the asymmetric version of the
Pudovik reaction allow the synthesis of non-racemic α-hydroxy phosphonate.7,8
Subsequent reactions of hydroxy-phosphonates with methyl chloroformate (3.32) gives
corresponding carbonate(s) (3.33). The allylic carbonates are excellent substrate for
Pd(0)-catalyzed addition of nucleophile(s) (3.34) which produce vinyl phosphonates
(3.35) (Figure 3.7).8,9 The nucleophile chosen for this work is methyl acetoacetate (3.36).
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Figure 3.7 General strategy for synthesis of monocyclic phosphonate analog

3.4. Result and Discussion
The synthesis of 7-membered monocyclic analogs began with the synthesis of carbonates
3.33(a–i). The Pudovik reaction of aldehydes 3.29(a–c) with dimethyl phosphite
promoted by Et3N gave corresponding racemic -hydroxy phosphonates which were
subsequently converted to desired carbonates 3.33(a–c) by reaction with methyl
chloroformate in presence of catalytic amount of dimethyl aminopyridine (DMAP) and
an excess of pyridine (Scheme 3.2).

Scheme 3.2 Synthesis of carbonates employing Pudovik reaction
The synthesis of carbonates with long alkyl side chain was carried out by cross
metathesis of the acrolein derived carbonate (3.33a) with corresponding long chain
terminal alkenes (3.37, Scheme 3.3).8c Hence, carbonate (3.33a) was subjected to cross
metathesis reaction with an excess amount (7-10 equivalents) of the corresponding C12(3.37a), C14- (3.37b), C18- (3.37c) and C20- (3.37d) terminal alkene using Grubbs 2nd
generation catalyst to give carbonates containing C10- (3.33d), C12- (3.33e), C16- (3.33f)
and C18- (3.33g) side chains, respectively (Scheme 3.3).
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Scheme 3.3 Synthesis of carbonates through cross metathesis
Non-racemic (R)- and (S)- carbonates (3.33a–(R) and 3.33a–(S)) were prepared by
sequential application of asymmetric Pudovik reaction and an enzymatic resolution
method developed by the Spilling group.7 These enantiomerically pure carbonates were
subjected to cross metathesis with 1-dodecene (3.37a) to give corresponding non-racemic
C10- side chain carbonates 3.33h and 3.33i, respectively. The cross metathesis reactions
gave mixtures of both E- & Z- products with the E-carbonate being the predominant
product (Scheme 3.4).

Scheme 3.4 Synthesis of non-racemic carbonates with C10 side chain
The carbonates (3.33(a–i)) were subjected to Pd (0)-catalyzed addition of methyl
acetoacetate (3.36) to give the desired vinyl phosphonates 3.35(a–i) in 70 - 80 % yield
(Table 3.1) exclusively with E-geometry across the vinyl bond (Scheme 3.5).
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Scheme 3.5 Synthesis of vinyl phosphonates through Pd(0) catalyzed π-allyl chemistry
Table 3.1 Synthesis of vinyl phosphonates (yields)
R

Yield
(%)

R

Yield
(%)

R

Yield
(%)

H–
3.35a

44

n - C10H21 –
3.35d

78

n - C18H37 –
3.35g

72

C5H11 –
3.35b

78

n - C12H25 –
3.35e

76

n – C10H21 (R) –
3.35h

81

Ph –
3.35c

47

n - C16H33 –
3.35f

73

n – C10H21 (S) –
3.35i
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Addition of acetoacetate (3.36) to the carbonate 3.33a was complicated by formation of a
di-addition product (3.35k) (Scheme 3.6) in addition to the desired vinyl phosphonate
(3.35a). The vinyl phosphonate substituted acetoacetate (3.35a) was able to react with an
additional π-allyl species from carbonate 3.33a to generate the di-addition product. This
event is proabably favored by lack of steric crowding in the π-allyl intermediate derived
from carbonate 3.33a.
The reaction condition was modified from standard protocol to favor the mono-addition
product (3.33a) relative to the di-addition product (3.33k). When the reaction was
performed with large excess (10-15 equivalents) of methyl acetoacetate and a highly
dilute solution of the carbonate, there was significant improvement of the yield of mono
addition product (~48% versus 33%).
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Scheme 3.6 Palladium(0) catalyzed -allyl chemistry with carbonate 3.33a
The addition of acetoacetate to carbonate 3.33c produced both desired vinyl phosphonate
(3.35 c) and unexpected allyl phosphonate (3.35j). The allyl phosphonate was produced
by the migration of the double bond in the presence of Pd(0) catalyst. The double bond
migration in 3.35c to the allylic position could be promoted by the increased stability of
alkene due to conjugation with the phenyl group. The spectral analysis (IR, 1H NMR, 13C
NMR) of this allyl phosphonate suggested that the compound exists as an enol-form of
the -keto ester (Scheme 3.7).

Scheme 3.7 Palladium(0) catalyzed -allyl chemistry with carbonate 3.33c
Both the vinyl phosphonates 3.35c and 3.35j were individually isolated by using column
chromatography and their structures were confirmed by X-ray crystallography (Figure
3.3). Both vinyl phosphonates (3.35c and 3.35j) were taken for further steps of the
synthesis as they should give the same alkyl phosphonate after hydrogenation.
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Figure 3.8 Projection view of 3.35c & 3.35j (50% thermal ellipsoids)
Hydrogenation of the vinyl phosphonates (3.35(a–j)) was carried out in methanolic
solution using molecular hydrogen over palladium (0) on carbon to give the saturated
phosphonates 3.37(a–i) in quantitative yield (Scheme 3.8).
Alkyl phosphonates 3.37 (a–i) were subjected to mono demethylation by treating with
stoichiometric amounts of sodium iodide in refluxing acetone (or, acetonitrile) to yield
the corresponding mono sodium salts. The sodium salts were subsequently converted to
the monophosphonic acids 3.38(a–i) by treating the methanolic solution of sodium salts
with Amberlite IR120® resin at room temperature (Scheme 3.8). The formation of both
the sodium salts and the monophosphonic acids was followed and confirmed by 1H and
31

P NMR and were used without further purification.

The monophosphonic acids were cyclized with EDC, HOBt and Hünig’s base to give the
corresponding monocyclic products(s) (3.16–3.22) in 45 - 59% yield (Table 3.2). When
R ≠ H, corresponding monocycles were obtained as 1:1 diastereomeric mixtures (Scheme
3.8) with typical 31P NMR chemical shift of ~ 27 and ~24 ppm. Individual diastereomers
were separated by repeated column chromatography.
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Scheme 3.8 Synthesis of monocyclic analogs of cyclophostin
Table 3.2 Synthesis of monocyclic phosphonate analaogs (yields over 3 steps)
R

Yield
(%)

R

Yield
(%)

R

Yield (%)

H–
3.16

45

n - C10H21 –
3.19 a& b

46

n - C18H37 –
3.22 a& b

59

C5H11 –
3.17 a& b

56

n - C12H25 –
3.20 a& b

45

n – C10H21 (R)
–
3.19(R-) a& b

45
(ee >85%)

Ph –
3.18 a& b

52

n - C16H33 –
3.21a& b

48

n – C10H21 (S) –
3.19(S-) a& b

53
(ee >86%)

To check the enatiomeric purity of the non-racemic monocyclic analogs with C10–side
chain, and the stereospecificity of the overall synthetic strategy, the enantiomeric excess
(ee) of the purified ‘a’ diastereomer (31P NMR, δ 26.8 ppm) of the non-racemic
monocyclic analog 3.19(R-) and 3.19(S-) was measured HPLC. Compared to the
corresponding racemic diastereomer 3.19a, enantiomeric excess of 3.19(R)a and 3.19(S)a
(ee) were found to be >85% and >86, respectively. This analysis revealed that the
enantiomeric excess of the non racemic substrates 3.33h (ee = > 95%) and 3.33i (ee = >
95%) is mostly preserved in the synthesis. However, there was slight erosion of
enantiomeric excess (ca 10 %). This erosion could have been originated during the cross
metathesis reactions of the nonracemic carbonates where there was formation of the Z84

isomer (ca 10 %). Since, the Z-isomer was not separated from the E-isomer, it may have
caused scrambling of stereochemistry during addition of methyl acetoacetate (3.36)
across the Pd(0)--allyl intermediate (Scheme 3.5).
The conjugation between the enol phosphonate bond and carboxyl ester can be removed
by reducing the carboxyl ester to an alcohol. The obvious way to carry out such reduction
is to use hydride (H-) from aluminum based reagents like lithium aluminum hydride
(LiAlH4) or a boron based reagent such as sodium borohydride (NaBH4). Since LiAlH4
tends to be more aggressive, it could also react at the enol-phosphate bond in addition to
the desired transformation (eg. reduction of the double bond). On the other hand, milder
reducing agents like diisobutyl aluminum hydride (DIBAL-H) allow controlled reduction
of esters. Hence, this was the reagent chosen the current purpose.
Initial treatment of unsubstituted monocyclic analog (3.16) with 2 equivalents of DIBALH at -78 oC led to partial conversion (ca 30%) to required alcohol. The reaction was
driven to completion by using 4 equivalents of DIBAL-H which selectively reduced the
ester moiety to give the corresponding alcohol (3.23) (Scheme 3.9). This compound
should illuminate the role of the conjugation between the enol-phosphonate bond and the
carboxyl ester on the inhibition of acetylcholine esterase.

Scheme 3.9 DIBAL-H reduction of ester
The synthesis of the 6-membered phosphonate analog was achieved using a different
approach. Vinyl phosphonate (3.39) seemed a good starting material for this purpose. The
presence of phosphonate group in vinyl phosphonates activates the olefinic bonds,
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making them good substrate for Michael addition. Such addition of methyl acetoacetate
(3.36) to dimethyl vinyl phosphonate (3.39) should provide the alkyl phosphonate
required for the synthesis of 6-membered phosphonate analog.
Hence, dimethyl vinyl phosphonate (3.39) was subjected to phospha-Michael addition of
methyl acetoacetate (3.36) using potassium t-butoxide as base to give the required alkyl
phosphonate (3.40) in good yield (62 %). The alkyl phosphonate (3.40) was converted to
corresponding monophosphonic acid (3.41) and finally to cyclic product (3.24) as
previously described (Scheme 3.10).

Scheme 3.10 Synthesis of 6-membered monocyclic analog
The synthesis proposed for the corresponding 5-membered phosphonate heterocycle
(3.25, Figure 3.6) was unsuccessful. A major hurdle for the synthesis was the formation
of the alkyl phosphonate (3.45).Various attempts for the synthesis of the phosphonate
(3.45) failed. For example, treatment of the triflate (3.44)10,11 with methyl acetoacetate
(3.36) failed to give the required C-alkylation product. Instead, it underwent O-alkylation
leading to the enol ether (3.46) (Scheme 3.11).
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Scheme 3.11 Attempted synthesis of 5-membered ring analog
To understand the effect of the orientation of the enol-phosphate bond (E- vs Z-) on
activity of the phosphonate analogs, exocyclic enol-phosphate analogs were proposed to
synthesize.
It was envisioned that exocyclic E- and Z-enol phosphate analogs (3.26 and 3.27) could
be synthesized by trapping the enolate of the β-keto lactone by phosphorylation. Since
the enolate geometry (E- vs. Z-) of β-keto esters can be controlled by choice of base,
(inorganic versus organic), 2-acetyl butyrolactone (3.47) was chosen as common starting
material. Hence, the butyrolactone, on treatment with sodium hydride (NaH) followed by
dimethyl chlorophosphate (3.48), gave the Z-enol phosphate (3.27) in 62% yield. A
similar reaction in presence of Hunig’s base (diisopropyl ethyl amine, iPr2NEt) gave the
E-enol phosphate (3.26) in 65% yield (Scheme 3.12).12 The E- and Z- isomers were
assigned on the basis of the 31P NMR chemical shift.
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Scheme 3.12 Synthesis of exocyclic enol-phosphate analogs of cyclophostin

3.5. Synthesis of monocyclic phosphonate analogs of (±)-cyclipostin P
Similar to the synthesis of (±)-cyclipostin P from cyclophostin, the monocyclic
phosphonate analogs of the cyclipostins could be synthesized by replacing the methyl
ester of the monocyclic phosphonate analog (3.16) with an alkyl bromide of appropriate
chain length.
Initially diastereomeric mixture of the monocyclic analog 3.21 was subjected to a one-pot
transesterification with 2 equivalents of allyl bromide (3.49) and 5 mol% tetra n-butyl
ammonium iodide (TBAI) in refluxing toluene. There was only 50 % conversion (based
on

31

P NMR) after 14 hours of reflux to give corresponding allyl phosphonate ester

(3.50).
A similar reaction with diastereomeric mixture of monocyclic analog 3.21 and 2
equivalents of hexadecyl bromide (3.51) gave a new set of diastereomers after only 50 %
conversion. The isolation of the products out of a mixture of 4 comparatively non polar
phospho-lipid like molecules was chromatographically complicated (Scheme 3.13).
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Scheme 3.13 Transesterification of monocyclic phosphonate analog
The unsubstituted monocyclic analog (3.16) was subjected to the transesterification
reaction with 4 equivalents of allyl bromide (3.49) in above mentioned reaction
condition. The reaction went upto ~ 65 % conversions after overnight reflux to give
corresponding ally phosphonate (3.53) (Scheme 3.14).

Scheme 3.14 Tranesterification of parent monocyclic phosphonate analog with allyl
bromide
These two sets of reaction led to the conclusion that there is formation of a 1:1 mixture of
diastereomers and an excess of the alkylating reagent is required to push the
transesterifition to completion.
Finally,

the

unsubstituted

monocyclic

analog

(3.16)

was

subjected

to

the

tranesterification reaction with 10 equivalents of hexadecanyl bromide (3.35) to drive the
reaction to completion. Indeed, the reaction went to >98 % completion (based on

31

P

NMR) within 6 hours and gave monocyclic phosphonate analog of cyclipostin P (3.36) in
86 % isolated yield (Scheme 3.15).

89

Scheme 3.15 Synthesis of monocyclic phosphonate analog of cyclipostin P
The above series of reaction once again, demonstrated the efficiency of the one-pot
tranesterification reaction compared to the other methods for this purpose. The
phosphonate analogs synthesized above will be subject for biological assay against
various serine hydrolases.

3.6. Investigation of Biological Activities of Phosphonate Analogs of the
Cyclipostins and Cyclophostin
3.6.1. Biochemical assay of phosphonates as inhibitor of AchE5
The monocyclic phosphonate analogs were subjected to an assay of their inhibition
activity against acetyl cholinesterase (AChE) from human and electric eel using the
Ellman assay method, in collaboration with Prof. Dupureur’s group in the department.
The activity is reported as the inhibitory concentration required to reduce the enzyme
activity to 50% of the activity in absence of any inhibitors (IC50 values). The lower the
IC50 values, the higher are the inhibitory activities of the compound towards the
corresponding enzyme.
Enzyme inhibition by the phosphonate analogs was studied by using the following
equation:
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Where, E = enzyme, I = Inhibitor, KI = rate of binding ( or, affinity towards enzyme),
E:I = enzyme – inhibitor complex, k2 = rate of inhibition,
EI = product of enzyme inhibition, K-2 = rate of recovery of enzyme activity
( measurement for reversibility of inhibition of enzyme).
It was found that the 7-membered and 6-membered monocyclic analog (3.16 and 3.23)
retain the inhibition potency of the most potent bicyclic phosphonate analog (based on
their IC50 values). However, they followed the opposite mode of inactivation of the
enzyme. While the 7-membered analog had faster binding than 6-membered analogs, the
latter had faster rate of inhibition than the 7-membered analog.5
The conjugation between the enol-phosphate bond and ester functionality was essential
for the inhibition potency of these analogs against AChE as the analog containing
reduced ester functionality exhibited >100 fold less activity than its precursor. Similarly,
E – enol-phosphate analog (3.26) was found to be more active that the Z- enol-phosphate
analog (3.27) (IC50 values of 70 versus >1000 μM) which showed the requirement of Egeometry of the enol – phosphate bond for the biological activity of these analogs. The
individual analogs along with their IC50 values are tabulated below (Table 3.3).5
The difference in IC50 values was found to be the result of a difference in the affinity of
inhibitors (phosphonate analogs) towards the enzyme. All analogs exhibited a
comparable rate of inhibition except the 6-membered ring analog which has lower
affinity towards enzyme but inactivates the enzyme at a faster rate (as fast as 10–20 fold).
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Table 3.3 Test for the inhibition activity of racemic monocyclic analogs towards AChE
Analog

AchE IC50 (µM)
Human
Eel
~3

70

6

110

~7

3

5

20

~50

~300

>300

>1000

>1000

>1000

~400

~1000

70

400

>1000

>1000
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The rates of inhibition of enzyme for the active phosphonates were found to be
comparable to those obtained for diisopropyl fluorophosphonate (DIFP).

3.6.2. Biochemical assay of phosphonate analogs as inhibitors of
different serine hydrolases
Phosphonate analogs with alkyl chains at the γ-carbon (C4- carbon) were tested for their
ability to inhibit AChE, Human Pancreatic lipases (rHPL), Dog Gastric Lipases (rDGL),
Ginea Pig Lipase related protein 2 (GPLRP2), cutinase from Fusarium solani pisi and
Rv0183 from Mycobacterium tuberculosis in collaboration with Dr. Jean-François
Cavalier at CNRS-Marseilles, France.
No significant inhibition was observed with rHPL, rDGL and GPLRP2. However,
Cutinase and Rv0183 were inhibited and the best inhibitors were the cis diastereomer of
monocycle (31P NMR (δ) = 24.2 ppm) with C10 - and C16 - side chain where the proton at
the C3-carbon and the methoxy group at phosphonate center are cis to each other.
The non-racemic monocyclic analogs with C10 – side chain (3.19(R-) and 3.19(S-)) were
tested against cutinase and Rv0183 in order to examine the influence of the chirality at
both the phosphorus and carbon center on inhibition of these enzymes. In the case of
cutinase, no obvious stereopreference at the phosphorus center was observed with Rabsolute configuration at the carbon center. However, in case of the analog with Sabsolute configuration at carbon, S-configuration at phosphorus was essential for the
potent inhibition of the enzyme.
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Table 3.4 Test for inhibition activity of selected analogs towards cutinase and Rv0183
Analog

IC50 (μM)
Cutinase

Rv0183

6

NA

8

35

14

228

17

38

10

34

390

333

10

39

5

92

94

On the other hand, strong enantiodiscrimination for the S-configuration of the phosphorus
center by Rv0183 was observed. The enzyme shows no effect of configuration at the
carbon center. The overall result is tabulated above (Table 3.4).

3.7. Summary
In summary, 14 new monocyclic analogs of cyclophostin have been synthesized and
their inhibitory activity towards members of serine hydrolase viz acetyl cholinesterase
(AchE), hormone sensitive lipase (HSL), cutinase, lipases (rHPL, rDGL and GPLRP2),
and Rv0183 from Mycobacterium tuberculosis were measured. The size of the
phosphonate ring has little effect on the inhibition activity against AChE. The group on
the -carbon of the phosphonate ring can affect as well as modify the biological activity
of the monocyclic analog. An ester functionality in conjugation with the enol-phophate
bond is essential to the biological activity.
This work also involved the synthesis of a monocyclic phosphonate analog of
cyclipostin P. Similar analogs of other potent cyclipostins could be synthesized by using
the one-pot transesterification of monocyclic phosphonate analogs.
This work provided a fundamental premise for the understanding of the structureactivity relationship between monocyclic phosphonate analogs and their inhibitory
activity towards AChE and other serine hydrolases. Some of the phosphonate analogs
have shown selectivity among serine hydrolases with micromolar potency.
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3.8. General Experimental
General Experimental Procedures
Glassware for all experiments were oven-dried and cooled and used under Argon
atmosphere unless otherwise mentioned. 1H,

13

C and

31

P NMR were taken in Bruker

Avance ARX-300 NMR spectrometer at 300, 75 and 121 MHz, respectively.
Tetramethylsilane (TMS, δ 0.00) or chloroform-D (CDCl3, δ 7.27 ppm for 1H NMR and
77.23 ppm in

13

C NMR) were used as internal reference. High resolution mass spectral

analyses were carried out on a JEOL MStation-JMS700 spectrometer. Phosphoric acid
(H3PO4, 85%) was used as external reference for 31P NMR.
Synthesis of carbonates
Carbonates 3.12a, 3.12b & 3.12c were synthesized according to literature procedure.
Ref. He, A.; Yan, B.; Thanavaro, A.; Spilling, C. D.; Rath, N.P. J. Org. Chem. 2004, 69,
8643.
General procedure for synthesis of carbonate(s) via cross metathesis reaction
To a solution of carbonate (1mmol) and alkene (5 - 10 mmol) in CH2Cl2 (2 mL) was
added Grubbs 2nd generation catalyst (5 mol %) followed by CuI (7 mol %). After stirring
the solution for 2 minutes at room temperature, septum was replaced by a condenser
connected to an argon bubbler. Then, the reaction flask was placed in an oil bath
preheated at 45 oC. After completion of the reaction (TLC and

31

P NMR analysis),

solvent was removed under vacuum to give the crude product. Purification of the crude
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product by column chromatography (SiO2, 20 – 50% EtOAc in hexanes) gave the
carbonate as mixture of both E- and Z-isomer.

(E)-1-(dimethoxyphosphoryl)tridec-2-en-1-yl methyl carbonate (3.33d). To a
solution of carbonate 3.33a (1.12 g, 5 mmol) and 1-dodecene (3.37a) (11.1 mL, 50
mmol) in dry CH2Cl2 (10 mL) was added Grubbs 2nd generation catalyst (0.21 g, 0.25
mmol) followed by CuI (0.07 g, 0.35 mmol) to give pure 3.33d (1.43 g, 79%) after
chromatography of crude product. IR (neat, NaCl) 1756 cm-1; 1H NMR (CDCl3) δ 5.97
(1H, ddt, JHH = 15.2, 6.7 Hz, JHP = 3.7 Hz), 5.55 (1H, ddd, JHH = 15.2, 7.6 Hz, JHP = 5.2
Hz), 5.45 (1H, dd, JHH = 8.0 Hz, JHP = 12.4 Hz), 3.81 (d, 3H, JHP = 10.6 Hz), 3.81 (3H, s),
3.8 (d, 3H, JHP = 10.6 Hz), 2.08 (2H, ddd, JHH = 13.9, 6.6 Hz, JHP = 3.4 Hz), 1.37 (2H, t,
JHH = 6.7 Hz), 1.25 (16H, br s), 0.87 (3H, t, JHH = 6.6 Hz); 13C NMR (CDCl3) δ 155.0 (d,
JCP = 9.9 Hz), 139.4 (d, JCP = 12.5 Hz), 120.3 (d, JCP = 3.8 Hz), 73.3 (d, JCP = 170.2 Hz),
55.5, 54.0 (d, JCP = 7.2 Hz), 32.6, 32.1, 29.8, 29.6, 29.5, 29.3, 28.8 (d, JCP = 2.4 Hz),
22.9, 14.3; 31P NMR (CDCl3) δ 20.8, 20.5 (E:Z = 10:1); HRMS (FAB, NBA, MH+) calcd.
for C17H34O6P: 365.2092, found 365.2103.

(R,E)-1-(dimethoxyphosphoryl)tridec-2-en-1-yl methyl carbonate (3.33h). To a
solution of carbonate 3.33a-(R) (0.67 g, 3 mmol) and 1-dodecene (3.37a) (6.7 mL, 30
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mmol) in dry CH2Cl2 (6 mL) was added Grubbs 2nd generation catalyst (0.13 g, 0.15
mmol) followed by CuI (0.04 g, 0.21 mmol) to give pure 3.33h (0.8 g, 72%, E:Z = 14:1)
after chromatography of crude product. HRMS (FAB, NBA, MH+) calcd for C17H34O6P:
365.2092, found 365.2089; [α]D25= + 27.53 (c = 0.015, CHCl3).

(S,E)-1-(dimethoxyphosphoryl)tridec-2-en-1-yl methyl carbonate (3.33i). To a
solution of carbonate 3.33a- (S) (0.67 gm, 3 mmol) and 1-dodecene (3.37a) (6.7 mL, 30
mmol) in dry CH2Cl2 (6 mL) was added Grubbs 2nd generation catalyst (0.13 g, 0.15
mmol) followed by CuI (0.04 g, 0.21mmol) to give pure 3.33i (0.8 g, 73%, E:Z = 14:1)
after chromatography of crude product. HRMS (FAB, NBA, MH+) calcd. for C17H34O6P:
365.2092, found 365.2096, [α]D25 = - 26.21 (c = 0.015, CHCl3).

(E)-1-(dimethoxyphosphoryl)pentadec-2-en-1-yl methyl carbonate (3.33e). To a
solution of carbonate 3.33a (1.12 g, 5 mmol) and 1-tetradecene (3.37b) (12.7 mL, 50
mmol) in dry CH2Cl2 (10 mL) was added Grubbs 2nd generation catalyst (0.21 g, 0.25
mmol) followed by CuI (0.07 g, 0.35 mmol) to get pure 3.33e (1.5 g, 76%) after
chromatography of crude product. IR (neat, NaCl) 1755 cm-1; 1H NMR (CDCl3) δ 5.95
(1H, ddt, JHH = 15.2, 6.7 Hz, JHP = 3.8 Hz), 5.55 (1H, ddd, JHH = 15.2, 7.6 Hz, JHP = 5.2
Hz), 5.45 (1H, dd, JHH = 7.8Hz, JHP = 12.4 Hz), 3.81 (d, 3H, JHP = 10.6 Hz), 3.81 (3H, s),
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3.80 (d, 3H, JHP = 10.6 Hz), 2.08 (2H, ddd, JHH = 13.9, 6.7 Hz, JHP = 3.5 Hz), 1. 37 (2H, t,
JHH = 6.7), 1.24 (18H, br s), 0.87 (3H, t, JHH = 6.6 Hz); 13C NMR (CDCl3) δ 154.9 (d, JCP
= 9.8 Hz), 139.3 (d, JCP = 12.5 Hz), 120.3 (d, JCP = 3.8 Hz), 73.2 (d, JCP = 170.3 Hz),
55.5, 54 (d, JCP = 7.2 Hz), 32.6, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 28.8 (d, JCP
= 2.4 Hz), 22.9, 14.3; 31P NMR (CDCl3) δ 20.9, 20.5 (E:Z = 8:1); HRMS (FAB, NBA,
MH+) calcd for C19H37O6PNa: 415.2225, found 415.2227

(E)-1-(dimethoxyphosphoryl)nonadec-2-en-1-yl methyl carbonate (3.33f). To a
solution of carbonate 3.33a (1.12 g, 5 mmol) and 1-octadecene (3.37c) (8 mL, 25 mmol)
in dry CH2Cl2 (10 mL) was added Grubbs 2nd generation catalyst (0.21 g, 0.25 mmol)
followed by CuI (0.07 g, 0.35 mmol) to get pure 3.33f (1.57g, 70%) after
chromatography of crude product. IR (neat, NaCl), 1755 cm-1; 1H NMR (CDCl3) δ 5.96
(1H, ddt, JHH = 14.6, 7.1 Hz, JHP = 3.8 Hz), 5.55 (1H, ddd, JHH = 7.7, 15.2 Hz, JHP = 5.2
Hz), 5.44 (1H,dd, JHH = 7.8 Hz, JHP = 12.3 Hz), 3.82 (3H, s), 3.81 (d, 3H, JHP = 10.6 Hz),
3.81 (d, 3H, JHP = 10.6 Hz), 2.1 (2H, ddd, JHH = 7, 13.7 Hz, JHP = 3.2 Hz), 1.37 (2H, t, JHH
= 6.5 Hz ), 1.25 (26H, br s), 0.87 (3H, t, JHH = 6.44 Hz); 13C NMR (CDCl3) δ 155 (d, JCP
= 9.8 Hz), 139.3 (d, JCP = 12.4 Hz), 120.3 (d, JCP = 3.8 Hz), 73.3 (d, JCP = 170.3 Hz),
55.5, 54 (d, JCP = 7.3 Hz), 32.6, 32,1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.3, 28.8, 28.7, 22.9,
14.4; 31P NMR (CDCl3) δ 20.8, 20.5 (E:Z = 10:1); HRMS (FAB, NBA, MNa+) calcd for
C23H45O6PNa: 471.2851, found 471.2860.

99

(E)-1-(dimethoxyphosphoryl)henicos-2-en-1-yl methyl carbonate (3.33g). To a
solution of carbonate 3.33a (0.67 g, 3 mmol) and 1-eicocene (3.37d) (4.21 mL, 15
mmol) in dry CH2Cl2 (6 mL) was added Grubbs 2nd generation catalyst (0.13 g, 0.15
mmol) followed by CuI (0.04 g, 0.21 mmol) to give pure 3.33g (1.1 g, 70%) after
chromatography of crude product. IR (neat, NaCl) 1755 cm-1; 1H NMR (CDCl3) δ 5.97
(1H, ddt, JHH = 14.9, 6.7 Hz, JHP = 3.8 Hz), 5.56 (1H, ddd, JHH = 15.1, 7.7 Hz, JHP = 5.3
Hz), 5.46 (1H, dd, JHH = 7.8 Hz, JHP = 12.2 Hz), 3.82 (3H, s), 3.81 (d, 3H, JHP = 10.6
Hz), 3.81 (d, 3H, JHP = 10.6 Hz), 2.1 (2H, JHH = 6.7, 13.7 Hz, JHP = 3.4 Hz), 1.39 (2H, t,
JHH = 6.7 Hz ), 1.26 (30 H, br s), 0.88 (3H, t, JHH = 6.7 Hz); 13C NMR (CDCl3) δ 155 (d,
JCP = 9.8 Hz), 139.4 (d, JCP = 12.5 Hz), 120.3 (d, JCP = 3.8 Hz), 73.3 (d, JCP = 170.3 Hz),
55.5, 54 (d, JCP = 7.1 Hz), 32.6, 32,1, 30, 29.9, 29.8, 29.6, 29.5, 29.3, 28.8 (d, JCP =
2.4Hz), 22.9, 14.4; 31P NMR (CDCl3) δ 20.8, 20.5 (E:Z = 10:1); HRMS (FAB, NBA,
MH+) calcd. for C25H49O6PNa: 499.3164, found 499.3170.
General procedure for synthesis of vinyl phosphonate(s)
To a stirring solution of carbonate (1 mmol) and methyl acetoacetate (3 mmol) in dry
THF (2.5 mL) was added Pd2(dba)3 (0.02 mmol) followed by dppe (0.5 mmol) and was
stirred at room temperature for 3-4 minutes. The septum was replaced by a condenser
connected to an argon bubbler and the reaction flask was placed in an oil bath preheated
at 45 oC and. After completion of the reaction (TLC and 31P NMR analysis), the reaction
mixture was partitioned between brine and EtOAc. The organic layer was collected and
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the aqueous layer was extracted with additional EtOAc. The collected organic layers
were dried over anhydrous Na2SO4, evaporated under reduced pressure to give crude
product. Purification of the crude by column chromatography (SiO2, 20 – 70% EtOAc in
hexanes) gave the vinyl phosphonate(s).

(E)-methyl 2-acetyl-5-(dimethoxyphosphoryl)pent-4-enoate (3.35a) and (E)-methyl
2-acetyl-5-(dimethoxyphosphoryl)-2-((E)-3-(dimethoxyphosphoryl)allyl)pent-4enoate (3.35k). To a solution of Pd2(dba)3 (0.06 g, 0.06 mmol) and dppe (0.07 g, 0.18
mmol) in anhydrous THF (5 ml) was added methyl acetoacetate (3.36) (1.13 ml, 9 mmol)
followed by addition of solution of phosphono allylic carbonate (3.33a) (0.67 g, 3 mmol)
in THF (20 ml) through addition funnel connected to argon bubbler, at room temperature
to provide the vinyl phosphonate (3.35a) as pale yellow oil (0.32 g, 40%). IR (neat,
NaCl) 1743, 1717, 1635 cm-1; 1H NMR (CDCl3) δ 6.67 (1H, m), 5.7 (1H, m), 3.73 (6H,
d, JHP =10.85 Hz), 3.67 (3H, s), 3.61 (1H, t, JHH = 7.3 Hz), 2.76 (2H, tt, JHH = 7.1 Hz, 1.7
Hz), 2.25 (3H, s); 13C NMR (CDCl3) δ 201.5, 169.4, 149.9 (d, JCP = 5.1 Hz), 119 (d, JCP
=186.9 Hz), 58.1, 53.1, 52.7 (d, JCP = 7.4 Hz), 32.6 (d, JCP = 23.4 Hz), 29.1;

31

P NMR

(CDCl3) δ 20.6; HRMS (FAB, NBA, MH+) calcd for C10H18O6P 265.0841, found
265.0829; and vinyl phosphonate (3.35k) as yellow oil (0.14 g, 23% for 1.5 mmol). IR
(neat, NaCl) 1739, 1713, 1633 cm-1; 1H NMR (CDCl3) δ 6.52 (2H, m), 5.72 (2H, m),
3.77 (3H, s), 3.7 (12H, d, JHP =11.1 Hz ), 2.78 (2H, m , 2.17 (3H, s); 13C NMR (CDCl3) δ
202.2, 170.9, 146.9 (d, JCP = 5.3 Hz), 121.3 (d, JCP =186.2 Hz), 62.7, 53.1, 52.5 (d, JCP =
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5.9 Hz), 37 (d, JCP = 23.3 Hz), 27.1 (d, JCP = 8.6 Hz); 31P NMR (CDCl3) δ 19.6; HRMS
(FAB, NBA, MH+) calcd for C15H27O9P2 412.1130, found 413.1143

(E)-methyl

2-acetyl-3-(2-(dimethoxyphosphoryl)vinyl)octanoate

(3.35b).

To

a

solution of carbonate 3.33b (0.29 g, 1 mmol) and methyl acetoacetate (3.36) (0.33 mL, 3
mmol) in dry THF (2 mL) was added Pd2(dba)3 (0.02 g, 0.02 mmol) and dppe (0.02 g,
0.05 mmol) to give 3.35b as pale yellow oil (1.17 gm, 70%). IR (neat, NaCl) 1743, 1717;
1

H NMR (CDCl3) δ 6.55 (0.5H, ddd, JHH = 17.13, 9.5 Hz, JHP = 21.5 Hz), 6.45 (0.5H,

ddd, JHH = 17.13, 9.5 Hz, JHP = 21.5 Hz), 5.68 (0.5H, dd, JHH = 17.13, JHP = 21.5 Hz),
5.61 (0.5H, ddd, JHH = 17.13 Hz, JHP = 21.5 Hz), 3.67 (9H, m), 3.51 (1H, 2d, JHH = 9.4,
9.3 Hz), 2.95 (1H, 2q, JHH = 9.4 and 9.4 Hz), 2.21 (1.5H, s), 2.15 (1.5H, s), 1.28 (8H, m);
0.83 (3H, t, JHH = 6.44 Hz); 13C NMR (CDCl3) δ 201.3, 168.6 (168.4), 153.4 (153.3) (d,
JCP = 4.6 Hz), 118.8 (118.7) (d, JCP =184.5 Hz), 63.8 (63.7) (d, JCP = 1.0 Hz), 52.7 (52.5),
52.4 (d, JCP = 5.6 Hz), 44.0 (43.9) (d, JCP = 21.8 Hz), 31.8 (31.6), 31.5 (d, JCP = 1.3 Hz),
30.1 (29.9), 26.8 (26.7), 22.5, 14.0; 31P NMR (CDCl3) δ 20.7, 20.6; HRMS (FAB, NBA,
MH+) calcd. for C15H27O6PNa: 357.1442, found 357.1450.
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(E)-methyl 2-acetyl-5-(dimethoxyphosphoryl)-3-phenylpent-4-enoate (3.35c) and
(2Z,3Z)-methyl

5-(dimethoxyphosphoryl)-2-(1-hydroxyethylidene)-3-phenylpent-3-

enoate (enol form) (3.35j). To a solution of carbonate 3.33c (0.75 g, 2.5 mmol) and
methyl acetoacetate (0.87 mL, 7.6 mmol) in THF (6 mL) was added Pd2(dba)3 (0.05 g,
0.05 mmol) and dppe (0.05 g, 0.13 mmol) to give 3.35c as pale yellow solid (0.32 g,
46%). IR (neat), 1742, 1714 cm-1; 1H NMR (CDCl3) δ 7.26 (m, 5H), 6.73 (1H, m), 5.75
(1H, m), 4.28 (1H, m), 4.1(1H, d, JHH = 11.27 Hz), 3.66 (6H, m). 3.61 (3H, s), 2.14 (3H,
s);

13

C NMR (CDCl3) δ 200.4 (200.3), 167.7 (167.3), 152.3 (152.26) (d, JCC = 5.2 Hz),

137.9 (137.6), 129.1 (128.9), 128.2 (128.1), 128.1, 127.8 (127.6), 117.8 (117.5) (d, JCP =
185.4 Hz), 64.1 (63.5), 52.7 (52.5), 52.3 (d, JCP = 5.7 Hz), 49.3 (48.9) (d, JCP = 22.2 Hz),
30.4 (30.1); 31P NMR (CDCl3) δ 20.87, 20.1 ppm; HRMS (FAB, NBA, MH+) calcd. for
C16H21O6P: 340.1153, found 341.1157; and 3.35j as white solid (0.34 g, 47%). IR (neat)
1646, 1611 cm-1; 1H NMR (CDCl3) δ 13.02, (1H, s), 7.37 – 7.25 (5H, m), 6.18 (1H, JHH =
7.6 Hz), 3.76 (6H, d, = 10.87 Hz). 3.71 (3H, s), 2.7 (2H, dd, JHH = 7.6 Hz, JHp = 22.6 Hz),
1.88 (3H, s);

13

C NMR (CDCl3) δ 175.47, 172.92, 140.73, 138.22, 128.86, 128.02,

126.30, 121.1, 99.38, 53.03 (d, JCP = 11.43 Hz), 52.24, 27.88 (d, JCP = 139.88 Hz), 19.77;
31

P NMR (CDCl3) δ 30.46; HRMS (FAB, NBA, MH+) calcd. for C16H22O6P: 340.1153,

found 341.1150.

(E)-methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)vinyl)tridecanoate (3.35d). To the
stirring solution of carbonate 3.33d (0.182 g, 0.5 mmol) and methyl acetoacetate (3.36)
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(0.17 mL,1.5 mmol) in dry THF (1mL) was added Pd2(dba)3 (0.01g, 0.01mmol) followed
by dppe (0.1g, 0.025 mmol) to give 3.35d as pale yellow oil (0.16 g, 78%). IR (neat,
NaCl), 1743, 1719 cm-1; 1H NMR (CDCl3) δ 6.59 (0.5H, ddd, JHH = 17.1, 9.6 Hz, JHP =
21.5 Hz), 6.49 (0.5H, ddd, JHH = 17.1, 9.6 Hz, JHP = 21.5 Hz), 5.7 (0.5H, dd, JHH = 17.1
Hz, JHP = 21.5 Hz), 5.65 (0.5H, dd, JHH = 17.1Hz, JHP = 21.5 Hz), 3.67 (9H, m), 3.54 (1H,
2d, JHH = 9.4 and 9.2 Hz), 2.98 (1H, 2q, JHH = 9.3 Hz), 2.24 (1.6H, s), 2.18 (1.4H, s), 1.23
(30H, br s), 0.87 (3H, t, JHH = 6.7 Hz); 13C NMR (CDCl3) δ 201.5, 168.7 (168.5), 153.5
(d, JCP = 9.1 Hz ), 118.8 (d, JCP = 171.7 Hz), 63.9 (63.8), 52.8 (52.7), 52.5 (d, JCP = 5.4
Hz), 44.3 (44), 32.1, 31.9 (31.8), 30.3 (30.1), 29.8, 29.6, 29.5, 27.3 (27.20), 22.9, 14.3;
31

P NMR (CDCl3) δ 20.7, 20.6; HRMS (FAB, NBA, MH+) calcd. for C20H38O6P:

405.2406, found 405.2403.

(2R,3R)-

and

(2S,3R)-

methyl

2-acetyl-3-((E)-2-(dimethoxyphosphoryl)vinyl)-

tridecanoate (3.35h). To a stirring solution of carbonate 3.33h (0.37 g, 1 mmol) and
methyl acetoacetate (0.33 mL, 3 mmol) in dry THF (2 mL) was added Pd2(dba)3 (0.02 g,
0.02 mmol) followed by dppe (0.02 g, 0.05 mmol) to give 3.35h as pale yellow oil (0.33
g, 81%). IR (neat, NaCl) 1742, 1719 cm-1; 1H NMR (CDCl3) δ 6.56 (0.5H, ddd, JHH =
17.1, 9.6 Hz, JHP = 21.4 Hz), 6.51 (0.5H, ddd, JHH = 17.1, 9.5 Hz, JHP = 21.4 Hz), 5.71
(0.5H, dd, JHH = 17.2Hz, JHP = 21.4 Hz), 5.64 (0.5H, dd, JHH = 17.1Hz, JHP = 21.4 Hz),
3.71 (9H, m), 3.54 (1H, 2d, JHH = 9.3 and 9.2 Hz), 2.97 (1H, 2q, JHH = 9.2 Hz ), 2.23
(1.6H, s), 2.18 (1.4H, s), 1.23 (18H, br s), 0.87 (3H, t, JHH = 6.66 Hz); 13C NMR (CDCl3)
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δ 201.4, 168.7 (168.5), 153.5 (153.4) (d, JCP = 8.3 Hz), 118.9 (118.7) (d, JCP = 184.6 Hz),
63.9 (63.8), 52.8 (52.6), 52.5 (d, JCP = 5.5 Hz), 44.3 (44), 32.1, 31.9 (31.8), 30.3 (30.1),
29.7, 29.6, 29.5, 27.3 (27.2), 22.9, 14.3;

31

P NMR (CDCl3) δ 20.7, 20.6; HRMS (FAB,

NBA, MH+) calcd. for C20H38O6P: 405.2406, found 405.2402.

(2R,3S)-

and

(2S,3S)-

methyl

2-acetyl-3-((E)-2-(dimethoxyphosphoryl)vinyl)-

tridecanoate (3.35i). To a stirring solution of carbonate 3.33i (0.61 g, 1.66 mmol) and
methyl acetoacetate (3.36) (0.54 mL, 5 mmol) in dry THF (4 mL) was added Pd2(dba)3
(0.03 g, 0.03 mmol) followed by dppe (0.03 g, 0.08 mmol) to give 3.35i as pale yellow
oil (0.48 g, 71%). IR (neat, NaCl) 1742, 1719 cm-1; 1H NMR (CDCl3) δ 6.56 (0.5H, ddd,
JHH = 17.1, 9.5 Hz, JHP = 21.5 Hz), 6.51 (0.5H, ddd, JHH = 17.1, 9.5 Hz, JHP = 21.5 Hz),
5.71 (0.5H, dd, JHH = 17.2 Hz, JHP = 21.5 Hz), 5.64 (0.5H, dd, JHH = 17.1Hz, JHP = 21.5
Hz), 3.71 (9H, m), 3.54 (1H, 2d, JHH = 9.3 and 9.2 Hz), 2.97 (1H, 2q, JHH = 9.2 Hz), 2.23
(1.6H, s), 2.18 (1.4H, s), 1.23 (18H, br s), 0.87 (3H, t, JHH = 6.66 Hz); 13C NMR (CDCl3)
δ 201.1, 168.4 (168.3), 153.3 (153.2) (d, JCP = 9.2 Hz), 118.6 (118.4) (d, JCP = 184.3 Hz),
63.6, 52.7 (d, JCP = 7.1 Hz), 63.6, 52.5 (52.3), 52.1(d, JCP = 5 Hz), 44 (43.7), 31.8, 31.7
(31.5), 30 (29.8), 29.5, 29.3, 29.2, 27 (26.9), 22.6, 14;

31

P NMR (CDCl3) δ 20.6, 20.5;

HRMS (FAB, NBA, MH+) calcd. for C20H38O6P: 405.2406, found 405.2409.
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(E)-methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)vinyl)pentadecanoate (3.35e). To a
stirring solution of carbonate 3.33e (1.26 g, 3.2 mmol) and methyl acetoacetate (3.36)
(1.05 mL, 9.6 mmol) in dry THF (6.5 mL) was added Pd2(dba)3 (0.06 g, 0.64 mmol)
followed by dppe (0.06 g, 0.16 mmol) to give 3.35e as pale yellow oil (1.13 g, 80%). IR
(neat, NaCl) 1743, 1719 cm-1; 1H NMR (CDCl3) δ 6.59 (0.5H, ddd, JHH = 17.1, 9.5 Hz,
JHP = 21.5 Hz), 6.49 (0.5H, ddd, JHH = 17.1, 9.5 Hz, JHP = 21.5 Hz), 5.72 (0.5H, dd, JHH =
17.1Hz, JHP = 21.5 Hz), 5.65 (0.5H, dd, JHH = 17.1Hz, JHP = 21.5 Hz), 3.71 (9H, m), 3.5
(1H, 2d, JHH = 9.4 and 9.2 Hz), 2.98 (1H, 2q, JHH = 9.1 and 9.3 Hz, JHH = 1.6 Hz), 2.21
(1.5H, s), 2.15 (1.5H, s), 1.22 (22H, br s), 0.88 (3H, t, JHH = 6.7 Hz); 13C NMR (CDCl3) δ
201.5, 168.7 (168.6), 153.5 (d, JCP = 4.4 Hz), 118.9 (185) (d, JCP = 184.8 Hz), 63.9
(63.8), 52.6 (52.7), 52.5 (d, JCP = 5.6 Hz), 44.3 (44), 32.1, 31.9 (31.8), 30.3 (30.1), 29.9,
29.8, 29.7, 29.6, 29.5, 27.3 (27.2), 22.9, 14.3;

31

P NMR (CDCl3) δ 20.7, 20.6; HRMS

(FAB, MH+) calcd. for C22H42O6P: 433.2718, found 433.2720.

(E)-methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)vinyl)nonadecanoate (3.35f).To a
stirring solution of carbonate 3.33f (0.45 g, 1mmol) and methyl acetoacetate (3.36) (0.64
mL, 3 mmol) in dry THF (2mL) was added Pd2(dba)3 (0.02g, 0.02 mmol) followed by
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dppe (0.02g, 0.05 mmol) to give 3.35f as waxy solid (0.36 g, 72%). IR (neat, NaCl),
1743, 1637 cm-1; 1H NMR (CDCl3) δ 6.59 (0.5H, ddd, JHH = 17.1, 9.5 Hz, JHP = 21.5 Hz),
6.45 (0.5H, ddd, JHH = 17.1, 9.4 Hz, JHP = 21.5 Hz), 5.72 (0.5H, dd, JHH = 17.1 Hz, JHP =
21.5 Hz), 5.65 (0.5H, dd, JHH = 17.1 Hz, JHP = 21.5 Hz), 3.71 (9H, m), 3.54 (1H, 2d, JHH =
9.4 and 9.2 Hz), 2.97 (1H, 2q, JHH = 9.1 and 9.3 Hz), 2.21 (1.5H, s), 2.15 (1.5H, s), 1.22
(30H, br s), 0.85 (3H, t, JHH = 6.66 Hz); 13C NMR (CDCl3) δ 201.3, 168.6 (168.5), 153.4
(153.3) (d, JCP = 8.4 Hz), 118.8 (118.6) (d, JCP = 184.3 Hz), 63.8 (63.7), 52.7 (52.5), 52.7
(d, JCP = 5.6 Hz), 44.2 (43.9) (d, JCP = 2.2 Hz), 32.1, 31.8 (31.7), 30.2 (30), 29.9, 29.8,
29.7, 29.6, 29.5, 29.4, 27.2 (27.1), 22.8, 14.3;

31

P NMR (CDCl3) δ 20.7, 20.6; HRMS

(FAB, NBA, MH+) calcd. for C26H50O6P: 485.3345, found 489.3340.

(E)-methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)vinyl)henicosanoate (3.35g). To a
stirring solution of carbonate 3.33g (0.48 g, 1mmol) and methyl acetoacetate (3.36) (0.33
mL, 3 mmol) in dry THF (2 mL) was added Pd2(dba)3 (0.02 g, 0.02 mmol) followed by
dppe (0.02 g, 0.05 mmol) to give the product 3.35g as pale yellow oil (0.35 g, 70%). IR
(neat, NaCl) 1742, 1713 cm-1; 1H NMR (CDCl3) δ 6.56 (0.5H, ddd, JHH = 17.1, 9.5 Hz,
JHP = 21.4 Hz), 6.45 (0.5H, ddd, JHH = 17.1, 9.5 Hz, JHP = 21.5 Hz), 5.67 (0.5H, dd, JHH =
17.1 Hz, JHP = 21.5 Hz), 5.60 (0.5H, dd, JHH = 17.1 Hz, JHP = 21.5 Hz), 3.67 (9H, m),
3.54 (1H, 2d, JHH = 9.4 and 9.2 Hz), 2.97 (1H, 2q, JHH = 9.4 and 9.2 Hz), 2.21 (1.5H, s),
2.15 (1.5H, s), 1.21 (34H, br s), 0.84 (3H, t, JHH = 6.6 Hz); 13C NMR (CDCl3) δ 201.3,
168.6 (168.4), 153.4 (153.3) (d, JCP = 4.6 Hz), 118.8 (118.6) (d, JCP = 184.6 Hz ), 63.8
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(63.7), 52.7 (52.5), 52.4 (d, JCP = 5.5 Hz), 44.2 (43.9) (d, JCP = 2.3 Hz), 32.0, 31.8 (31.7),
30.2 (30), 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 27.2 (27.1), 22.8, 14.3; 31P NMR (CDCl3) δ
20.7, 20.6; HRMS (FAB, NBA, MH+) calcd. for C26H50O6P: 485.3345, found 489.3340.
General procedure for hydrogenation of vinyl phosphonate
To a solution of vinyl phosphonate (1 mmol) in methanol (3 ml) was added 10%
palladium on charcoal (0.07 g, 0.07 mmol). The solution was first flushed with argon,
followed by hydrogen gas. A reservoir of hydrogen was provided by a balloon. After
completion of the reaction (31P NMR analysis), the reaction mixture was filtered through
Celite® which was washed with additional CH2Cl2. The solvent was evaporated under
reduced pressure to give the saturated phosphonate.

Methyl 2-acetyl-5-(dimethoxyphosphoryl)pentanoate (3.37a). To a solution of vinyl
phosphonate 3.35a (0.18 g, 0.66 mmol) in methanol (2 ml) was added 10% palladium on
charcoal (0.07 g, 0.07 mmol). The solution was first flushed with argon, followed by
hydrogen gas. A reservoir of hydrogen was probided by a balloon. After completion of
reaction (31P NMR analysis), the reaction mixture was filtered through Celite® which was
furthur washed with CH2Cl2 (5 × 20 ml). The solvent was evaporated under reduced
pressure to give saturated phosphonate (3.37a) as colorless oil (0.18 g, 100%). IR (neat,
NaCl) 1737, 1719 cm-1; 1H NMR (CDCl3) δ 3.66 (d, 3H, JHP = 10.77 Hz), 3.68 (3H, s),
3.38 (1H, t, JHH = 7.25 Hz), 2.17 (3H, s) 1.86 (2H, q, JHH = 7.16, 15.75 Hz), 1.7 (2H, m),
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1.53 (2H, m); 13C NMR (CDCl3) δ 202.9, 170.3, 59.5, 52.9, 52.8 (d, JCP = 6.6 Hz), 29.4,
29.1 (d, JCP = 17.4 Hz) 24.9 (d, JCP = 141 Hz), 20.9 (d, JCP = 4.9 Hz); 31P NMR (CDCl3,
ppm) δ 34.41; HRMS (FAB, NBA, MH+) calcd for C10H20O6P: 267.0997, found
267.0988.

Methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)ethyl)octanoate (3.37b).To a solution of
3.35b (0.65 g, 1.96 mmol) in methanol (5 mL) was added palladium on charcoal (0.21 g,
0.2 mmol) and the solution was firstly flushed with argon followed by purging with
hydrogen gas to give the saturated phosphonate 3.37b as colorless oil (0.65 g, 100%). IR
(neat, NaCl) 1739, 1716 cm-1; 1H NMR (CDCl3) δ 3.73 (9H, m), 3.45 (1H, d, JHH = 8.3
Hz), 2.26 (1H, br s), 2.23 (4H, s), 1.67 (m, 4H), 1.25 (br, 8H), 0.87 (t, 3H, JHH = 6.7 Hz);
13

C NMR (CDCl3) δ 202.9, 169.7 (169.69), 63.2(63.1), 52.6, 52.5 (d, JCP = 6.5 Hz), 38.1

(d, JCP = 17.2a Hz), 32.0 (d, JCP = 7.1 Hz), 30.6 (30.4), 29.6, 26.1, 22.7, 14.2; 31P NMR
(CDCl3) δ 35, 34.9; HRMS (FAB, NBA, MH+) calcd. for C15H29O6P: 336.1780, found
337.1779.

Methyl 2-acetyl-5-(dimethoxyphosphoryl)-3-phenylpentanoate (3.37c).To a solution
of 3.35d (or, 3.35e) (0.29 g, 0.84 mmol) in methanol (3 mL) was added palladium on
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charcoal (0.09 g, 0.08 mmol) and the solution was firstly flushed with argon followed by
purging with hydrogen gas to give the saturated phosphonate 3.37c as colorless oil (0.30
g, 100%). IR (neat, NaCl) 1745, 1717 cm-1; 1H NMR (CDCl3) δ 7.34 (m, 5H), 4.28(1H,
m), 4.1(1H, d, JHH = 11.27 Hz), 3.66 (6H, m), 3.61 (3H, s), 2.14 (3H, s);

13

C NMR

(CDCl3) δ 201.8, 168.8 (168.2), 139.5 (139.2), 129.1, 128.8, 128.4, 127.7, 127.6, 66.6
(65.8), 52.8, 52.5 (d, JCP = 6.5 Hz), 46.1 (45.6) (d, JCP = 19.1 Hz), 30.3 (30.0), 26.9 (26.8)
(d, JCP = 16.4 Hz), 23.5 (23.4), 21.6 (d, JCP = 8.7 Hz); 31P NMR (CDCl3) δ 34.64 ppm;
HRMS (FAB, MH+) calcd. for C16H24O6P: 343.1310, found 343.1311.

Methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)ethyl)tridecanoate (3.37d). To the
solution of 3.35d (0.44 g, 1.08 mmol) in methanol (5 mL) was added palladium on
charcoal (0.01 g, 0.11 mmol) and the solution was firstly flushed with argon followed by
purging with hydrogen gas to give the saturated phosphonate 3.37d as colorless oil (0.44
g , 100%). IR (neat, NaCl) 1737, 1712 cm-1; 1H NMR (CDCl3) δ 3.73 (6H, d, JHD = 10.8
Hz ), 3.73 (3 H, app d), 3.45(1H, d, JHH = 8.3 Hz ), 2.26 (1H, br s), 2.23 (3H, s), 1.76 –
1.6 (4H, m), 1.25 (18 H, br s), 0.88 (3H, t, JHH = 6.44 Hz); 13C NMR (CDCl3) δ 202.9,
169.7, 63.2, 52.6, 52.5, 38.2 (38), 32.1, 30.5 (d, JCP = 10.5 Hz), 30, 29.9, 29.8, 29.7, 29.6,
29.5, 26.5, 22.9, 14.3;

31

P NMR (CDCl3) δ 35, 34.9; HRMS (FAB+) calcd for

C20H39O6PNa: 429.2381, found 429.2351.
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(2R,3S)- and (2S,3S)-methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)ethyl)tridecanoate
(3.37h). To a solution of 3.35h (0.44 g, 1.08 mmol) in methanol (5 mL) was added
palladium on charcoal (0.01 g, 0.11 mmol) and the solution was firstly flushed with argon
followed by purging with hydrogen gas to give the saturated phosphonate 3.37h as
colorless oil (0.44 g, 100%). IR (neat, NaCl) 1738, 1714 cm-1; 1H NMR (CDCl3) δ 3.73
(6H, d, JHP = 10.8 Hz ), 3.73 (3 H, app d), 3.46 (1H, d, JHH = 8.3 Hz ), 2.26 (1H, br s),
2.23 (3H, s), 1.76 – 1.6 (4H, m), 1.25 (18 H, br s), 0.88 (3H, t, JHH = 6.6 Hz); 13C NMR
(CDCl3) δ 203, 169.7, 63.2, 52.6 (d, JCP = 6 Hz), 52.5, 38.2 (38), 32.1, 30.5 (d, JCP = 10.5
Hz), 30, 29.9, 29.8, 29.7, 29.6, 29.5, 26.5, 22.9, 14.3;

31

P NMR (CDCl3) δ 35, 34.9;

HRMS (FAB, NBA, MH+) calcd for C20H40O6P: 407.2562, found 407.2557.

(2S,3R)- and (2R,3R)-methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)ethyl)tridecanoate
(3.37i). To a solution of 3.35i (0.46 g, 1.13 mmol) in methanol (4 mL) was added
palladium on charcoal (0.01 g, 0.11 mmol) and the solution was firstly flushed with argon
followed by purging with hydrogen gas to give the saturated phosphonate 3.35i as
colorless oil (0.46 g, 100%). IR (neat, NaCl) 1735, 1713 cm-1; 1H NMR (CDCl3) δ 3.69
(6H, d, JHP = 10.7 Hz ), 3.69 (3 H, app d), 3.43(1H, d, JHH = 8.2 Hz), 2.26 (1H, br s), 2.19
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(3H, s), 1.68 – 1.56 (4H, m), 1.21 (18H, br s), 0.83 (3H, t, JHH = 6.5 Hz);

13

C NMR

(CDCl3) δ 202.9, 169.6, 63.1, 52.5 (d, JCP = 6.6 Hz), 52.5, 38.1 (37.9), 32, 30.5 (d, JCP =
10.5 Hz), 30, 29.9, 29.8, 29.7, 29.6, 29.4, 26.4, 22.8, 14.2; 31P NMR (CDCl3) δ 35, 34.9;
HRMS (FAB, NBA, MH+) calcd for C20H40O6P: 407.2562, found 407.2561.

Methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)ethyl)pentadecanoate (3.37e). To a
solution of 3.35e (0.33 g, 0.757 mmol) in methanol (4 mL) was added palladium on
charcoal (0.08 g, 0.08 mmol) and the solution was firstly flushed with argon followed by
purging with hydrogen gas to give the saturated phosphonate 3.37e as colorless oil (0.33
g, 100%). IR (neat, NaCl) 1736, 1712cm-1; 1H NMR (CDCl3) δ 3.73 (6H, JHP = 10.8 Hz),
3.73 (3H, app d), 3.46 (1H, d, JHH = 8.3,Hz ), 2.27 (1H, br s), 2.23 (3H, s), 1.77 – 1.6
(4H, m), 1.25 (20 H, br s), 0.88 (3H, t, JHH = 6.7 Hz);

13

C NMR (CDCl3) δ 203, 169.7,

63.2, 52.6 (d, JCP = 7.1 Hz), 52.5, 38.2 (38), 32.1, 30.6 (d, JCP = 10.6 Hz), 30, 29.9, 29.8,
29.7, 29.6, 29.5, 26.5, 22.9 14.3;

31

P NMR (CDCl3) δ 35, 34.9; HRMS (FAB, NBA,

MH+) calcd for C22H44O6P: 435.2875, found 435.2868.

Methyl 2-acetyl-3-(2-(dimethoxyphosphoryl)ethyl)nonadecanoate (3.37f). To a
solution of 3.35f (0.22 g, 0.45 mmol) in methanol (3 mL) was added palladium on
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charcoal (0.05 g, 0.05mmol) and the solution was firstly flushed with argon followed by
purging with hydrogen gas to give the saturated phosphonate 3.37f as colorless oil (0.22
g, 100%). IR (neat, NaCl) 1736, 1718 cm-1; 1H NMR (CDCl3) 3.72 (6H, d, JHP = 10.7
Hz), 3.71 (3H, app d), 3.44(1H, d, JHH = 8.9Hz), 2.24 (1H, br s), 2.21 (3H, s), 1.73 - 1.58
(4H, m), 1.23 (30H, br s), 0.86 (3H, t, JHH = 6.7 Hz);

13

C NMR (CDCl3) δ 203, 169.7,

63.1, 52.6 (d, JCP = 7.1 Hz), 52.5, 38.3, 38, 32.1, 30.5 (d, JCP = 10.2 Hz), 29.9, 29.7, 29.6,
29.5, 26.5, 23.5, 22.9, 20.7, 14.3;

31

P NMR (CDCl3) δ 35, 34.9; HRMS (FAB, NBA,

MH+) calcd for C26H52O6P: 491.3501, found 491.3507.

Methyl

2-acetyl-3-(2-(dimethoxyphosphoryl)ethyl)henicosanoate

(3.37g).

To

a

solution of 3.35g (0.28 g, 0.55 mmol) in methanol (5 mL) was added palladium on
charcoal (0.06 g, 0.06 mmol) and the solution was firstly flushed with argon followed by
purging with hydrogen gas to give the saturated phosphonate 3.37g as colorless oil (0.29
g, 100%). IR (neat, NaCl) 1735, 1712 cm-1; 1H NMR (CDCl3) 3.73 (6H, d, JHP = 10.8
Hz), 3.73 (3H, app d), 3.46 (1H, d, JHH = 8.3 Hz), 2.26 (1H, br s), 2.23 (3H, s), 1.78 - 1.55
(4H, m), 1.25 (34H, br s), 0.88 (3H, t, JHH = 6.7 Hz);

13

C NMR (CDCl3) δ 203, 169.7,

63.2, 52.6 (d, JCP = 6.2 Hz), 52.5, 38.2 (38), 32.1, 30.5, 29.9, 29.8, 29.7, 29.6, 26.5, 22.9,
14.3; 31P NMR (CDCl3) δ 35, 34.9; HRMS (FAB, NBA, MH+) calcd for C26H57O6PNa:
519.3814, found 519.3818.
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Methyl 2-acetyl-4-(dimethoxyphosphoryl)butanoate (3.40). To a suspension of
potassium t-butoxide (0.56 g, 5 mmol) in THF (14 mL) was slowly added methyl
acetoacetate (3.36) (1.63 mL, 10 mmol) followed by addition of dimethyl vinyl
phosphonate (3.39) (0.6 mL, 5 mmol) over 5 minutes. The resulting reaction mixture was
stirred at room temperature for 2 h. After completion of the reaction (TLC and 31P NMR
analysis), it was quenched with saturated NH4Cl solution. The layers were separated and
and the aqueous layer was re-extracted with EtOAc (2 × 10 mL). The combined organic
layer was dried over anhydrous Na2SO4 and solvent was evaporated under reduced
pressure to give crude product. Purification by column chormatography (SiO2, 30 – 60 %
EtOAc in hexanes) gave the alkyl phosphonate (3.40) (0.76 g, 60%). IR (neat, NaCl)
1742, 1716 cm-1; 1H NMR (CDCl3) δ 3.72 (d, 6H, JHP = 10.55 Hz), 3.72 (3H, s), 3.61
(1H, t, JHH = 7.2 Hz), 2.23 (3H, s), 2.09 (2H, m), 1.74 (3H, m);

13

C NMR (CDCl3) δ

202.5, 169.8, 59.1(d, JCH = 13.9 Hz), 53, 52.9 (d, JCP = 6.6 Hz), 29.7, 22.5 (d, JCP = 141
Hz), 21.3 (d, JCP = 4.3 Hz); 31P NMR (CDCl3) δ 33.53; HRMS (FAB, NBA, MH+) calcd
for C9H18O6P: 252.0841, found 252.0844.
General procedure for the synthesis of monocylic phosphonate analog
To a solution of alkyl phosphonate (1 mmol) in acetonitrile (2.6 mL) was added NaI (1.1
equivalents) and the resulting mixture was refluxed under Argon overnight. After
completion of the reaction (31P NMR analysis, δ (CD3OD) = 27 – 28 ppm) solvent was
removed under reduced pressure to give mono-sodium salt as solid.
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To the suspension of the sodium salt in methanol was added AmberliteIR-120H® resin
resin (prewashed with methanol) and resulting mixture was shaken in an orbit shaker.
After completion of the reaction (31PNMR analysis, δ (CD3OD) = ~ 34 ppm), resin was
filtered off and washed with additional methanol. Solvent was removed under reduced
pressure to give free monophosphonic acid as a red viscous liquid.
To a solution of monophosphonic acid (1 mmol) in freshly distilled CH2Cl2 (6 mL) was
added EDC (1.5 mmol) and HOBt (1.5 mmol) followed by Hunig’s base (1.5 mmol).
After the completion of the reaction (31P NMR analysis), additional CH2Cl2 was added to
the reaction mixture and was washed with saturated NaHCO3. The organic layer was
collected, dried over anhydrous Na2SO4, evaporated under reduced pressure to give crude
product. Purification of the crude product by chromatography (SiO2, 10 – 60 % EtOAc in
hexanes) gave the product as mixture of diastereomers which were further separated by
repeated column chromatography.

Methyl 2-methoxy-7-methyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6-carboxylate 2oxide (3.16). To a solution of phosphonate (3.37a) (0.12 g, 0.43 mmol) in acetonitrile (2
ml) was added NaI (0.07 g, 0.48 mmol) and the resulting mixture was heated at reflux
overnight to give the mono-sodium salt as solid which was converted to corresponding
phosphonic acid by AmberliteIR-120H® resin. The solvent was evaporated under reduced
pressure to give the phosphonic acid (3.38a) (0.12 g) as a viscous red liquid. The crude
phosphonic acid (0.11 g, 0.45 mmol) was dissolved in dry methylene chloride (9 ml), and
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then EDC (0.11 g, 0.58 mmol) and HOBt (0.09 g, 0.67 mmol) were added followed by
Hunig’s base (0.12 ml, 0.67 mmol). After 24 h, the solvent was removed under reduced
pressure and the residue was dissolved in 20 ml of EtOAc. The solution was washed
saturated aq. NaHCO3, dried over MgSO4 and evaporated under reduced pressure.
Purification of the crude product by column chromatography (SiO2, 20 – 40 % EtOAc in
hexanes) gave the monocyclic phosphonate (3.16) (0.06 g, 45%). IR (neat, NaCl) 1716,
1646 cm-1; 1H NMR (CDCl3) δ 3.81 (d, 3H, JHP = 11.2 Hz), 3.73 (3H, s), 2.65 (1H, m),
2.48 (1H, m), 2.32 (3H, s), 2.0 (4H, m);

13

C NMR (CDCl3) δ 168.4, 159.4 (d, JCP = 7.9

Hz), 119.6 (d, JCP = 4.6 Hz), 52.6 (d, JCP = 7.1 Hz), 52.3, 26.6 (d, JCP = 2.6 Hz), 26.6 (d,
JCP = 133.5 Hz), 21.4 (d, JCP = 7.5 Hz), 21.3;

31

P NMR (CDCl3) δ 25.0, HRMS (EI+)

calcd for C9H15O5P: 234.0657, found 234.0659.

Methyl

2-methoxy-7-methyl-5-pentyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6-

carboxylate 2-oxide (3.17a and b). To a solution of 3.37b (0.52 g, 1.55 mmol) in
acetonitrile (5 mL) was added sodium iodide (0.25 g, 1.69 mmol) and refluxed overnight
to give crude sodium salt (0.60 g) which was converted to monophosphonic acid (3.38b)
by using the above mentioned method.
To a solution of crude monophosphonic acid in dry methylene chloride (9 mL) was added
EDC (0.38 g, 1.99 mmol) and HOBt (0.16 g, 2.25 mmol) followed by Hunig’s base (0.4
mL, 2.25 mmol) to give crude monocyclic product. Purification by chromatography
(SiO2, 10 – 60% EtOAc in hexanes) gave 1:1.25 mixture of diastereomers (0.27g, 56%).
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Further chromatographic separation of diastereomers gave 3.17a as pale yellow oil. IR
(neat, NaCl) 1717 cm-1; 1H NMR (CDCl3) δ 3.82 (d, 3H, JHP = 11.18 Hz), 3.73 (3H, s),
2.97 (1H, m), 2.22 (3H, d, JHH = 1.28 Hz), 2.12–1.81 (4H, m), 1.61 (1H, m), 1.46 (1H,
m), 1.25 (6H, br s), 0.87 (3H, t, JHH = 6.5 Hz); 13C NMR (CDCl3) δ 169.34, 156.1 (d, JCP
= 7.28 Hz), 123.55 (d, JCP = 5.1 Hz), 52.39 (d, JCP = 7.1 Hz), 52.26, 37.63, 32.21, 31.1,
27.7, 25.31 (d, JCP = 6.8 Hz), 22.93, 22.3 (d, JCP = 134.3 Hz), 21.67, 14.44; 31P NMR
(CDCl3) δ 26.8; HRMS (FAB, NBA, MH+) calcd. for C14H26O5P: 305.1517, found
305.1523; and 3.17b as pale yellow oil. IR (neat, NaCl) 1717 cm-1; 1H NMR (CDCl3) δ
3.82 (3H, d, JHP = 11.18 Hz), 3.75 (3H, s), 2.88 (1H, m), 2.18 (3H, d, JHH = 1.3 Hz ),
2.14-1.87 (4H, m), 1.63 (1H, m), 1.47 (1H, m), 1.25 (6H, br s), 0.87 (3H, t, JHH = 6.5 Hz);
13

C NMR (CDCl3) δ 169.51, 155.27 (d, JCP = 9.3 Hz), 123.44 (d, JCP = 4.73 Hz), 52. 95

(d, JCP = 6.67 Hz), 52.32, 37.5, 32.13, 31.2, 30.1, 27.65, 25.51 (d, JCP = 7.91 Hz), 22.91,
22.64 (d, JCP = 133.33Hz), 21.51 (d, JCP = 1.87 Hz), 14.43; 31P NMR (CDCl3) δ 24.2;
HRMS (FAB, NBA, MH+) calcd. for C14H26O5P: 305.1517, found 305.1523.

Methyl

2-methoxy-7-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6-

carboxylate 2-oxide (3.18a and b). To a solution of alkyl phosphonate 3.37c (0.5 g, 1.46
mmol) in acetonitrile (5 mL) was added sodium iodide (0.24 g, 1.61 mmol) and refluxed
overnight to give crude monophosphonic acid (0.55 g) which was converted to
monophosphonic acid 3.38c by using the above mentioned method.
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To a solution of crude monophosphonic acid in dry methylene chloride (9 mL), EDC
(0.37 g, 1.9 mmol) and HOBt (0.30 g, 2.19 mmol) was added followed by Hunig’s base
(0.38 mL, 2.19 mmol) to give crude monocyclic product which was purified by
chromatography (SiO2, 10 – 20% EtOAc in hexanes) to give a 1:1 mixture of
diastereomers (0.28 g, 52%) which was taken for repeated chromatography for
diastereomer separation. Complete separation was not achieved. Only 3.18a could be
isolated in enriched form (95:5 ratio with 3.18b). IR (neat, NaCl) 1719 cm-1; 1H NMR
(CDCl3) δ 7.27(m, 5H), 4.28(1H, t, JHH = 7 Hz), 3.86 (3H, d, JHP = 11.15 Hz). 3.51 (3H,
s), 2.25 (3H, s), 2.19 (1H, m), 2.05 (1H, m), 1.98 (1H, t, JHH = 6 Hz); 13C NMR (CDCl3) δ
168.97, (168.78), 155.65 (d, JCP = 7.28Hz), (154.66); 141.35, (141.12); (129.04), 129;
(128.1), 127.91; (127.25), 127.15; 121.44 (d, JCP = 5.1 Hz), {53.07 (d, JCP = 6.9Hz )},
52.71 (d, JCP = 6.9 Hz), 52.33, 45.78 (45.63), 28.53 (d, JCP = 7.04 Hz), 23.16 (d, JCP =
133.1 Hz), {23.04 (d, JCP = 133.1 Hz), 22 (21.76); 31P NMR (CDCl3) δ 30.1; HRMS (EI+)
calcd. for C15H19O5P: 310.0970, found 310.0975. On the other hand, 3.18b could not be
enriched beyond 3:2 mixture with 3.18a.

Methyl

5-decyl-2-methoxy-7-methyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6-

carboxylate 2-oxide (3.19 a and b). To a solution of alkyl phosphonate 3.37d (0.47 g,
1.16 mmol) in acetonitrile (3 mL) was added sodium iodide (0.19 g, 1.28 mmol) and
refluxed overnight to give crude sodium salt which was converted to monophosphonic
acid 3.38d by using the above mentioned method.
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To a solution of crude

monophosphonic acid (0.45, 1.13 mmol) in dry methylene

chloride (7 mL) was added EDC (0.33 g, 1.7 mmol) and HOBt (0.23 g, 1.7 mmol)
followed by Hunig’s base (0.3 mL, 1.7 mmol) to give crude monocyclic product.
Purification of the crude product by column chromatography (SiO2, 10 – 30% EtOAc in
hexanes) gave 1:1.25 mixtures of diastereomers (0.21 g, 46%). Further chromatographic
separation of diastereomers gave 3.19a as pale yellow oil. IR (neat, NaCl) 1719 cm-1; 1H
NMR (CDCl3) δ 3.82 (3H, d, JHP = 11.2 Hz), 3.75 (3H, s), 2.99 (1H, m), 2.23 (3H, d, JHH
= 1.6 Hz ), 2.14 –1.87 (4H, m), 1.62 (1H, m), 1.48 (1H, m), 1.25 (16H, br s), 0.88 (3H, t,
JHH = 6.7 Hz); 13C NMR (CDCl3) δ 169.2 (d, JCP = 1.9 Hz), 155.9 (d, JCP = 7.3 Hz), 123.4
(d, JCP = 5.3 Hz), 52.2 (d, JCP = 7.1 Hz), 52.1, 37.4, 32.1, 30.9, 29.9, 29.8, 29.7, 29.5,
27.9, 25.1 (d, JCP = 6.9 Hz), 22.9, 22.1 (d, JCP = 134.4Hz), 21.51, 14.3; 31P NMR (CDCl3)
δ 26.8; HRMS (FAB, NBA, MNa+) calcd. for C19H35O5PNa: 397.2119, found 397.2125;
and 3.19b also as pale yellow oil. IR (neat, NaCl) 1719 cm-1; 1H NMR (CDCl3) δ 3.83
(3H, d, JHP = 11.1 Hz), 3.76 (3H, s), 2.88 (1H, m), 2.18 (3H, d, JHH = 1.3 Hz ), 2.26–1.87
(4H, m), 1.63 (1H, m), 1.45 (1H, m), 1.25 (16H, br s), 0.88 (3H, t, JHH = 6.7 Hz);

13

C

NMR (CDCl3) δ 169.3 (d, JCP = 1.7 Hz), 155.1 (d, JCP = 9.4 Hz), 123.3 (d, JCP = 4.6 Hz),
52.8 (d, JCP = 6.7 Hz), 52.1, 37.3, 32.1, 31.1, 29.9, 29.8, 29.7, 29.5, 27.8, 25.3 (d, JCP =
7.8 Hz), 22.9, 22.5 (d, JCP = 133.4 Hz), 21.3 (d, JCP = 1.9 Hz), 14.3; 31P NMR (CDCl3) δ
24.2; HRMS (FAB, NBA, MH+) calcd. for C19H35O5PNa: 397.2119, found 397.2115.
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(5S)-methyl

5-decyl-2-methoxy-7-methyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6-

carboxylate 2-oxide (3.19(R)a and b). To a solution of alkyl phosphonate 3.37h (0.21 g,
0.5 mmol) in acetonitrile (1 mL) was added sodium iodide (0.082 g, 0.55 mmol) and
refluxed overnight to give crude sodium salt which was converted to monophosphonic
acid 3.38h by using the above mentioned method.
To a solution of crude monophosphonic acid (0.20 g, 0.5 mmol) in dry methylene
chloride (11 mL) was added EDC (0.14 g, 0.75 mmol) and HOBt (0.1 g, 0.75 mmol)
followed by Hunig’s base (0.13 mL, 0.75 mmol) to give crude monocyclic product.
Purification of the crude product by column chromatography (SiO2, 10 – 30% EtOAc in
hexanes) gave 1:1.1 mixtures of diastereomers (0.08 g, 45%). Further chromatographic
separation of the diastereomers gave 3.19(R)a as pale yellow oil. IR (neat, NaCl) 1717
cm-1; 1H NMR (CDCl3) δ 3.82 (3H, d, JHP = 11.2 Hz), 3.74 (3H, s), 2.99 (1H, m), 2.23
(3H, d, JHH = 1.6 Hz ), 2.22 – 1.97 (4H, m), 1.62 (1H, m), 1.46 (1H, m), 1.25 (16H, br s),
0.88 (3H, t, JHH = 6.7 Hz); 13C NMR (CDCl3) δ 169.2 (d, JCP = 1.7 Hz), 155.9 (d, JCP =
7.2 Hz), 123.4 (d, JCP = 5.3 Hz), 52.2 (d, JCP = 7.1 Hz), 52.1, 37.4 (d, JCP = 1.5 Hz), 32.1,
30.9, 29.8, 29.7, 29.5, 27.9, 25.1 (d, JCP = 6.8 Hz), 22.9, 22.1 (d, JCP = 134.4 Hz), 21.5 (d,
JCP = 1.3 Hz), 14.3;

31

P NMR (CDCl3) δ 26.8; HRMS (FAB, NBA, MH+) calcd. for

C19H35O5P: 374.2222, found 374.2227; ee = > 85% and 3.19(R)b also as pale yellow oil.
IR (neat, NaCl) 1717 cm-1; 1H NMR (CDCl3) δ 3.83 (3H, d, JHP = 11.1 Hz), 3.76 (3H, s),
2.89 (1H, m), 2.19 (3H, s), 2.29 – 1.87 (4H, m), 1.63 (1H, m), 1.48 (1H, m), 1.26 (16H,
br s), 0.89 (3H, t, JHH = 6.6 Hz);

13

C NMR (CDCl3) δ 169.3, 155.1 (d, JCP = 9.3 Hz),

123.3 (d, JCP = 4.7 Hz), 52.8 (d, JCP = 6.7 Hz), 52.2, 37.3, 32.1, 31.0, 29.9, 29.8, 29.77,
29.7, 29.5, 27.8, 25.3(d, JCP = 7.8 Hz), 22.9, 22.4 (d, JCP = 133.6 Hz), 21.4 (d, JCP = 1.8
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Hz), 14.3; 31P NMR (CDCl3) δ 24.1; HRMS (FAB, NBA, MH+) calcd. for C19H36O5P:
375.2300, found 375.2307.

(5R)-methyl 5-decyl-2-methoxy-7-methyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6carboxylate 2-oxide (3.19 (S) a and b). To a solution of alkyl phosphonate 3.37i (0.46 g,
1.13 mmol) in acetonitrile (3 mL) was added sodium iodide (0.19 g, 1.25 mmol) and
refluxed overnight to give crude sodium salt which was converted to monophosphonic
acid 3.38i by using the above mentioned method.
To the solution of crude monophosphonic acid (0.432 g, 1.1 mmol) in dry methylene
chloride (11 mL) was added EDC (0.32 g, 1.65 mmol) and HOBt (0.23 g, 1.65 mmol)
followed by Hunig’s base (0.29 mL, 1.65 mmol) to give crude monocyclic product.
Purification of the crude product by column chromatography (SiO2, 10 – 30% EtOAc in
hexanes) gave 1:1.1 mixture of diastereomers (0.22 g, 53.4%).Further chromatographic
separation of the diastereomers gave 3.19(S)a as pale yellow oil. IR (neat, NaCl) 1717
cm-1; 1H NMR (CDCl3) δ 3.82 (3H, d, JHP = 11.2 Hz), 3.75 (3H, s), 2.99 (1H, m), 2.23
(3H, d, JHH = 1.6 Hz ), 2.14 – 1.87 (4H, m), 1.62 (1H, m), 1.47 (1H, m), 1.25 (16 H, br s),
0.88 (3H, t, JHH = 6.7 Hz); 13CNMR (CDCl3) δ 169.2 (d, JCP = 1.7 Hz), 155.9 (d, JCP = 7.2
Hz), 123.4 (d, JCP = 5.1 Hz), 52.2 (d, JCP = 7 Hz), 52.1, 37.4 (d, JCP = 1.5 Hz), 32.1, 30.9,
29.8, 29.7, 29.5, 27.9, 25.1 (d, JCP = 6.8 Hz), 22.9, 22.1 (d, JCP = 134.5 Hz), 21.5 (d, JCP =
1.4 Hz), 14.3; 31P NMR (CDCl3) δ 26.8; HRMS (FAB, NBA, MH+) calcd. for C19H36O5P:
375.2300, found 375.2307, ee = > 86% ; and 3.19(S)b as pale yellow oil. IR (neat, NaCl)
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1719 cm-1; 1H NMR (CDCl3) δ 3.82 (3H, d, JHP = 11.1 Hz), 3.75 (3H, s), 2.88 (1H, m),
2.18 (3H, d, JHH = 1.1 Hz ), 2.25 – 1.86 (4H, m), 1.63 (1H, m), 1.47 (1H, m), 1.24 (16H,
br s), 0.87 (3H, t, JHH = 6.6 Hz); 13CNMR (CDCl3) δ 169.3 (d, JCP = 1.8 Hz), 155.1 (d, JCP
= 9.3 Hz), 123.3 (d, JCP = 4.7 Hz), 52.8 (d, JCP = 6.7 Hz), 52.1, 37.3, 32.1, 31.2, 29.9,
29.8, 29.7, 29.5, 27.8, 25.3 (d, JCP = 7.8 Hz), 22.9, 22.4 (d, JCP = 133.3 Hz), 21.3 (d, JCP =
2 Hz), 14.3;

31

P NMR (CDCl3) δ 24.1; HRMS (FAB, MH+) calcd. for C19H35O5PNa:

397.2119, found 397.2128.

Methyl

5-dodecyl-2-methoxy-7-methyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6-

carboxylate 2-oxide (3.20a & b). To a solution of alkyl phosphonate 3.37e (0.32 g,
0.739 mmol) in acetonitrile (2 mL) was added sodium iodide (0.12 g, 0.81 mmol) and
refluxed overnight to give crude sodium salt which was converted to monophosphonic
acid 3.38e by using the above mentioned method.
To a solution of crude monophosphonic acid (0.30 g, 0.71 mmol) in dry methylene
chloride (7 mL) was added EDC (0.14 g, 1.1 mmol) and HOBt (0.15 g, 1.1 mmol)
followed by Hunig’s base (0.19 mL, 1.1 mmol) to give crude monocyclic product.
Purification of the crude product by column chromatography (SiO2, 10 – 30% EtOAc in
hexanes) gave 1:1.25 mixtures of diastereomers (0.14 g, 45%) which were further
separated by column chromatography to give 3.20a as pale yellow oil. IR (neat, NaCl)
1719 cm-1; 1H NMR (CDCl3) δ 3.83 (3H, d, JHP = 11.2 Hz), 3.75 (3H, s), 2.99 (1H, m),
2.23 (3H, d, JHH = 1.6 Hz ), 2.14 – 1.87 (4H, m), 1.63 (1H, m), 1.47 (1H, m), 1.25 (20H,
122

br s), 0.89 (3H, t, JHH = 6.7 Hz);

13

C NMR (CDCl3) δ 169.2, 155.9 (d, JCP = 7.1 Hz),

123.4 (d, JCP = 5.3 Hz), 52.2 (d, JCP = 7.8 Hz), 52.1, 37.4, 32.1, 30.9, 29.9, 29.8, 29.7,
29.6, 27.9, 25.1 (d, JCP = 6.8 Hz), 22.9, 22.6 (d, JCP = 134.3Hz), 21.5, 14.3; 31P NMR
(CDCl3) δ 26.8; HRMS (FAB, NBA, MH+) calcd. for C21H40O5P:403.2613, found
403.2613; and 3.20b as pale yellow oil. IR (neat, NaCl) 1719 cm-1; 1H NMR (CDCl3) δ
3.83 (3H, d, JHP = 11.2 Hz), 3.76 (3H, s), 2.88 (1H, m), 2.19 (3H, d, JHH = 1.2 Hz ), 2.14 –
1.87 (4H, m), 1.63 (1H, m), 1.47 (1H, m), 1.25 (6H, br s), 0.87 (3H, t, JHH = 6.5 Hz); 13C
NMR (CDCl3) δ 169.4, 155.1 (d, JCP = 9.4 Hz), 123.3 (d, JCP = 4.3 Hz), 52.8 (d, JCP = 6.7
Hz), 52.2, 37.3, 32.1, 31.0, 29.9, 29.8, 29.7, 29.6, 27.8, 25.3 (d, JCP = 7.7 Hz), 22.9, 22.4
(d, JCP = 133.5Hz), 21.3 (d, JCP = 2.0 Hz), 14.3; 31P NMR (CDCl3) δ 24.2; HRMS (FAB,
NBA, MNa+) calcd. for C21H39O5PNa: 425.2439, found 425.2427.

Methyl 5-hexadecyl-2-methoxy-7-methyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6carboxylate 2-oxide (3.21a and b). To a solution of alkyl phosphonate 3.37f (1.05 g,
2.14 mmol) in acetonitrile (5 mL) was added sodium iodide (0.35 g, 2.35 mmol) and
refluxed overnight to give crude sodium salt which was converted to monophosphonic
acid 3.38f by using the above mentioned method.
To a solution of crude monophosphonic acid (1.01 g, 2.12 mmol) in dry methylene
chloride (21 mL) was added EDC (0.61 g, 3.18 mmol) and HOBt (0.43 g, 3.18 mmol)
followed by Hunig’s base (0.56 mL, 3.18 mmol) to give crude monocyclic product.
Purification of the crude product by chromatography (SiO2, 10 – 30% EtOAc in hexanes)
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gave 1:1.25 mixtures of diastereomers (0.45 g, 46%) which were further separated by
column chromatography to give 3.21a as white solid. IR (neat, NaCl) 1720 cm-1; 1H
NMR (CDCl3) δ 3.82 (3H, d, JHP = 11.2 Hz), 3.74 (3H, s), 2.98 (1H, m), 2.23 (3H, d, JHH
= 1.5 Hz ), 2.14 – 1.88 (4H, m), 1.62 (1H, m), 1.45 (1H, m), 1.25 (30 H, br s), 0.88 (3H,
t, JHH = 6.7 Hz);

13

C NMR (CDCl3) δ 169.2 (d, JCP = 1.8 Hz), 155.9 (d, JCP = 7.3 Hz),

123.4 (d, JCP = 5.3 Hz), 52.2 (d, JCP = 7.1 Hz), 52.1, 37.4 (d, JCP = 1.5 Hz), 32.1, 30.9,
30.0, 29.9, 29.8, 29.7, 29.6, 27.9, 25.1 (d, JCP = 6.8 Hz), 22.9, 22.1 (d, JCP = 134.4 Hz),
21.5 (d, JCP = 1.3 Hz), 14.3; 31P NMR (CDCl3) δ 26.8; HRMS (FAB, NBA, MH+) calcd.
for C25H48O5P: 459.3239, found 459.3239; and 3.21b as white solid. IR (neat, NaCl)
1720 cm-1; 1H NMR (CDCl3) δ 3.82 (3H, d, JHP = 11.1 Hz), 3.76 (3H, s), 2.88 (1H, m),
2.18 (3H, s ), 2.11(1H, m), 1.99 (2H, m), 1.89 (1H, m), 1.63 (1H, m), 1.49 (1H, m), 1.25
(30H, br s), 0.89 (3H, t, JHH = 6.6 Hz); 13C NMR (CDCl3) δ 169.3 (d, JCP = 1.7 Hz), 155.1
(d, JCP = 9.5 Hz), 123.3 (d, JCP = 4.6 Hz), 52.8 (d, JCP = 6.7 Hz), 52.2, 37.3, 32.1, 31.0,
30.0, 29.9, 29.8, 29.7, 29.6, 29.3, 27.8, 25.3 (d, JCP = 7.9 Hz), 22.9, 22.4 (d, JCP = 133.4
Hz), 21.3 (d, JCP = 1.9 Hz), 14.3; 31P NMR (CDCl3) δ 24.1; HRMS (FAB, NBA, MH+)
calcd. for C25H48O5P: 459.3239, found 459.3244.

Methyl

2-methoxy-7-methyl-5-octadecyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine-6-

carboxylate 2-oxide (3.22a and b). To a solution of alkyl phosphonate 3.37g (0.29 g,
0.56 mmol) in acetonitrile (2 mL) was added sodium iodide (0.09 g, 0.62 mmol) and
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refluxed overnight to give crude sodium salt which was converted to monophosphonic
acid 3.38g by using the above mentioned method.
To a solution of crude monophosphonic acid (0.28 g, 0.56 mmol) in dry methylene
chloride (6 mL) was added EDC (0.16 g, 0.84 mmol) and HOBt (0.12 g, 0.84 mmol)
followed by Hunig’s base (0.15 mL, 0.84 mmol) to give crude monocyclic product.
Purification of the crude product by column chromatography (SiO2, 10 – 30% EtOAc in
hexanes) gave 1:1.25 mixtures of diastereomers (0.16 g, 59%) which were further
separated by column chromatography to give 3.22a as white solid. IR (neat, NaCl) 1719
cm-1; 1H NMR (CDCl3) δ 3.83 (3H, d, JHP = 11.18 Hz), 3.73 (3H, s), 2.99 (1H, m), 2.24
(3H, d, JHH = 1.6 Hz ), 2.14 – 1.88 (4H, m), 1.63 (1H, m), 1.47 (1H, m), 1.26 (32 H, br s),
0.89 (3H, t, JHH = 6.7 Hz); 13C NMR (CDCl3) δ 169.2, 155.9 (d, JCP = 7.5 Hz), 123.4 (d,
JCP = 5.3 Hz), 52.2 (d, JCP = 7.1 Hz), 52.1, 37.4, 32.1, 30.9, 30.0, 29.9, 29.8, 29.7, 27.9,
25.5 (d, JCP = 6.9 Hz), 22.9, 22.1(d, JCP = 134.5 Hz), 21.5, 14.3; 31P NMR (CDCl3) δ
26.8; HRMS (FAB, NBA, MH+) calcd. for C27H51O5PNa: 509.3371, found 509.3375; and
3.22b as white solid. IR (neat, NaCl) 1718 cm-1; 1H NMR (CDCl3) δ 3.83 (3H, d, JHP =
11.1 Hz), 3.76 (3H, s), 2.88 (1H, m), 2.19 (3H, d, JHH = 1.2 Hz ), 2.11(1H, m), 2.01 (2H,
m), 1.89 (1H, m)1.64 (2H, m), 1.50 (2H, m), 1.26 (26H, br s), 0.88 (3H, t, JHH = 6.6 Hz);
13

C NMR (CDCl3) δ 169.3, 155.1 (d, JCP = 9.3 Hz), 123.3 (d, JCP = 4.7 Hz), 52.8 (d, JCP =

6.7 Hz), 52.2, 37.3, 32.1, 31.0, 30, 29.9, 29.7, 29.6, 27.8, 25.3 (d, JCP = 8 Hz), 22.9, 22.4
(d, JCP = 133.3 Hz), 21.3 (d, JCP = 2.1 Hz), 14.3; 31P NMR (CDCl3) δ 24.2; HRMS (FAB,
MH+) calcd. for C27H51O5PNa: 509.3371, found 509.3363.
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Methyl 2-methoxy-6-methyl-3,4-dihydro-2H-1,2-oxaphosphinine-5-carboxylate 2oxide (3.23). To a solution of phosphonate (3.40) (0.10 g, 0.4 mmol) in dry acetonitrile
(0.5 ml) was added NaI (0.07 g, 0.48 mmol) and refluxed overnight to give crude sodium
salt which was converted to monophosphonic acid 3.41 (0.10 g) by using the above
mentioned method.
To a solution of phosphonic acid (0.09 g, 0.38 mmol) in dry methylene chloride (1.2 ml)
was added EDC (0.09 g, 0.49 mmol) and HOBt (0.07 g, 0.57 mmol) were added followed
by Hunig’s base (0.09 ml, 0.77 mmol). After 24 h, additional amount of CH2Cl2 was
added and the solution was washed with saturated aq. NaHCO3. Organic layer was
collected, dried over MgSO4 and evaporated under reduced pressure to give the crude
monocyclic product. Purification of the crude product by column chromatography (SiO2,
10 – 30% EtOAc in hexanes) gave the cyclic phosphonate (3.23) (0.03 g, 55%).IR (neat,
NaCl) 1717, 1637 cm-1; 1H NMR (CDCl3) δ 3.81 (d, 3H, JHP = 11.2 Hz), 3.72 (3H, s),
2.87 (1H, m), 2.65 (1H, m), 2.29 (3H, d, JHP = 1.6 Hz), 1.99 (2H, m); 13C NMR (CDCl3)
δ 167.6, 161.4 (d, JCP = 9.9 Hz), 108.2 (d, JCP = 11.6 Hz), 52.7 (d, JCP = 7.1 Hz), 52.1,
22.3(d, JCP = 9.4 Hz), 21.0 (d, JCP = 5.3 Hz), 18.7 (d, JCP = 127.8 Hz); 31P NMR (CDCl3)
δ 23.26; HRMS (EI+) calcd for C8H13O5P: 220.0500, Found 220.0491.
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6-(hydroxymethyl)-2-methoxy-7-methyl-2,3,4,5-tetrahydro-1,2-oxaphosphepine

2-

oxide (3.23). To a solution of monocyclic phosphonate analog (3.16) (0.07 g, 0.28 mmol)
in dichloromethane (1 mL) at -78 oC was added DIBAL-H (1.1 mL 1M solution in
hexane) dropwise. The solution was allowed to warm slowly to room temperature. After
the rection was complete (TLC and

31

P NMR analysis), the reaction mixture was

partitioned between Et2O and saturated solution of Rochelle’s salt. The layers were
separated and the aqueous phase was re-extracted with Et2O (2 × 4 mL). The combined
Et2O layers were dried over anhydrous Na2SO4, and the solvent was evaporated under
reduced pressure to give the crude product. Purification of the crude product by column
chromatography (SiO2, 40 – 80% EtOAc in hexanes) gave the allylic alcohol (3.23) as
colorless oil (0.05 g, 76%). IR (neat, NaCl) 3361 cm-1; 1H NMR (CDCl3) δ 4.2 (1H, dd,
JHH = 0.8 Hz, 12 Hz), 4.03 (1H, dd, JHH = 0.7 Hz, 11 Hz) 3.8 (d, 3H, JHP = 11 Hz), 2.36
(2H, t, JHH = 5.2 Hz), 2.14 (1H, m), 2.04 (1H, m), 2.0 (3H, s), 1.91 (2H, m);

13

C NMR

(CDCl3) δ 145 (d, JCP = 7.5 Hz), 124.37 (d, JCP = 5 Hz), 52.34 (d, JCH = 7 Hz), 53, 29.8,
27.3(d, JCP = 134.1Hz), 22 (d, JCP = 7.1 Hz), 14.51; 31P NMR (CDCl3) δ 27.1; HRMS
(EI+) calcd. for C8H15O4P: 206.0708, found 206.0711.

(E)-dimethyl (1-(2-oxodihydrofuran-3(2H)-ylidene)ethyl) phosphate (3.26). To a
solution of 2-acetyl butyrolactone (3.47) (0.28 mL, 2.5 mmol) in dry CH2Cl2 (7 mL)
Hunig’s base (2.2 mL, 12.5 mmol) was added in single batch at room temperature and
the resulting solution was stirred for 5 minutes at room temperature. Then, the solution
was brought to -30 oC bath (acetone/dry ice) and dimethyl chlorophosphate (3.48) (0.4
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mL, 3 mmol) was added dropwise. The resulting solution was stirred at -30 oC for ~ 30
minutes. Then, it was let come to room temperature while slowly pink color developed.
After the completion of the reaction (TLC and

31

P NMR analysis), the reaction mixture

was diluted with additional CH2Cl2 (7 ml) and saturated NH4Cl was added to it. Organic
layer was separated and the aqueous phase was extracted with EtOAc (20 mL × 2). The
combined organic layer was dried over anhydrous Na2SO4. Solvent was removed under
reduced pressure to give the crude product. Purification of the crude product by column
chromatography (SiO2, 20 – 30% EtOAc in hexanes) gave 3.26 (0.32 g, 65 %). IR (neat,
NaCl) 1751, 1688 cm-1; 1H NMR (CDCl3) δ 4.28 (t, 2H, JHH = 7.5 Hz), 3.84 (d, 6H, JHP =
11.5 Hz), 3.01 (2H, m), 2.49 (3H, d, JHH = 2.2); 13C NMR (CDCl3) δ 170.9, 157.4 (d, JCP
= 7.1 Hz), 111.8 (d, JCP = 9.2 Hz), 65, 55.4 (d, JCP = 6.4 Hz), 26.2, 16.8;

31

P NMR

(CDCl3)δ - 4.73; HRMS (FAB, NBA, MH+) calcd. for C8H14O5P: 236.0528, found
237.0525.

(Z)-dimethyl (1-(2-oxodihydrofuran-3(2H)-ylidene)ethyl) phosphate (3.27). To a
suspension of sodium hydride (0.12 g, 3 mmol, 60% dispersion in mineral oil) in THF
(14 mL) was added 2-acetyl butyrolactone (3.47) (0.28 ml, 2.5 mmol) dropwise at room
temperature over ~ 2 minutes. The mixture was stirred until effervescence ceased, then it
was cooled to 0 oC, and dimethyl chlorophosphate (3.48) (0.41 ml, 3 mmol) was added
dropwise. After 30 minutes (TLC and
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P NMR analysis), reaction was quenched by
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addition of saturated aqueous NH4Cl (10 mL). The organic layer was separated and the
aqueous layer was re-extracted with EtOAc (20 mL × 2). The combined organic layer
was dried with anhydrous Na2SO4, filtered and the solvent was evaporated under reduced
pressure go give the crude product. The crude product was purified by column
chromatography (SiO2, 20 – 30% EtOAc in hexanes) to give enol phosphate (3.27) (0.36
g, 62 %). IR (neat, NaCl) 1754, 1685 cm-1; 1H NMR (CDCl3) δ 4.28 (t, 2H, JHH = 7.6
Hz), 3.88 (d, 6H, JHP = 11.5 Hz), 2.9 (2H, m), 2.16 (3H, dd, JHH = 1.6, 3.6 Hz); 13C NMR
(CDCl3) δ 167.5, 152.8 (d, JCP = 7 Hz), 110.3 (d, JCP = 8.6 Hz), 64.5, 55.6 (d, JCP = 6.5
Hz), 26.6, 20.2;
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P NMR (CDCl3) δ -5.45; HRMS (FAB, NBA, MH+) calcd. for

C8H14O6P: 236.0528, found 237.0534.

(Z)-methyl 3-((dimethoxyphosphoryl)methoxy)but-2-enoate (3.37). To a suspension
of NaH (60 % dispersed in mineral oil, 1.8 g, 4.63 mmol) in THF (9.4 mL) at 0 oC was
added methyl acetoacetate (3.36) (0.56 mL, 5.1 mmol) dropwise. The resulting mixture
was stirred at 0 oC until effervescence ceased. A solution of triflate (3.44) (1.26 g, 4.63
mmol) in THF (3 mL) was added dropwise at room temperature. After the completion of
the reaction (TLC and 31P NMR analysis), reaction mixture was partitioned between with
Et2O and saturated aqueous NH4Cl. The organic layer was collected and the aqueous
phase was re-extracted with EtOAc (15 mL × 2). The combined organic phases were
dried with anhydrous Na2SO4, filtered and evaporated under reduced pressure to give the
crude product. Purification of the crude product by column chromatography (SiO2, 50%
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EtOAc in hexanes - 100% EtOAc) gave the phosphonate (3.37) as yellowish oil (0.68 g,
60%). IR (neat, NaCl) 3454, 1699, 1643 cm-1; 1H NMR (CDCl3) δ 5.03 (1H, s), 4.42 (2H,
d, JHH = 9.39 Hz), 3.89 (6H, d, JHP = 10.76 Hz), 3.65 (3H, s) 2.04 (3H, s);

13

C NMR

(CDCl3) δ 167.9 (d, JCP = 11 Hz), 166.5, 98.6, 63.1 (d, JCP = 169.1 Hz), 54.9 (d, JCP = 6.5
Hz), 51.8, 20.3;
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P NMR (CDCl3) δ 21.12; HRMS (FAB, NBA, MNa+) calcd for

C8H15O6PNa: 261.0503, found 261.0504.

(E)-methyl 3-((2S,6R)-6-(4-methoxyphenyl)tetrahydro-2H-pyran-2-yl)acrylate. To a
solution of monocyclic phosphonate analog (3.16) (0.06 g, 0.26 mmol) and allyl bromide
(3.49) (0.065 mL, 0.77 mmol) in dry toluene (1 mL) was added TBAI (0.005 g, 0.013
mmol) at room temperature. After stirring the mixture for 1 min at room temperature, the
septum was replaced by a reflux condenser attached to argon bubbler. Then, the assembly
was taken to an oil bath preheated at 110 oC and continued to reflux. After12 h, the 31P
NMR analysis showed 65% conversion. Then, solvent was removed under reduced
pressure and the crude product was taken to column chromatography (SiO2, 20 – 40%
EtOAc in hexanes) to give allyl phosphonate analog (3.53) (0.027 g, 60%) as a colorless
liquid. IR (neat, NaCl) 1756 cm-1; 1H NMR (CDCl3) δ 6.03 – 5.90 (1H, m), 5.38 (1H, dd,
JHH = 17.1, 1.4 Hz), 5.28 (1H,dd, JHH = 10.4, 1.0 Hz), 4.65 (2H, m ), 3.58 (3H, s), 2.68
(1H, m), 2.5 (1H, m), 2.33 (3H,s), 2.22- 1.86 (4H, m); 13C NMR (CDCl3) δ 168.2 (d, JCP
= 1.7 Hz ), 159.4 (d, JCP = 7.8 Hz), 132.7 (d, JCP = 6.2 Hz ), 119.3 (d, JCP = 4.6 Hz),
118.7, 66.4 (d, JCP = 6.5 Hz), 52.1, 27.8, 26.9 (d, JCP = 133.0 Hz), 26.4 (d JCP = 2.6 Hz),
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21.3 (d, JCP = 7.6 Hz), 21.1 (d, JCP = 1.6 Hz);

31

P NMR (CDCl3) δ 23.5; HRMS (FAB,

NBA, MNa+) calcd. for C11H18O5P: 261.0892, found 261.0902.

Synthesis of monocyclic phosphonate analog of Cyclipostin P (3.28): To a solution of
monocyclic phosphonate analog (3.16) (0.024 g, 0.1 mmol) and 1-bromohexadecane
(3.51) (0.15 g, 0.5 mmol) in dry toluene (0.5 mL) was added TBAI (0.003 mmol, 0.002 g,
5 mol %) at room temperature. After stirring the mixture for 1 min at room temperature,
the septum was quickly replaced by a reflux condenser attached to argon bubbler. Then,
the assembly was taken to an oil bath preheated at 110 oC and continued to reflux. After
completion of reaction (TLC and 31P NMR analysis), solvent was removed under reduced
pressure and the crude product was taken to column chromatography (SiO2, 10 – 30%
EtOAc in hexane) to give phosphonate analog (3.28) (0.037g, 86 %) as a waxy solid. IR
(neat, NaCl), 1717 cm-1; 1H NMR (CDCl3) δ 4.12 (2H, m), 3.73 (3H, s), 2.65 (1H, m),
2.47 (1H, m), 2.31 (3H, s), 2.18 – 1.89 (4H, m), 1.68 (2H, p, JHH = 6.9 Hz ), 1.37 – 1.24
(26H, br s), 0.86 (3H, t, JHH = 6.6 Hz);
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C NMR (CDCl3) δ 168.22 (d, JCP = 1.7 Hz),

159.43 (d, JCP = 7.8 Hz), 119.20 (d, JCP = 4.6 Hz), 66.24 (d, JCP = 7.0 Hz), 52.00, 32.08,
30.57 (d, JCP = 6.0 Hz), 29.85, 29.81, 29.80, 29.71, 29.66, 29.52, 27.68, 26.42, 26.78 (d,
JCP = 133.6 Hz), 26.41 (d, JCP = 2.7 Hz), 25.61, 22.85, 21.29 21.67 (d, JCP = 7.5 Hz),
21.12 (d, JCP = 1.6 Hz), 14.44; 31P NMR (CDCl3) δ 23.1; HRMS (FAB, NBA, MH+)
calcd. For C24H46O5P: 445.3083, found 445.3076.

131

HPLC analysis of non-racemic monocyclic analog with C10-side chain
HPLC analysis of non-racemic monocyclic phosphonate analogs with C10-side chain was
carried out by using following method and condition:
 = 230 nm, solvent = 8 % IPA/heptane, flow= 1mL/min, column= Whelko SS
Only the diastereomer with

31

PNMR () = 26.8 ppm of C10 side chain was taken for

analysis. First, the racemic diastereomer of C10 side chain was taken as reference
samples.
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4. Chapter IV
Relay Cross Metathesis of Vinyl phosphonates
4.1. Olefin metathesis: Introduction
Olefin metathesis is a powerful method for the construction of carbon-carbon double
bonds. The term ‘olefin metathesis’ was introduced by Calderon in 1972 to describe a
catalytic process involving double bond reorganization of olefins. Initially, the processes
were poorly characterized and both homo- and heterogenous catalysts were used. Among
the first catalysts employed are MoO3/AlO3 and a mixture of salts of aluminum and
tungsten (AlX3/ WX3).1
A mechanism proposed for olefin metathesis described the process proceeding through
“pair-wise” fashion. Both olefins bind to metal catalyst to form a ‘quasicyclobutane’
intermediate (4.2) which rearranges to give the metathesis product (4.3). This mechanism
could explain most of the outcome of metathesis reactions. However, there were many
observations which could not be explained on the basis of this pair-wise mechanism
(Figure 4.1).2

Figure 4.1 Pairwise mechanism for cross metathesis
A major breakthrough in terms of characterization of the reaction and catalyst design for
olefin metathesis came after Chauvin proposed his ‘carbene’ mechanism (or ‘non-pair
mechanism’) (Figure 4.2). According to the Chauvin mechanism, the metal complex
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initially forms an alkylidene (4.4) with an olefin; which undergo alkylidene exchange
through ‘cyclobutane’ intermediate(s) (4.7 and 4.11).2

Figure 4.2 Chauvin Mechanism for olefin metathesis3a
Immediately, Casey, Katz, Schrock, Grubbs and others began to develop “carbene” based
catalysts (or metal-alkylidene catalysts) for olefin metathesis (Figure 4.3). The first
successful catalyst was a molybdenum-alkylidene (4.13). However, it suffered from
limitations due to its high oxophilicity which led to intolerance of various functional
groups. However, Grubbs ruthenium based catalysts (4.14 - 4.17) alleviate these
limitations to a greater extent and these catalysts have shown a wide variety of functional
group tolerance.4, 5

Figure 4.3 Catalysts for olefin metathesis
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With the availability of these efficient catalysts, olefin metathesis has become an
extremely powerful synthetic transformation in current organic synthesis. It encompasses
three closely related reactions: (a) ring opening metathesis polymerization (ROMP) (b)
ring-closing metathesis (RCM) and (c) cross metathesis (CM) (Figure 4.4).4

Figure 4.4 Types of olefin metathesis
As compared to ROMP and RCM, olefin cross metathesis is a somewhat less exploited
area. This is partly due to the very nature of the reaction. The intermolecular cross
metathesis of olefins catalyzed by a “metal-carbene” can lead to three possible products
(Figure 4.5) which include the desired cross-coupled dimer (4.28) along with two
undesired homo dimers (4.29 and 4.30). The efficiency of the reaction heavily depends
upon the selectivity during the coupling. In addition, the reaction suffers from lack of
both entropic and enthalpic driving force since it neither involve a ring-strain release as in
ROMP nor the advantage of intramolecular reactions like in RCM.2 Hence, the reaction
can lead to a statistical mixture of products.4
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Figure 4.5 Fate of intermolecular cross metathesis
In a seminal paper, Grubbs and coworkers outlined a general model for selectivity in
cross metathesis.6 Based on the ability of an olefin to homodimerize as compared to other
olefins and the reactivity of the homodimers towards cross metathesis; they placed
various olefins into 4 different categories. Thus, olefins falling into type I category
undergo fast homodimerization and the homodimers undergo secondary cross metathesis.
Type II olefins, on the other hand, undergo slow homodimerization and the homo dimers
are sluggish toward the secondary cross metathesis. Similarly, type III olefins do not
undergo homodimerization while type IV olefins are spectators towards cross metathesis
and do not deactivate the catalyst (Figure 4.5).

Figure 4.6 Classification of olefins towards cross metathesis6
According to this classification, terminal vinyl phosphonates fall into type III, which
means there is no homodimerization, making these compounds good substrates towards
olefin cross metathesis. However, vinyl phosphonates with an internal olefinic bond (or
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substituted vinyl phosphonates) were not mentioned/classified to any type. A series of
cross metathesis reactions were attempted based on this classification which is discussed
in next section.

4.2. Cross metathesis of terminal vs. internal vinylphosphonates
1.

A series of cross metathesis reactions of vinyl phosphonates was carried out. It was
observed that the terminal vinyl phosphonate (4.31) underwent smooth cross metathesis
with 1-heptene (4.32) to produce the corresponding new vinyl phosphonate (4.33).
When the vinyl phosphonate (4.33) was subjected to cross metathesis reaction with two
equivalents of methyl acrylate (4.34), the standard vinyl phosphonate underwent
reaction to a very small extent (~11%) to produce cross metathesis product (4.35).
However, the substituted vinyl phosphonates (4.36 and 4.37) failed to react with methyl
acrylate (4.34) even after an extended period (Scheme 4.1).

2.

Scheme 4.1 Cross metathesis of terminal and internal vinyl phosphonate
3.

This set of experiments clearly demonstrated the reactivity differences between the
terminal and internal vinyl phosphonates. The terminal vinyl phosphonates belong to the
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type III cross metathesis substrates while internal vinyl phosphonates belong to type IV
substrates. This observation led to the specific aim of the study.

4.3. Specific aim of the study
4.

Olefin cross metathesis reaction is one of the long standing interests of the Spilling
research group. The reactivity differences between terminal and internal vinyl
phosphonate towards cross metathesis reaction is an impediment to the development of
methods for elaboration of the chemistry of the substituted vinyl phosphonates.
Therefore, the specific aim of this study is to develop a method for the cross metathesis
of internal vinyl phosphonates.

4.4. Relay events in olefin metathesis
As mentioned in the previous section, there are some olefins which are spectators towards
cross metathesis due to either steric or electronic reasons. However, such olefins are often
encountered during organic synthesis sometimes as pivotal synthetic intermediates. The
relay processes should allow activation of inert olefins towards olefin metathesis.
In 1985, Katz and Sivavec reported a novel rearrangement in olefin metathesis between
alkyne and olefin (Figure 4.7). It was demonstrated that an alkyne can function as an
olefin metathesis relay. In the example, enyne (4.38) was treated with tungsten alkylidene
(4.39) to yield the tricyclic product (4.40).7

Figure 4.7 First example of relay process in olefin metathesis by Katz and Sivavec
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According to the proposed mechanism, the tungsten alkylidene (4.41) adds to the alkyne
moiety of the enyne (4.42) via a [2 + 2] cycloaddition leading to metallo-cyclobutene
specices (4.43). The metallocyclobutene species undergoes rearrangement to form a new
metal-carbenenoid species (4.44). This intermediate, due to restricted rotation in
molecule (4.45), favors intramolecular metathesis process leading to formation of
tricyclic product (4.46) (Figure 4.8). Similar reactions with aliphatic enynes did not give
such rearranged product. Instead, they undergo oligomerization which depicts the role of
enyne geometry in the overall results of these reactions.7

Figure 4.8 Suggested mechanism for relay events in olefin metathesis
Grubbs and coworker further extended and applied “relay” events in metathesis towards
the synthesis of bicyclic structures. By placing an alkyne moiety in suitable position such
as in 4.47, they were able to orchestrate the “relay” event to produce various bicycles
(4.53) using a ruthenium metathesis catalyst (4.48).8,9
Contrary to the mechanism proposed by Katz and Sivavec, Grubbs and coworkers
proposed that the relay event was initiated by formation of ruthenium-carbene species
(4.50). The carbenoid then undergoes intramolecular [2+2] cycloaddition with the alkyne
bond to form a metallo-cyclobutene species (4.51) which undergoes rearrangement to
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generate new ruthenium alkylidene (4.52). This alkylidene undergoes ring closing
metathesis to produce the bicyclic product (4.53). This work demonstrated successful
application of relay events in olefin metathesis in conformationally flexible aliphatic
substrates. It was also reported that the nature of the olefin substitution on enyne
substrate (eg. 4.47) can affect the overall product formation, by altering the site for initial
loading of catalyst (Figure 4.9).8

Figure 4.9 Relay event in Ru-catalyzed olefin metathesis based on by Grubbs and
coworkers
The work provided the foundation for the ring closing enyne metathesis which has
become a useful method for synthesis of cyclic heterocycles and bicyclic moieties of
natural product.10,11
Hoye and coworkers reported concept of using relay events in ring closing metathesis
reactions to activate metathetically refractory olefins (type IV substrates, Figure 4.6).
They found that the diene (4.55) was unable to undergo direct ring closing metathesis to
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produce the corresponding cyclic product (4.57). It was reasoned that there was no
loading of ruthenium alkylidene on to the diene to initiate the reaction.12
Hoye and cowokers circumvented the lack of reactivity by tethering a “type I” olefin to
the diene. Conceptually, the additional olefin initiates a relay event remote from the
target site of cross metathesis. The tethered olefin allows initial loading of the metal
carbene into the molecule (4.59). The metal is then, relayed to the type IV olefin by
ejection of a cyclic product to produce new metal alkylidene (4.60). The new metal
alkylidene (4.60) undergoes further ring closing metathesis to complete the cycle giving
the required cyclic product (4.57) (Figure 4.10).13,14

Figure 4.10 Example of relay ring - closing metathesis of diene by Hoye and coworkers.
The overall concept of relay ring closing metathesis can be represented as follows:
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Figure 4.11 General concept of relay ring closing metathesis (RRCM)
Although terminal vinyl phosphonates are classified as type III olefins, we have shown
that internal vinyl phosphonates (4.63) are type IV cross metathesis substrates.
Installation of type I or II structural moiety tethered at the phosphonate center (4.69)
should activate the vinyl phosphonate bond towards olefin metathesis via a relay
mechanism. This would expand the synthetic utility of vinyl phosphonates (Figure 4.12).

Figure 4.12 Planned relay cross metathesis of vinyl phosphonates
It was hoped that the allyl ester at the phosphonate center would be the site for the initial
loading of ruthenium alkylidene giving a new alkylidene such as 4.70. This intermediate
should undergo intramolecular ring closing metathesis with the olefinic bond to produce
5-membered cyclic phosphorane (4.71), which should lead to formation of a new metal145

alkylidene (4.72). The formation of this intermediate metal alkylidene (4.68) should lead
to cross metathesis product (4.74).

4.5. Results and discussion
4.5.1. Transesterification on vinyl phosphonates
The first part of the work involved synthesis of the allyl vinyl phosphonates. The required
allyl vinyl phosphonates were first synthesized by using methods described in the
literature: a) conversion of phosphate diesters to mono phosphonic acid and/or followed
by conversion to monochloro- derivative; b) reaction of phosphonate salt with allyl
bromide; c) Lewis acid catalyzed transesterification using metal salts.
Initially, the standard vinyl phosphonate (4.33) was converted to the mono chloro
phosphonate (4.78) by treatment with oxalyl chloride (4.76) and catalytic amount of
DMF (4.77) (Vilsmeier-Haack conditions). The mono chloro phophonate on reaction
with allyl alcohol (4.79) gave the required mono allyl vinyl phosonate (4.80) in moderate
yield (45%) (Scheme 4.2).

Scheme 4.2 Synthesis of allyl vinyl phosphonate
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Alternatively, the vinyl phosphonate (4.33) was refluxed with stoichiometric amount of
sodium iodide to give the corresponding sodium salt (4.81). The sodium salt was then
reacted with allyl bromide (4.82) in methanolic solution to give the monoallyl vinyl
phosphonate (4.80) in lower yield (~ 25 %).
Attempts to use similar methods to convert thf ring substituted vinyl phophonate (4.36)
into corresponding monochloro phosphonate derivate (4.83) gave low conversion.
Extended reaction time resulted into decomposition (Scheme 4.3).

Scheme 4.3 Attempted synthesis of chloro vinyl phosphonate (4.83)
Alternatively, vinyl phosphonate (4.36) was converted to the sodium salt (4.83) by
refluxing with stoichiometric amount of sodium iodide in acetonitrile. The sodium salt
was then directly reacted with an excess of allyl bromide (4.82) in presence of crown
ether. The reaction produced the required mono allyl vinyl phosponate (4.84) with
disappointing yield (~13 %) (Scheme 4.4).

Scheme 4.4 Synthesis of allyl vinyl phosphonate (4.84)
The results for the synthesis of the allyl vinyl phosphonate from chlorophosphonate and
sodium phosphonate salt were unsatisfactory and led to the search for alternative
synthetic methods. A Lewis acid promoted transesterification of dimethyl phosphonate
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esters was attempted. Conceptually, the activation of the phosphoryl group towards
nucleophilic attack by allyl alcohol was proposed.
The model vinyl phosphonate (4.33) was reacted with allyl alcohol using 5 mol % of
different metal triflates such as Cu (II), Sc (III), Bi (III), Yb(III), Zn(II), Ba (II), Ag(I)
along with Cu(OAc)2, Ti(OiPr)4, Ti (OiPr)3Cl, Fe(NO3)3.9H2O at 60 oC for 5 hours.
Unfortunately, the reaction failed to give the desired transesterification product (4.80).
Subsequent runs with stoichiometric amount of Bi(OTf)3 and refluxing allyl alcohol as
solvent also failed to give the desired product (Scheme 4.5).

Scheme 4.5 Lewis acid mediated synthesis of allyl vinyl phosphonate
Finally, synthesis of allyl vinyl phosphonate was attempted by using transesterification of
phosphate and phosphonates described in the previous chapters (Chapter II and III).
In an initial reaction, a solution of the model vinyl phosphonate (4.33) in toluene was
refluxed with 1.1 equivalents of allyl bromide (4.82) and 5 mol % tetra n-butyl
ammonium iodide (TBAI) which resulted in 53 % conversion into the allyl vinyl
phosphonates. However, the reaction produced both mono- and di-allylated vinyl
phosphonates (4.80 and 4.86). In subsequent reaction with excess of allyl bromide (4.82,
5 eq), 10 mol% TBAI and 5.5 hours of heating in a microwave reactor resulted in ~78%
conversion into the desired products. It was observed that the ratio of mono- versus diallylated product lowers as the duration of reaction increases (Scheme 4.6). The overall
observations are tabulated below (Table 4.1).
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Scheme 4.6 Transesterification of model vinyl phosphonate
Table 4.1 Formation of mono- vs. di-allyl vinyl phosphonate
Entry
1
2
3
4
5
6
7
8

Allyl-Br
(eq)
1.1
5
5
5
10
5
5
5

Concn.
(M)
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.5

TBAI
(mol %)
5
5
5
5
5
10
10
10

Time (h)
7
0.5 (μw)
1.5 (μw)
5.5 (μw)
7.5 (μw)
24
5.5 (μw)
5.5 (μw)

NMR
conversion
53 %
15%
25%
31%
62.7%
36 %
49%
78%

Ratio of
4.80:4.86
10:1
100:0
15:1
10:1
3:1
9:1
5:1
1.8:1

Next, thf-substituted vinyl phosphonate (4.36) was subjected to TBAI catalyzed
transesterification in presence of 5 mol% TBAI and allyl bromide (4.82, 5 eq). After 36
hours of refluxing in toluene at 110 oC, there was 76% conversion with 1.8:1 ratio of
mono:di-allylated vinyl phosphonate (4.84 and 4.87) (Scheme 4.7).

Scheme 4.7 Synthesis of thf-substituted allyl vinyl phosphonates
Finally, the advance vinyl phosphonate (4.37) was subjected to a transesterification
reaction using 20 mol% of TBAI and excess allyl bromide (4.82, 5 eq). After 5.5 hours of
heating in a microwave reactor, there was 96% conversion with 1:1.8 ratio of mono- and
di-allyl vinyl phosphonate (4.88 and 4.89) (Scheme 4.8).
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Scheme 4.8 Synthesis of allyl vinyl phosphonate from advanced vinyl phosphonate
With the allyl vinyl phosphonate on hand, the cross metathesis reaction with type I and II
substrates such as styrene and methyl acrylate was examined. The results are described in
next section.

4.5.2. Cross metathesis of mono allyl vinyl phosphonates:
Initially, mono allyl vinyl phosphonates were subjected to cross metathesis reactions as
mentioned at the beginning of this section. Thus, the vinyl phosphonates were treated
with methyl acrylate (4.34), a type II olefin, in presence of 10 mol% Grubbs catalyst and
CuI. The reaction was over within 2 hours as indicated by formation of a new peak at ca
43 ppm in the

31

P NMR spectrum.18a In most cases, the isolated yield of the cross

metathesis product was found to be above 70% (Scheme 4.9).
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Scheme 4.9 Cross metathesis of mono allyl vinyl phosphonates with acrolein
The advanced vinyl phosphonate (4.37) was prepared during an earlier exploration to
establish the methodology for stereoselective synthesis of tetrahydrofuran (THF) and
tetrahydropyran (THP) rings.19 It also carries a significant part of the (-)-centrolobine
structure, an anti-leishmaniasis agent.20
The allyl vinyl phosphonate (4.88) could represent an advanced precursor for (-)centrolobine via relay cross metathesis with p-hydroxy styrene. It was also planned to
synthesize different analogs of centrolobine by conducting the cross metathesis with
various styrenes (4.94 – 4.96). A series of styrenes would also allow comparing the
overall reactivity of allyl vinyl phosphonate (4.88) with type I substrates during the relay
cross metathesis reaction.
The advanced mono allyl vinyl phosphonate (4.88) was subjected to cross metathesis
reaction with styrenes (4.94 – 4.96) as a representative substrate for type I olefins. Thus,
the cross metathesis of these vinyl phosphonates were carried out in presence of 5
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equivalents or more of type I olefins viz. styrene (4.94), 4-fluro styrene (4.95) and 4benzyloxy styrene (4.96). In all cases, the corresponding cross metathesis product was
obtained in modest yield. The reaction was complete in 2 hours and average yield for
these reaction were found to be around 50% (Scheme 4.10).

Scheme 4.10 Synthesis of precursor and analogs of (-)-centrolobine
Surprisingly, the dimer (4.100) derived from the vinyl phosphonates (4.88) was isolated
in small amount. The dimeric product (4.100) was not observed during the cross
metathesis of the vinyl phosphonate with methyl acrylate, a type II substrate.

Scheme 4.11 Structure of the dimer side product
5.

The formation of the dimeric product (4.100) reveals the competition between cross
metathesis partners arising from the inherent reactivity of substrates towards the reaction.
Since type II substrates undergo slower homodimerization, they should undergo faster
cross metathesis reaction leading to the formation of the heterodimer. On the other hand,
styrenes undergo faster homodimerization. Although the homo dimer derived from type I
participate in the cross metathesis reaction, the rate should be slower as compared to the
reactivity of the metal alkylidene (4.67).

6.
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4.5.3. Cross metathesis of diallyl vinyl phosphonates
Although diallyl phosphonates are reported to undergo ring closing metathesis to give
phosphorus heterocycle, their behavior towards olefin metathesis might change in the
presence of an additional vinyl moiety in the molecule. It has been reported that the mode
of cyclization of these types of substrates depends upon the olefin substitution. Formation
of a six-membered ring is preferred over a seven-membered ring. Similarly, it has also
been reported that 7-membered rings are preferred over 8-membered rings.18a,b In fact,
the diallyl vinyl phosphonates should follow their monoallyl phosphonates counterpart
towards cross metathesis reaction to give cross metathesis product(s) since this pathway
involves formation of 5-membered phosphorus heterocycles which should be heavily
favored over 7-membered rings (Figure 4.13).

Figure 4.13 Chemistry of diallyl phosphonates: known vs. proposed
To test the hypothesis, the diallyl vinyl phosphonate (4.86) was subjected to cross
metathesis with methyl acrylate (4.34) using standard conditions. The corresponding
cross metathesis product was obtained in good yield along with the 5-membered
phosphate heterocycle (4.106).20a,34
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Subsquently, other diallyl phosphonates (4.87, 4.89) were also subjected to cross
metathesis with acrolein (4.34) to give the corresponding products along with the
phosphate heterocycle (4.109) with yields comparable to the reaction of mono allyl vinyl
phosphonates (Scheme 4.12).

Scheme 4.12 Relay cross metathesis of diallyl vinyl phosphonates
Hence, a new method for transformation of vinyl phosphonate through allyl group
incorporation followed by relay cross metathesis was developed.

4.6. Summary
In general, internal vinyl phosphonates do not undergo the cross metathesis reaction.
Hence, they belong to type IV substrates for cross metathesis reactions. However,
installation of allyl group as the phosphonate ester changed their behavior toward cross
metathesis reaction. Both mono- and di-allyl vinyl phosphonates underwent facile cross
metathesis reaction to give the corresponding metathesis products.
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4.7. General Experimental
General Experimental Procedures
Glassware for all experiments were oven-dried and cooled and used under Argon
atmosphere unless otherwise mentioned. 1H NMR,

13

C NMR and

31

P NMR were

recorded in Bruker Avance ARX-300 NMR spectrometer at 300, 75 and 121 MHz
respectively. Tetramethylsilane (TMS, δ 0.00) or chloroform-D (CDCl3, δ 7.27 ppm for
1

H NMR and 77.23 ppm in

13

C NMR) were used as internal reference. Phosphoric acid

(H3PO4, 85%) was used as external reference for 31P NMR.
General procedure for relay cross metathesis
To a solution of vinyl phosphonate (1 mmol) and allyl bromide (3 - 5 mmol) in dry
toluene (0.5 mL) was added TBAI (5 - 10 mol%) at room temperature. After stirring the
mixture for 1 min at room temperature, the septum was quickly replaced by a reflux
condenser attached to argon bubbler. Then, the assembly was taken to an oil bath
preheated at 110 oC and continued to reflux. Alternatively, the reaction mixture was
heated in a microwave reactor. After completion of the reaction (TLC and

31

P NMR

analysis), solvent was removed under reduced pressure and the crude product was taken
to column chromatography (SiO2, 20 – 60% EtOAc in hexanes) to give mono and diallyl
vinylphosphonate.

(E)-diallyl hept-1-en-1-ylphosphonate & (E)-diallyl hept-1-en-1-ylphosphonate (4.80
and 4.86). To a solution of vinyl phosphonate (4.33) (0.08g, 0.39 mmol) and allyl
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bromide (4.34, 0.25mL, 5 eq) in dry toluene (0.45 mL) was added TBAI (0.008 g, 5
mol%) and the resulting mixture was heated at reflux. After completion of the reaction
(TLC and 31P NMR analysis), solvent was removed under reduced pressure and the crude
product was taken to column chromatography (SiO2, 10 – 40 % EtOAc in hexanes) to
give pure 4.80 (0.028 g). IR (neat, NaCl) 2958, 2929, 2859, 1098, 1050 cm-1; 1H NMR
(CDCl3) δ 6.8 (1H, ddt, JHH = 17.1, 6.6 Hz, JHp = 21.7 Hz), 5.93 (1H, m), 5.62 (1H, ddd
= 17.1, 1.6, JHP = 21.7 Hz), 5.34 (1H, ddd, JHH = 17.1, 3.0, 1.5 Hz), 5.23 (1H, dd, JHH =
10.4, 1.3 Hz), 4.50 (2H, m), 3.70 (3H, d, JHP = 11.1 Hz), 2.22 (2H, dq, JHH = 7.1, 1.9
Hz), 1.44 (2H, m), 1.27 (4H, m), 0.87 (3H, t, JHH = 6.8 Hz); 13C NMR (CDCl3) δ 155.2
(d, JCP = 4.5 Hz), 133.2 (d, JCP = 6.5 Hz), 118.1, 115.8 (d, JCP =187.7 Hz), 66.3 (d, JCP =
5.1 Hz), 52.4 (d, JCP = 5.7 Hz ), 34.4 (d, JCP = 22.0 Hz), 31.4, 27.6, 22.6, 14.1; 31P NMR
(CDCl3) δ 20.8; HRMS (FAB, NBA, MH+) calcd for C11H22O3P: 233.1306, found
233.1305; and 4.86 (0.025 g) after chromatography of crude product. IR (neat, NaCl)
2959, 2953, 2869, 1097, 1012 cm-1; 1H NMR (CDCl3) δ 6.81 (1H, ddt, JHP = 17.1, 6.6
Hz, JHP = 21.6 Hz), 5.94 (2H, m), 5.66 (1H, ddd = 17.1, 1.6 Hz, JHP = 21.7 Hz), 5.34
(2H, ddd, JHH = 17.1, 3.0, 1.5 Hz), 5.23 (2H, dd, JHH = 10.4, 1.2 Hz), 4.51 (4H, dd, JHH =
7.2, 6.1 Hz), 2.22 (2H, dq, JHH = 7.1, 1.9 Hz), 1.45 (2H, m), 1.29 (4H, m), 0.88 (3H, t,
JHH = 6.8 Hz); 13C NMR (CDCl3) δ 154.9 (d, JCP = 4.5 Hz), 133.2 (d, JCP = 6.6 Hz), 118,
116.4 (d, JCP = 187.8 Hz), 66.3 (d, JCP = 5.4 Hz), 34.4 (d, JCP = 22.2 Hz), 31.4, 27.6, 22.6,
14.2;

31

P NMR (CDCl3) δ 19.8; HRMS (FAB, NBA, MH+) calcd for C13H24O3P:

259.1463, found 259.1455.
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(E)-allyl methyl (2-(tetrahydrofuran-2-yl)vinyl)phosphonate (4.84) and (E)-diallyl
(2-(tetrahydrofuran-2-yl)vinyl)phosphonate (4.87). To a solution of vinyl phosphonate
(4.36) (0.12g, 0.58 mmol) and allyl bromide (4.82) (0.15 mL, 1.75 mmol) in dry toluene
(2 mL) was added TBAI (0.011 g, 5 mol%). The resulting solution was heated to reflux.
After 36 hours, there was 76% conversion based on 31P NMR analysis. Then, the solvent
was removed under reduced product and the crude product was taken to column
chromatography to give pure 4.84 (0.062g,) after chromatography of crude product. IR
(neat, NaCl), 2959,2955, 2865, 1095 cm-1; 1H NMR (CDCl3) δ 6.80 (1H, dd, JHP = 17.1,
9.5 Hz), 5.93 (2H, m), 5.36 (1H, dd JHH = 17.1, 9.5 Hz, JHP = 21.5 Hz ), 5.25 (1H, dd,
JHH = 10.4, 1.0 Hz), 4.52 (3H, m ), 3.92 ( 1H, m), 3.83 (1H, m), 3.72 (3H, d, JHP = 11.2
Hz), 2.11 (1H, m), 2.94 (2H, p, JHH = 7.0 Hz), 1.69 (1H, m));

13

C NMR (CDCl3) δ

153.89 (d, JCP = 5.33 Hz), 132.30 (d, JCP = 9.7 Hz), 118.15, 114.65 (d, JCP =188.25 Hz),
78.46 (d, JCP = 21.8 Hz), 68.80, 66.41 (d, JCP = 5.3 Hz ), 52.52 (d, JCP = 5.86 Hz ), 31.57,
25.62; 31P NMR (CDCl3) δ 20.75, 20.72 ppm; HRMS (FAB, MH+) calcd for C10H18O4P:
233.0943, found 233.0946; and 4.87 (0.04). IR (neat, NaCl), 2928, 2873, 1246, 1016 cm1 1

; H NMR (CDCl3) δ 6.77 (1H, ddt, JHH = 17.1, 9.5 Hz, JHP = 21.5 Hz ), 5.93 (3H, m),

5.34 (2H, dd JHH = 17.1 Hz, JHP = 21.5 Hz), 5.22 (2H, dd, JHH = 10.4, 1.3 Hz), 4.52 (5H,
m ), 3.93 (1H, m), 3.84 (1H, m), 2.12 (1H, m), 1.90 (2H,p, JHH = 6.9 Hz), 1.66 (1H, m);
13

C NMR (CDCl3) δ 153.61 (d, JCP = 5.2 Hz), 132.25 (d, JCP = 10.0 Hz), 118.08, 115.05

(d, JCP =188.32 Hz), 78.40 (d, JCP = 21.8 Hz), 68.74, 66.36 (d, JCP = 5.35 Hz), 31.50,
25.57; 31P NMR (CDCl3) δ 20.39 ppm; HRMS (FAB, NBA, MH+) calcd for C12H20O4P:
259.1099, found 259.1094.
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Allyl

methyl

((E)-2-((2S,6R)-6-(4-methoxyphenyl)tetrahydro-2H-pyran-2-

yl)vinyl)phosphonate)(4.88)

and

Diallyl

((E)-2-((2S,6R)-6-(4-methoxyphenyl)-

tetrahydro-2H-pyran-2-yl)vinyl)phosphonate (4.89). To the solution of vinyl
phosphonate (4.37) (0.065g, 0.2 mmol) and allyl bromide (4.82) (0.051 mL, 0.6 mmol) in
dry toluene (0.5 mL) was added TBAI (0.0.015 g, 20 mol%) and the resulting mixture
was heated at reflux. After 5.5 hours of heating in microwave reactor, the reaction had >
96% conversion based on

31

P NMR analysis. The solvent was removed under reduced

pressure and the crude product was taken to column chromatography to give pure 4.88
(0.019 g). IR (neat, NaCl) 2921, 2847, 1205, 1077 cm-1; 1H NMR (CDCl3) δ 7.29 (2H, d,
JHH = 10.7 Hz), 6.88 (2H, d, JHH = 10.7 Hz), 6.80 (1H, dd, JHH = 17.1, 9.4 Hz, JHP = 21.5
Hz), 6.04 (1H, dd, JHH = 17.2 Hz, JHP = 21.5 Hz), 5.36 (1H, dd, JHH = 17.1, 1.5 Hz), 5.23
(1H, dd, JHH = 10.4, 1.2 Hz), 4.52 (2H, m), 4.40 (1H, br doublet, JHH = 11.21 Hz ), 4.16
(1H, br doublet, JHH = 11.58 Hz), 3.80 (3H, s), 3.71 (d, 3H, JHP = 11.2 Hz), 1.99 (1H, m),
1.79 (2H, m), 1.69 (1H, m), 1.51 (1H, m), 1.34 (1H, m);

13

C NMR (CDCl3) δ 159.02,

153.53 (d, JCP = 5.51 Hz), 135.31, 133.09 (d, JCP = 6.49 Hz), 127.15, 118.11 (d, JCP =
3.32 Hz), 114.12 (d, JCP = 188.27 Hz), 113.78, 79.50, 66.35 (d, JCP = 5.3 Hz), 55.42,
52.50 (d, JCP = 5.6 Hz), 33.60, 30.87, 24.12;

31

P NMR (CDCl3) δ 21.4, 21.3; HRMS

(FAB, NBA, MH+) calcd for C18H26O5P: 353.1518, found 353.1524; and 4.89 (0.027g).
IR (neat, NaCl) 2921, 2847, 1205, 1077 cm-1; 1H NMR (CDCl3) δ 7.30 (2H, d, JHH = 8.6
Hz), 6.89 (2H, d, JHH = 8.6 Hz), 6.80 (1H, ddd, JHH = 17.1, 9.4 Hz, JHP = 21.5 Hz), 6.07
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(1H, dd, JHH = 17.1 Hz, JHP = 21.5 Hz), 5.95 (2H, m), 5.35 (2H, dddd, JHH = 17.1, 4.5, 3.0
Hz, JHP = 1.4 Hz), 5.23 (2H, ddd, JHH = 10.4, 5.5 Hz, JHP = 1.1 Hz), 4.52 (4H, m), 4.41
(1H, dd, JHH = 10.8 Hz, JHP = 1.8 Hz), 4.16 (1H, br doublet, JHH = 11.6 Hz), 3.81 (3H, s),
1.99 (1H, m), 1.79 (2H, m), 1.69 (1H, m), 1.51 (1H, m), 1.34 (1H, m); 13C NMR (CDCl3)
δ 159.02, 153.20 (d, JCP = 5.47 Hz), 135.33, 133.10 (d, JCP = 4.63 Hz), 127.15, 118.06 (d,
JCP = 3.65 Hz), 114.68 (d, JCP = 188.15 Hz), 113.78, 66.31 (d, JCP = 5.4 Hz), 55.43,
33.62, 30.86, 24.13;

31

P NMR (CDCl3) δ 20.4; HRMS (FAB, NBA, MH+) calcd for

C20H38O5P: 379.1674, found 379.1672.
General procedure for relay cross metathesis
To a solution of allyl vinyl phosphonate (1 mmol) and the alkene coupling partner (2 – 5
mmol) in CH2Cl2 (2 mL) was added Grubbs 2nd generation catalyst (10 mol%) followed
by CuI (10 mol %). After stirring the solution for 2 minutes at room temperature, the
septum was replaced by a condenser connected to an argon bubbler. The reaction flask
was placed in an oil bath preheated at 55 oC. After the completion of the reaction (TLC
and

31

P NMR analysis), solvent was removed under reduced pressure to give the crude

product. Purification of the crude product by column chromatography (SiO2, 1 – 5%
EtOAc in hexane) gave the cross metathesis product. The 5-membered phosphorus
heterocycles were eluted using 50 – 70% EtOAc in hexanes.

(E)-methyl

3-((2S,6R)-6-(4-methoxyphenyl)tetrahydro-2H-pyran-2-yl)acrylate

(4.93). To a solution of allyl vinyl phosphonate (4.88) (0.018g, 0.05 mmol) and acrolein
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(4.34) (0.009mL, 0.10 mmol) in dry CH2Cl2 (1 mL) was added Grubbs 2nd generation
catalyst (0.004 g, 0.005 mmol) followed by CuI (0.001 g, 0.005 mmol) to give pure 4.93
(0.010g, 73 %) after chromatography of crude product. IR (neat, NaCl) 2927, 2850, 1513
cm-1; 1H NMR (CDCl3) δ 7.30 (2H, m), 6.99 (1H, dd, JHH = 15.7, 4.0 Hz ), 6.88 (2H, m),
6.31 (1H, dd, JHH = 15.7, 1.9 Hz), 4.41 (1H, dd, JHH = 10.8, 2.0 Hz), 4.21 (1H, dp, JHH =
11.5, 2.0 Hz), 3.81 (3H, s), 3.74 (3H, s), 2.02 (1H, m), 1.87 – 1.70 (3H, m), 1.59 – 1.50
(1H, m), 1.42 – 1.34 (1H, m);

13

C NMR (CDCl3) δ 167.39, 159.04, 148.59, 135.36,

127.19, 119.56, 113.82, 79.56, 55.46, 51.73, 33.57, 31.02, 24.15; HRMS (FAB, NBA,
MH+) calcd for C16H20O4Na: 299.1259, found 299.1251.

(2R,6S)-2-(4-methoxyphenyl)-6-((E)-styryl)tetrahydro-2H-pyran

(4.97).

To

the

solution of allyl vinyl phosphonate (4.88) (0.02g, 0.06 mmol) and styrene (4.94)
(0.013mL, 0.11 mmol) in dry CH2Cl2 (1 mL) was added Grubbs 2nd generation catalyst
(0.005 g, 0.006 mmol) followed by CuI (0.001 g, 0.006 mmol) to give pure 4.97 (0.014g,
82 %) after chromatography of crude product. IR (neat, NaCl) 2927, 2850, 1513 cm-1; 1H
NMR (CDCl3) δ 7.44 - 7.21 (7H, m), 6.92 – 6.88 (2H, m), 6.4 (1H, d, JHH = 16.0 Hz),
6.31 (1H, dd, JHH = 16.0, 5.8 Hz), 4.45 (1H, dd, JHH = 11.1, 1.7 Hz), 4.21 (1H, dd, JHH =
11.1, 5.7 Hz), 3.82 (3H, s), 3.80 (d, 3H, JHP = 10.6 Hz), 2.02 (1H, m), 1. 87 – 1.70 (3H,
m), 1.66 – 1.50 (1H, m);

13

C NMR (CDCl3) δ 159.09, 137.33, 135.77, 131.23, 129.88,

128.67, 127.58, 127.51, 126.67, 113.88, 79.83, 78.89, 55.51, 33.60, 31.90, 24.27; HRMS
(FAB, MH+) calcd for C20H22O2: 294.1619, found 294.1618.
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(2S,6R)-2-(4-fluorophenethyl)-6-(4-methoxyphenyl)tetrahydro-2H-pyran (4.89). To a
solution of allyl vinyl phosphonate (4.88) (0.035g, 0.1 mmol) and 4-flurostyrene (4.94)
(0.025 mL, 0.21 mmol) in dry CH2Cl2 (1.6 mL) was added Grubbs 2nd generation catalyst
(0.009 g, 0.01 mmol) followed by CuI (0.002 g, 0.01 mmol) to give pure 4.98 (0.009g,
60%) after chromatography of crude product. IR (neat, NaCl) 2927, 2850, 1513 cm-1; 1H
NMR (CDCl3) δ 7.36 (4H, m), 7.03 (2H, m), 6.89 (2H, m), 6.61 (1H, d, JHH = 16.1 Hz ),
6.22 (1H,dd, JHH = 16.1, 5.8 Hz), 4.40 (1H, d, JHH = 14.1, 1.9 Hz ), 4.20 (1H, dd, JHH =
11.0, 5.7 Hz), 3.82 (3H, s), 2.00 (1H, m), 1.82 (3H, m), 1.56 (2H, m); 13C NMR (CDCl3)
δ 162.41(d, JCF = 244.87 Hz), 159.1, 135.69, 133.46 (d, JCF = 3.23 Hz),130.94 (d, JCF =
2.15 Hz), 128.74, 128.12 (d, JCF = 8.0 Hz), 127.49, 115.69, 115.40, 113.88, 79.85, 78.76,
55.49, 33.56, 31.87, 24.23;

HRMS (FAB, NBA, MNa+) calcd for C16H20O4FNa:

299.1259, found 299.1251.

(2S,6R)-2-((E)-4-(benzyloxy)styryl)-6-(4-methoxyphenyl)tetrahydro-2H-pyran
(4.99). To a solution of allyl vinyl phosphonate (4.88) (0.032 g, 0.091 mmol) and 4benzyloxy styrene (4.96) (0.038 g, 0.182 mmol) in dry CH2Cl2 (1.5 mL) was added
Grubbs 2nd generation catalyst (0.077 g, 0.009 mmol) followed by CuI (0.002 g, 0.009
mmol) to get pure 4.99 (0.018 g, 50%) after chromatography of crude product. IR (neat,
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NaCl) 2927, 2850, 1513 cm-1; 1H NMR (CDCl3) δ 6.58 (1H, d, JHH = 15.99 Hz), 6.18
(1H, dd, JHH = 15.99, 5.94 Hz), 5.07 (2H, s), 4.44( 1H, br d, JHH = 9.93 Hz), 4.18 (1H,
m), 3.81 (3H, s ), 2.01 (1H, m), 1.78 (3H, m), 1.55 (3H, m), 0.87 (3H, t, JHH = 6.6 Hz);
13

C NMR (CDCl3) δ 159.05, 158.47, 137.17, 135.80, 130.34, 129.45, 129.21, 128.78,

128.16, 127.83, 127.68, 127.51, 115.03, 113.86, 79.81, 79.06, 70.20, 55.49, 33.59, 31.95,
24.27. For literature comparision, see ref. 20a.

(Z)-1-((2R,6S)-6-(4-methoxyphenyl)tetrahydro-2H-pyran-2-yl)-2-((2S,6R)-6-(4methoxyphenyl)tetrahydro-2H-pyran-2-yl)ethane (4.100). IR (neat, NaCl) 2931, 1723,
1611, 1514, 1247 cm-1; 1HNMR (CDCl3) δ 7.36 (4H, m), 6.60 (1H, d, JHH = 16.1 Hz),
6.89 (2H, m), 6.12 (1H,dd, JHH = 15.7, 1.9 Hz), 4.41 (1H, br d, JHH = 11.9, 2.0 Hz ), 4.20
( 1H, m, 3.81, 3.74, 2.00 (1H,m), 1.77 (3H, m), 1.54 (1H, m), 1.40 (1H, m);

13

CNMR

(CDCl3) δ 159.1, 135.7, 127.4, 113.9, 79.7, 78.3, 55.5, 33.6, 31.6, 24.2; HRMS (FAB,
NBA, MNa+) calcd for C26H32O4Na: 431.2198, found 431.2191.

2-methoxy-2,5-dihydro-1,2-oxaphosphole 2-oxide (4.91). IR (neat, NaCl) 1207, 1027
cm-1; 1HNMR (CDCl3) δ 7.16 (1H, dd, JHH = 46.9, 8.6 Hz), 6.2 (1H, ddd, JHH = 33.9,
8.55, 2.3 Hz), 4.79 (2H, m ), 3.75 (3H, d, JHP = 11.9 Hz); 31P NMR (CDCl3) δ 43.7. For
comparision of similar compounds, see: ref. 18a
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(E)-methyl 4-((2-oxido-1,2-oxaphosphol-2(5H)-yl)oxy)but-2-enoate (4.109). IR (neat,
NaCl) 1756, 1209, 1035 cm-1; 1HNMR (CDCl3) δ 7.20 (1H, ddt, JHH = 8.6, 1.6 Hz, JHP =
46.9 Hz), 6.96 (1H, ddt, JHH = 15.6, 4.1 Hz, JHP = 0.9 Hz), 6.22 (1H, ddt, JHH = 8.5, 2.4
Hz JHP = 34.5 Hz), 6.11 (1H, ddt, JHH = 15.7, 2.0 Hz, JHP = 4.0 Hz), 4.80 (4H, m), 3.76
(3H, s);

13

CNMR (CDCl3) δ 166.40, 149.19 (d, JCP = 17.6 Hz), 142.19 (JCP = 6.2 Hz),

121.8, 116.7 (d, JCP = 163.6 Hz), 71.00 (d, JCP = 13.4 Hz), 65.1 (d , JCP = 5.8 Hz), 51.99.
For literature comparision, see ref. 18a.
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